

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**THIRD INTERIM FEE APPLICATION OF FTI CONSULTING, INC. FOR
COMPENSATION EARNED AND EXPENSES INCURRED FOR THE PERIOD FROM
JUNE 1, 2020 THROUGH SEPTEMBER 30, 2020**

Name of Applicant:	FTI Consulting, Inc.
Name of Client:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Period for which Compensation and Expense Reimbursement Are Sought in this Application:	June 1, 2020 through September 30, 2020
Petition Date:	September 16, 2019
Retention Date:	December 2, 2019, <i>nunc pro tunc</i> to September 19, 2019
Total Amount of Compensation and Expense Reimbursement Sought to be Allowed in this Application:	\$1,440,572.15
Total Amount of Compensation Sought to be Allowed in this Application:	\$1,440,367.00
Total Amount of Expense Reimbursement Sought to be Allowed in this Application:	\$205.15

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Total Amount of Compensation and Expense Reimbursement Previously Allowed Pursuant to the Interim Compensation Order:	\$657,382.80
Compensation Sought in this Application and Already Paid Pursuant to the Interim Compensation Order:	\$299,802.40
Expenses Sought in this Application and Already Paid Pursuant to the Interim Compensation Order:	\$96.90
Blended Hourly Rate of Included Professionals:	\$756.06
Number of Professionals Included in This Application:	15

This is a: ____ monthly X interim ____ final application

FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, (“**FTI**”) financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants (the “**Committee**”) of Purdue Pharma L.P., et al. (the “**Debtors**”), hereby makes its Third Interim Fee Application for Compensation Earned and Expenses Incurred for the Period from June 1, 2020 through September 30, 2020 (this “**Application**”) and respectfully represents as follows:

Introduction

1. FTI provided services to the Committee in accordance with the instructions and directions of the Committee. FTI is compensated on an hourly fee basis, plus reimbursement of actual and necessary expenses incurred by FTI.

2. By this Application, FTI seeks allowance of (i) compensation for actual and necessary professional services rendered by FTI as financial advisor to the Committee for the period from June 1, 2020 through September 30, 2020 (the “**Compensation Period**”) in the

amount of \$1,440,367.00 and (ii) reimbursement for expenses incurred in the Compensation Period in the amount of \$205.15, for a total of \$1,440,572.15 for the Compensation Period.

3. The statutory bases for the relief requested herein are sections 330 and 331 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”), and Rule 2016-1 of the Local Rules for the United States Bankruptcy Court for the Southern District of New York (the “**Local Rules**”), and the United States Trustee’s Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed Under 11 U.S.C. § 330 for Attorneys in Larger Chapter 11 Cases, effective as of November 1, 2013 (the “**U.S. Trustee Guidelines**”). This Application has been prepared in accordance with General Order M-447, the Amended Guidelines for Fees and *Disbursements for Professionals in the Southern District of New York* (June 17, 2013) promulgated pursuant to Local Bankruptcy Rule 2016-1(a) (the “**Local Guidelines**”), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 529] (the “**Interim Compensation Order**”).

4. This Application summarizes the services rendered by FTI on behalf of the Committee during the Compensation Period. While it is not possible or practical to describe each and every activity undertaken by FTI, FTI has maintained contemporaneous time records which include a detailed chronology of the daily services rendered, describing the precise nature of the work, the specific tasks performed, and the time expended by each professional. A breakdown of the hours and fees by professional is annexed hereto as **Exhibit A**. A breakdown of the hours and fees by task code is annexed hereto as **Exhibit B**. A detailed copy of the time records for the Compensation Period is annexed hereto as **Exhibit C**.

5. FTI has incurred out-of-pocket disbursements during the Compensation Period broken down into categories of charges itemized in **Exhibit D**. A detailed breakdown of these charges is annexed hereto as **Exhibit E**. Each charge incurred by FTI was necessary and reasonable and was incurred as a direct result of FTI's representation of the Committee.

6. In accordance with the Interim Compensation Order, FTI has requested payment for 80% of the fees for actual and necessary services incurred during the Compensation Period in the amount of \$1,152,293.60 and for 100% of the expenses incurred during the Compensation Period in the amount of \$205.15 for a total amount of \$1,152,498.75. FTI submitted monthly fee statements during the Compensation Period, summarized as follows:

Docket No./Filed	Compensation Period	Fees and Expenses Incurred			Monthly Amounts Requested	Payments Received as of the Date of this
		Fees (100%)	Fees (80%)	Expenses (100%)	Fees (80%) + Expenses (100%)	
Docket No. 1651 Filed on 9/2/2020	June 1, 2020 - June 30, 2020	\$ 374,753.00	\$ 299,802.40	\$ 96.90	\$ 299,899.30	\$ 299,899.30
Docket No. 1725 Filed on 9/25/2020	July 1, 2020 - July 31, 2020	446,975.50	357,580.40	-	357,580.40	-
Docket No. 1850 Filed on 10/26/2020	August 1, 2020 - August 31, 2020	261,092.00	208,873.60	108.25	208,981.85	-
Docket No. 1950 Filed 11/13/2020	September 1, 2020 - September 31, 2020	357,546.50	286,037.20	-	286,037.20	-
Total		\$ 1,440,367.00	\$ 1,152,293.60	\$ 205.15	\$ 1,152,498.75	\$ 299,899.30

7. As of the date of this Application, FTI is owed \$1,140,564.60 for professional fees and \$108.25 for actual and necessary expenses for a total of \$1,140,672.85.

Jurisdiction

8. The Court has jurisdiction over this Application under 28 U.S.C. § 1334. Venue of this proceeding is proper pursuant to 28 U.S.C. §§ 1408 and 1409. This is a core proceeding within the meaning of 28 U.S.C. § 157(b)(2).

Background

9. On September 16, 2019 (the “**Petition Date**”), the Debtors each filed with the United States Bankruptcy Court for the Southern District of New York (this “**Court**”) their voluntary petitions for relief under chapter 11 of the Bankruptcy Code. For the bankruptcy process, the Debtors selected Davis Polk & Wardwell as counsel (“**Davis Polk**”) and AlixPartners LLP as financial advisor (“**Alix**”).

10. The Debtors continue to operate their businesses and manage their properties as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

11. On September 18, 2019, the Court entered an order [Docket No. 59] authorizing the joint administration and procedural consolidation of the Debtors’ chapter 11 cases pursuant to Bankruptcy Rule 1015(b). No examiner has been appointed in the chapter 11 cases pursuant to section 1104 of the Bankruptcy Code.

12. On November 21, 2019, the Court entered its Interim Compensation Order [Docket No. 529] establishing the procedures for interim compensation and reimbursement of expenses incurred by professionals retained by the Debtors pursuant to sections 327 or 1103 of the Bankruptcy Code (“**Retained Professionals**”).

13. On December 2, 2019, the Court entered the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [Docket No. 553] (the “**Retention Order**”).

14. During the Compensation Period, FTI has represented the Committee, in connection with these chapter 11 cases, including with respect to, among other things, the Debtors’ domestic and international business plans, employee compensation plans, and historical cash transfers. The fees earned and the expenses incurred by FTI in connection with these activities are the subject of this Application and are described in more detail below and the exhibits hereto.

Terms and Conditions of Employment

15. FTI is compensated on an hourly fee basis, plus reimbursement of actual and necessary expenses incurred by FTI. For further information regarding the terms and conditions of FTI's retention, please see the Retention Order. The Committee has been given the opportunity to review and approve this Application.

Summary of FTI's Services Rendered

16. During the Compensation Period, FTI provided extensive financial services to the Committee. The primary services rendered by FTI include, but are not limited to, the categories set forth below (each a "**Task Code**") which were billed pursuant to the requirements of Section C(8)(c) of the U.S. Trustee Guidelines:

- a. **Task Code 1: Current Operating Results & Events (44.3 Hours):** During the Compensation Period, time detail under this task code related to FTI's work evaluating the Debtors' monthly operating reports, results, and current events. FTI prepared analyses comparing the Debtors' YTD performance relative to their business plans and prepared presentations to share findings and update the Committee.
- b. **Task Code 7: Analysis of Domestic Business Plan (250.4 Hours):** During the Compensation Period, FTI undertook detailed diligence of the Debtors' revised go-forward business plan including, (i) a thorough evaluation of financial forecasts and projections for both business segments and product-level detail, (ii) analysis of historical performance of the domestic business, (iii) participation in meetings with key employees and advisors of the Debtors, and the (iv) preparation of related analyses for the Committee and other

stakeholders. FTI also reviewed and conducted diligence on the reasonableness of the Debtors' proposed public health initiatives and their potential impact to the Debtors' financial performance. FTI prepared comprehensive presentations for the Committee to summarize the various analyses prepared on the Debtors' go-forward business plan.

c. **Task Code 9: Analysis of Employee Compensation Programs (147.4**

Hours): During the Compensation Period, FTI conducted extensive diligence into the Debtors' proposed insider and non-insider incentive and retention plans filed with the Court (KEIP and KERP). FTI reviewed historical compensation detail and corresponded with the UCC to renegotiate compensation amounts and terms with the Debtors. In conducting diligence, FTI prepared various analyses and presentations for the Committee to summarize key issues, including post-emergence compensation, performance metrics, participants, and plan size.

d. **Task Code 10: Analysis of Tax Issues (55.3 Hours)**: During the

Compensation Period, FTI was involved in analyzing and reviewing the impact of various tax-related matters, including tax refunds under the CARES Act, potential tax liabilities from the sale of the IAC businesses, and taxes resulting from the go-forward strategy of the domestic Purdue business. FTI participated in calls and meetings with both Counsel and other tax professionals to discuss the related analyses and prepare relevant materials to share with the Committee on these issues.

e. **Task Code 16: Analysis, Negotiate and Form of POR & DS (398.2 Hours):**

Entries under this task code relate to FTI's work during the Compensation Period focused on evaluating potential go-forward scenarios for the Purdue business to maximize distributable value to claimant groups. In conducting analyses related to the go-forward scenarios, FTI performed significant diligence into the Debtors' existing business plan and re-forecasted sales figures, working alongside the Debtors and the UCC to estimate distributable value under various sale and operating scenarios. This diligence culminated in an extensive presentation to the Committee on go-forward considerations, which was periodically updated and supplemented with related analyses throughout the Compensation Period to reflect the Debtors' latest thinking and actual performance of the Company.

f. **Task Code 18: Review of Historical Transactions (406.6 Hours):** During the Compensation Period, FTI performed significant work to evaluate the various historical cash, non-cash, and intercompany transfers between the Purdue and Rhodes businesses, the IACs, and other Sackler-owned legal entities / the Sackler family. This workstream involved significant effort in reviewing reports and supporting financial data prepared and provided by the Debtors and Sackler family's professionals as well as numerous correspondences with the UCC to review their analyses and findings. Diligence resulted in various work products, including analyses prepared by the FTI forensics team on the reasonableness of identified cash transfers by analyzing historical audited financial statements, diligence of the balance sheet assets and liabilities of the

Sackler families and their trusts, and presentations summarizing FTI's preliminary findings on potential considerations related to the historical transactions.

g. **Task Code 21: General Mtgs with Counsel and/or Ad Hoc Committee (43.0**

Hours): During the Compensation Period, FTI participated on numerous calls and meetings with the Committee and its counsel. During these calls and meetings, FTI discussed with the Committee and its counsel several key issues at hand, next steps, and the presentations of various analyses prepared by FTI's team.

h. **Task Code 28: Review of IAC Business (428.3 Hours)**: During the

Compensation Period, FTI analyzed and performed diligence of the IACs' businesses and operations. FTI conducted analyses of the IACs' revised September business plan, including a thorough evaluation of financial forecasts and projections for the three key operating regions and analysis of historical performance of the international businesses. In addition, FTI participated in meetings with key IAC employees and advisors on various matters, including strategic initiatives under the new IAC CEO, historical financials with the IAC CFO, the status of the sale process and related considerations with the IAC's investment banker, the status of vendor due diligence conducted, and evaluation of the IAC business plan by external advisors. Throughout the Compensation Period, FTI prepared as needed, presentations to update the Committee on the latest status of diligence on the IACs. Additional time spent in this task code

includes the coordination of ongoing diligence efforts with the Committee's and the Debtors' advisors.

Basis for Relief Requested

17. Section 331 of the Bankruptcy Code provides for interim compensation of professionals and incorporates the substantive standards of section 330 of the Bankruptcy Code that govern the Court's award of such compensation. See 11 U.S.C. § 331. Section 330 provides that the Court may award a professional employed under section 327 "reasonable compensation for actual, necessary services" and "reimbursement for actual, necessary expenses." 11 U.S.C. § 330(a)(1). Section 330(a)(3) also outlines specific criteria that the Court shall consider in determining the amount of reasonable compensation, including:

- a. the time spent on such services;
- b. the rates charged for such services;
- c. whether the services were necessary to the administration of, or beneficial at the time at which the service was rendered toward the completion of, a case under this title;
- d. whether the services were performed within a reasonable amount of time commensurate with the complexity, importance, and nature of the problem, issue, or task addressed;
- e. with respect to a professional person, whether the person is board certified or otherwise has demonstrated skill and experience in the bankruptcy field; and

- f. whether the compensation is reasonable based on the customary compensation charged by comparably skilled practitioners in cases other than cases under this title.

18. All of the services for which FTI seeks compensation were necessary for, beneficial to, and in the best interests of the Committee. FTI's fees are reasonable given the size and complexity of the Debtors' cases.

19. All of the services for which interim compensation is sought herein were rendered for and on behalf of the Committee. FTI respectfully submits that the professional services rendered were necessary, appropriate, and have contributed to the effective administration of the Debtors' chapter 11 cases and maximization of value. It is respectfully submitted that the services rendered to the Committee were performed efficiently, effectively, and economically, and the results have benefitted the Committee.

20. The hourly rates that FTI has charged are consistent with the market rate for comparable services. The hourly rates and fees charged by FTI are the same as those generally charged to, and paid by, FTI's other clients. FTI regularly reviews its hourly rates on an annual basis and, accordingly, the rates included in this Application reflect an ordinary course hourly rate increase.

21. Whenever possible, FTI sought to minimize the costs of its services to the Committee by utilizing talented junior professionals to handle more routine aspects of case administration. A small group of the same FTI professionals was utilized for the vast majority of the work in these cases to minimize the costs of intra-FTI communication and education about the Debtors' circumstances.

22. FTI believes that the expenses incurred are reasonable and economical relative to the services required by the Committee and were incurred as a direct result of FTI's representation of the Committee. These expenses are the type customarily charged to non-bankruptcy clients of FTI. None of the expenses relate to non-reimbursable overhead. FTI has adhered to allowable rates for expenses as fixed by 2016-1 of the Local Rules for the United States Bankruptcy Court of the Southern District of New York.

23. In accordance with the factors enumerated in section 331 of the Bankruptcy Code, the amounts requested herein are fair and reasonable given (i) the complexity of the cases, (ii) the time expended, (iii) the nature and extent of services rendered, (iv) the value of such services, and (v) the costs of comparable services other than in a case under the Bankruptcy Code.

24. FTI submits that pursuant to the criteria normally examined in bankruptcy cases and based upon the factors considered in accordance with sections 330 and 331 of the Bankruptcy Code and Bankruptcy Rule 2016, the results achieved provide more than sufficient justification for approval of compensation sought by FTI.

WHEREFORE, FTI respectfully requests that the Court enter an order:

- a. Granting this Application;
- b. Awarding FTI, on an interim basis, compensation for professional services rendered during the Compensation Period in the amount of \$1,440,367.00 and reimbursement of actual, reasonable and necessary expenses incurred by FTI during the Compensation Period in the amount of \$205.15;

Dated: New York, New York
November 16, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**CERTIFICATION UNDER GUIDELINES FOR FEES AND DISBURSEMENTS FOR
PROFESSIONALS IN RESPECT OF THE THIRD APPLICATION OF FTI
CONSULTING, INC. FOR INTERIM COMPENSATION AND REIMBURSEMENT OF
EXPENSES**

I, Matthew Diaz, hereby certify that:

1. I am a Senior Managing Director with the applicant firm, FTI Consulting Inc., (together with its wholly owned subsidiaries and independent contractors, “**FTI**”), as financial advisor for the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants (the “**Committee**”) for the jointly administered chapter 11 cases of Purdue Pharma L.P., et al (collectively, the “**Debtors**”), in respect of compliance with the *Amended Guidelines for Fees and Disbursements for Professionals in Southern District of New York Bankruptcy Cases* (June 17,

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

2013) promulgated pursuant to Local Bankruptcy Rule 2016-1(a) (the “**Local Guidelines**”), the *United States Trustee’s Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed Under 11 U.S.C. § 330* for Attorneys in Larger Chapter 11 Cases, effective as of November 1, 2013 (the “**U.S. Trustee Guidelines**”), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order,**” and collectively with the Amended Local Guidelines and UST Guidelines, the “**Guidelines**”).

2. This certification is made in respect of FTI’s application, dated November 16, 2020 (the “**Application**”), for interim compensation and reimbursement of expenses for the period commencing June 1, 2020, through and including September 30, 2020, (the “**Third Interim Compensation Period**”) in accordance with the Guidelines.

In respect of section B.1 of the Local Guidelines, I certify that:

- (a) I have read the application;
- (b) To the best of my knowledge, information, and belief formed after reasonable inquiry, the fees and disbursements sought fall within the Local Guidelines;
- (c) The Application respectfully requests that this Court enter an Order awarding FTI \$1,440,367.00 as compensation for services rendered during the Third Interim Compensation Period and \$205.15 as reimbursement of reasonable actual and necessary expenses incurred in connection with such services;
- (d) The fees and disbursement requested in the Application are billed in accordance with practices customarily employed by FTI and generally accepted by FTI’s clients; and
- (e) In providing a reimbursable service, FTI does not make a profit on that service, whether the service is performed by FTI in-house or through a third party.

3. In respect of section B.2 of the Local Guidelines and as required by the Interim Compensation Order, I certify that FTI has provided, on a monthly basis or as soon as reasonably possible, statements of FTI's fees and disbursements accrued during the previous month, to the Debtors and the Committee.

4. In respect of section B.3 of the Local Guidelines, I certify that the Debtors, the United States Trustee for the Region 2 and the Committee are each being provided a copy of the Application.

Dated: New York, New York
November 16, 2020

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Professional	Position	Specialty	Blended Billing Rate^{1,2}	Total Hours	Total Fees
Diaz, Matthew	Senior Managing Director	Restructuring	\$ 1,085.00	294.4	319,424.0
Simms, Steven	Senior Managing Director	Restructuring	1,295.00	9.6	12,432.0
Joffe, Steven	Senior Managing Director	Tax	1,125.00	26.9	30,262.5
Greenblatt, Matthew	Senior Managing Director	Forensics	985.00	41.3	40,680.5
Kyviakidis, Peter	Managing Director	Forensics	761.38	73.0	55,580.5
Nichols, David	Managing Director	Insurance	765.00	2.6	1,989.0
Suric, Emil	Senior Director	Healthcare Valuation	820.00	33.3	27,306.0
Costaldo, Nicole	Senior Director	Forensics	700.00	52.2	36,540.0
Shah, Jayshree	Senior Director	International Healthcare	930.00	27.0	25,110.0
Bromberg, Brian	Director	Restructuring	815.00	645.3	525,919.5
Kim, Ye Darm	Senior Consultant	Restructuring	560.00	454.7	254,632.0
Tirabassi, Kathryn	Senior Consultant	Restructuring	560.00	0.6	336.0
Mazzari, Meredith	Senior Consultant	Forensics	530.00	77.8	41,234.0
Kurtz, Emma	Consultant	Restructuring	415.00	165.4	68,641.0
Hellmund-Mora, Marili	Project Assistant	Restructuring	280.00	1.0	280.0
Grand Total				1,905.1	\$ 1,440,367.00

1. Blended billing rates are presented and reflect ordinary course rate increases and increases due to change in titles.

2. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT B
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	44.3	27,372.5
2	Cash & Liquidity Analysis	1.0	875.0
7	Analysis of Domestic Business Plan	250.4	195,976.0
8	Valuation and Related Matters	4.0	4,340.0
9	Analysis of Employee Comp Programs	147.4	113,128.0
10	Analysis of Tax Issues	55.3	50,923.5
11	Prepare for and Attend Court Hearings	2.5	1,400.0
13	Analysis of Other Miscellaneous Motions	0.6	336.0
16	Analysis, Negotiate and Form of POR & DS	398.2	318,134.0
18	Review of Historical Transactions	406.6	298,796.0
19	Case Management	32.1	23,965.0
21	General Mtgs with Counsel and/or Ad Hoc Committee	43.0	37,002.0
22	Meetings with Other Parties	26.8	24,210.5
24	Preparation of Fee Application	64.6	38,072.5
28	Review of IAC Business Plan	428.3	305,836.0
GRAND TOTAL^{1,2}		1,905.1	\$ 1,440,367.00

1. Blended billing rates are presented and reflect ordinary course rate increases effective 1/1/2020 and increases due to change in titles.

2. Billing rates of international professionals have been translated to USD using the relevant spot rate.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
1	6/1/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/2/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/3/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/4/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/5/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/9/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/11/2020	Diaz, Matthew	0.6	Review the Debtors' responses to the business plan/current results diligence questions.
1	6/11/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/12/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/15/2020	Diaz, Matthew	0.8	Review of the Debtors' YTD April 2020 financial report.
1	6/15/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/15/2020	Bromberg, Brian	1.0	Review of the Debtors' YTD April 2020 financial report.
1	6/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/17/2020	Bromberg, Brian	0.7	Prepare summary of the Debtors' performance re: March YTD financial report.
1	6/18/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/22/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/23/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/25/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/26/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/29/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	6/30/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/6/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/7/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/8/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/9/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/10/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/13/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/14/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/15/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/16/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
1	7/17/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/20/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/22/2020	Kurtz, Emma	0.6	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/23/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/24/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/27/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/28/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/29/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/30/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	7/31/2020	Diaz, Matthew	0.5	Review new product opportunity disclosed by Debtors and related documents and materials.
1	7/31/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/3/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/3/2020	Kurtz, Emma	1.7	Prepare June YTD operating report update slides for the Committee.
1	8/4/2020	Diaz, Matthew	0.6	Review of Debtors' June operating results.
1	8/4/2020	Kurtz, Emma	0.7	Prepare revisions to June YTD operating report update for the Committee per internal comments.
1	8/10/2020	Diaz, Matthew	1.5	Detail review of the updated ANZ presentation and related analysis.
1	8/10/2020	Diaz, Matthew	2.8	Detail review of the report on the Debtors' business update and the recovery analysis.
1	8/10/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/11/2020	Diaz, Matthew	3.1	Detail review of the updated report to the committee on the June results, recovery analysis and the cash transfer analysis.
1	8/11/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/12/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/13/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/14/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/17/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/18/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/19/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/20/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/21/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/24/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/25/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/26/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/27/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
1	8/28/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	8/31/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/1/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/2/2020	Diaz, Matthew	1.4	Review the Debtors' updated operating results.
1	9/2/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/3/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/4/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/8/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/9/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/10/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/11/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/14/2020	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/15/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/16/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/17/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/18/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/21/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/22/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/23/2020	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/24/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/25/2020	Diaz, Matthew	1.1	Review the Debtors' YTD July financial results.
1	9/25/2020	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/28/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	9/29/2020	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			44.3	
2	6/24/2020	Diaz, Matthew	0.6	Perform review of slides for presentation re: UCC call.
2	6/25/2020	Kim, Ye Darm	0.4	Review latest cash reporting update from Debtors.
2 Total			1.0	
7	6/1/2020	Bromberg, Brian	0.8	Discuss domestic business plan diligence process with team.
7	6/1/2020	Bromberg, Brian	0.7	Create topic list for business plan diligence discussion with team.
7	6/1/2020	Bromberg, Brian	1.3	Discuss business plan diligence process with counsel.
7	6/2/2020	Diaz, Matthew	1.0	Participate in a call with Dr. Brenkus to discuss the HRT motion.
7	6/2/2020	Bromberg, Brian	0.5	Discuss Domestic business plan with Houlihan team.
7	6/2/2020	Bromberg, Brian	2.1	Review domestic business plan report for presentation notes.
7	6/3/2020	Kim, Ye Darm	0.8	Process update to domestic business plan diligence deck re: product sales.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	6/3/2020	Bromberg, Brian	0.9	Review and edit domestic business plan document.
7	6/3/2020	Bromberg, Brian	1.5	Participate in call with PJT Partners re: Purdue business plan diligence.
7	6/3/2020	Bromberg, Brian	1.5	Review the latest domestic business plan report.
7	6/3/2020	Bromberg, Brian	1.7	Prepare clarification document for domestic business plan diligence questions.
7	6/4/2020	Bromberg, Brian	1.2	Discuss Rhodes data requests with team and transmit to Debtor advisors.
7	6/9/2020	Kim, Ye Darm	0.1	Review buyer log for domestic business asset inbounds.
7	6/9/2020	Kim, Ye Darm	0.6	Prepare summary of call for internal distribution re: inbounds for domestic asset.
7	6/9/2020	Bromberg, Brian	0.5	Discuss outstanding diligence reports and presentations with team.
7	6/9/2020	Bromberg, Brian	0.7	Participate in call with Debtor advisors re: BuTrans and summarize for team.
7	6/9/2020	Bromberg, Brian	0.6	Participate in call with Dr. Brenkus re: OTC Naloxone and summarize for team.
7	6/9/2020	Kim, Ye Darm	0.5	Participate in call with Dr. Brenkus re: public health initiatives.
7	6/10/2020	Diaz, Matthew	1.1	Review the updated Purdue domestic business plan diligence report.
7	6/10/2020	Bromberg, Brian	0.5	Review domestic business plan report for presentation notes.
7	6/10/2020	Bromberg, Brian	0.6	Review latest version of domestic presentation.
7	6/11/2020	Kim, Ye Darm	0.8	Process revisions to US business plan diligence presentation.
7	6/11/2020	Kim, Ye Darm	0.9	Review Debtors' response to US business plan diligence question.
7	6/11/2020	Bromberg, Brian	0.6	Present to diligence committee on Domestic deck.
7	6/11/2020	Bromberg, Brian	0.9	Discuss domestic business plan presentations and information sharing issues with team.
7	6/11/2020	Bromberg, Brian	0.9	Organize domestic business plan presentations and create agenda for diligence committee call.
7	6/11/2020	Bromberg, Brian	0.8	Incorporate new dataroom information into presentation notes.
7	6/11/2020	Bromberg, Brian	0.9	Participate in coordination pre-call before diligence call.
7	6/11/2020	Bromberg, Brian	0.3	Discuss changes to domestic business plan presentation ahead of diligence meeting.
7	6/11/2020	Bromberg, Brian	1.1	Review answers provided in dataroom to domestic business plan diligence question.
7	6/12/2020	Kim, Ye Darm	1.0	Process revisions to US business plan presentation for Non-PEO information.
7	6/12/2020	Kim, Ye Darm	0.6	Continue processing revisions to US business plan presentation for non-PEO info.
7	6/12/2020	Bromberg, Brian	0.3	Research follow up NCSG questions re: domestic business plan.
7	6/12/2020	Bromberg, Brian	0.9	Participate in call with NCSG re: domestic business plan.
7	6/12/2020	Bromberg, Brian	2.4	Create non PEO version of domestic business plan deck.
7	6/12/2020	Bromberg, Brian	0.5	Discuss information sharing of PEO documents with team.
7	6/12/2020	Bromberg, Brian	1.0	Review non PEO version of domestic business plan deck.
7	6/12/2020	Bromberg, Brian	0.8	Review documents provided in dataroom re: valuation considerations.
7	6/13/2020	Bromberg, Brian	0.5	Send outstanding NCSG questions and responses to internal team for review.
7	6/16/2020	Diaz, Matthew	1.1	Review the domestic business plan sensitivity cases.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	6/16/2020	Kim, Ye Darm	0.6	Review responses to diligence questions re: HRT funding agreement.
7	6/16/2020	Kim, Ye Darm	1.7	Review Opioid-only financial models for domestic business plan.
7	6/16/2020	Bromberg, Brian	1.0	Review hypothetical scenario models provided by Debtors.
7	6/17/2020	Bromberg, Brian	1.0	Present re: Domestic business plan on Committee call.
7	6/17/2020	Bromberg, Brian	0.8	Participate in call with Houlihan team re: Committee call.
7	6/17/2020	Bromberg, Brian	0.5	Discuss Domestic business plan with Houlihan team.
7	6/17/2020	Bromberg, Brian	0.5	Prepare notes on presentations for Domestic business plan.
7	6/19/2020	Bromberg, Brian	0.3	Discuss analysis of generic products on domestic business plan.
7	6/25/2020	Kim, Ye Darm	1.4	Review production in dataroom to identify documents related to diligence requests.
7	6/29/2020	Diaz, Matthew	0.5	Participate on a call with the Debtors' re: Rhodes strategic initiatives.
7	6/29/2020	Diaz, Matthew	0.8	Review the Debtors' proposed strategic initiatives re: Rhodes.
7	6/29/2020	Kim, Ye Darm	1.1	Participate in meeting and review presentation re: Rhodes Prodrug.
7	6/29/2020	Bromberg, Brian	0.8	Participate in diligence call re: Rhodes with Debtors.
7	6/29/2020	Bromberg, Brian	0.4	Discuss public benefit structures with Houlihan.
7	7/1/2020	Kim, Ye Darm	0.5	Review business plan support files for historical sales and EBITDA figures.
7	7/1/2020	Kim, Ye Darm	0.7	Review counsel's update to the AHC re: 2004 motions.
7	7/1/2020	Kim, Ye Darm	0.6	Process revisions to presentation re: Tribal diligence update presentation.
7	7/2/2020	Bromberg, Brian	0.8	Review Debtors' delayed bankruptcy case scenario presentation.
7	7/2/2020	Kim, Ye Darm	0.9	Review Debtors' delayed bankruptcy scenario presentation.
7	7/2/2020	Suric, Emil	1.7	Conduct preliminary Rhodes generics due diligence modeling and analysis.
7	7/3/2020	Kim, Ye Darm	2.2	Prepare updates to illustrative distributable value presentation.
7	7/4/2020	Diaz, Matthew	1.5	Review the financial update presentation for the NCSG.
7	7/5/2020	Kim, Ye Darm	1.8	Prepare slides for diligence update presentation to the NCSG.
7	7/5/2020	Kim, Ye Darm	1.2	Process revisions to the Mediation group financial presentation.
7	7/5/2020	Kim, Ye Darm	1.3	Prepare updates to slides re: Mediation group financial presentation.
7	7/5/2020	Kim, Ye Darm	1.1	Process revisions to the diligence update presentation to the NCSG.
7	7/5/2020	Diaz, Matthew	2.6	Perform detailed review of the financial diligence update presentation to the NCSG.
7	7/6/2020	Bromberg, Brian	3.4	Continue to evaluate opioid only scenario operating model.
7	7/6/2020	Bromberg, Brian	1.9	Evaluate opioid only scenario operating model from the Debtors.
7	7/6/2020	Kim, Ye Darm	0.3	Process updates to Mediation group financial presentation and diligence update presentation per Counsel's comments.
7	7/6/2020	Kim, Ye Darm	0.7	Review documents for information on PHI market sizing assumptions.
7	7/6/2020	Kim, Ye Darm	1.8	Review Debtors' opioid only business model.
7	7/6/2020	Kim, Ye Darm	0.3	Review PHI price scenarios analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	7/6/2020	Kim, Ye Darm	0.7	Participate in meeting with HL and Counsel re: diligence update presentations.
7	7/6/2020	Kim, Ye Darm	0.9	Participate in internal discussion re: diligence update presentations.
7	7/6/2020	Kim, Ye Darm	1.1	Process revisions to the Mediation group financial presentation and the diligence update presentation to the NCSG.
7	7/6/2020	Suric, Emil	0.5	Participate in due diligence call with subcommittee re: generic sales forecasts.
7	7/7/2020	Bromberg, Brian	1.3	Review previous public health initiatives slides to create new presentation.
7	7/7/2020	Bromberg, Brian	0.5	Submit additional requests to Debtors on opioid only scenario assumptions.
7	7/7/2020	Diaz, Matthew	0.8	Review latest information re: the PHI initiatives for diligence update.
7	7/7/2020	Diaz, Matthew	0.5	Participate in a call with the Debtors to discuss the domestic business plan.
7	7/7/2020	Diaz, Matthew	1.3	Review the opioid only forecast and related due diligence questions.
7	7/7/2020	Diaz, Matthew	2.2	Review the sensitized business plan and related assumptions.
7	7/7/2020	Kim, Ye Darm	1.3	Prepare one-pager re: PHI diligence for D&P.
7	7/7/2020	Kim, Ye Darm	0.9	Review PHI analyses to prepare summary sheet to share with D&P.
7	7/7/2020	Kim, Ye Darm	0.6	Review historical audited financial statements for margin assumptions.
7	7/8/2020	Bromberg, Brian	1.3	Review Debtors' continued operations scenario and related assumptions.
7	7/8/2020	Bromberg, Brian	1.0	Participate in call with Debtors regarding delayed bankruptcy costs.
7	7/8/2020	Bromberg, Brian	0.7	Review and provide revisions re: public health initiatives diligence update presentation.
7	7/8/2020	Bromberg, Brian	0.9	Review prior OxyContin forecast model for previous sales assumptions.
7	7/8/2020	Bromberg, Brian	0.4	Prepare template for data request of Debtors re: domestic business plan diligence.
7	7/8/2020	Bromberg, Brian	0.7	Finalize template for data request re: domestic business plan diligence.
7	7/8/2020	Diaz, Matthew	0.6	Prepare for the call with the Debtors re the OxyContin forecasts in the domestic business plan.
7	7/8/2020	Diaz, Matthew	1.0	Participate in call with the Debtors and advisors to discuss OxyContin forecast assumptions.
7	7/8/2020	Kim, Ye Darm	0.7	Process revisions to PHI one-pager for D&P.
7	7/8/2020	Kim, Ye Darm	1.2	Review Debtor-provided files re: historical OxyContin margins.
7	7/8/2020	Kim, Ye Darm	1.3	Review business forecast cash assumptions and prior materials provided by Debtors.
7	7/8/2020	Bromberg, Brian	2.1	Review end of year cash projection per Debtors' business plan.
7	7/8/2020	Suric, Emil	0.5	Participate in internal discussion on next steps on Debtors' forecast diligence process.
7	7/9/2020	Diaz, Matthew	1.3	Review the updated domestic business plan cash flow forecasts.
7	7/9/2020	Bromberg, Brian	1.3	Review updated Debtors business plan model and scenarios.
7	7/9/2020	Bromberg, Brian	0.3	Discuss latest updates re: public health initiatives on call with team.
7	7/10/2020	Bromberg, Brian	0.5	Discuss public health initiatives updates with Debtor advisors.
7	7/10/2020	Bromberg, Brian	1.3	Process updates to presentation on public health initiatives.
7	7/10/2020	Bromberg, Brian	0.5	Discuss public health initiatives presentation with internal team.
7	7/10/2020	Bromberg, Brian	0.5	Review public health initiatives diligence update deck.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	7/10/2020	Diaz, Matthew	1.2	Review the PHI diligence update presentation.
7	7/10/2020	Kim, Ye Darm	0.5	Participate in discussion re: PHI diligence update.
7	7/10/2020	Kim, Ye Darm	0.7	Process updates to draft PHI diligence update deck.
7	7/14/2020	Bromberg, Brian	0.8	Participate in call with Debtors on new domestic business scenarios.
7	7/14/2020	Bromberg, Brian	0.9	Review the updated public health initiatives diligence update deck.
7	7/14/2020	Diaz, Matthew	0.7	Review the updated PHI diligence slides.
7	7/14/2020	Kim, Ye Darm	1.4	Process revisions to PHI overview presentation for the DOJ.
7	7/14/2020	Kim, Ye Darm	1.6	Process revisions to presentation on PHI initiatives for DOJ.
7	7/15/2020	Bromberg, Brian	1.2	Review public health initiatives deck for PEO information.
7	7/15/2020	Kim, Ye Darm	0.4	Continue review of source materials for the PHI presentation re: PEO documents.
7	7/15/2020	Kim, Ye Darm	0.6	Review source documents for PHI presentation re: PEO.
7	7/15/2020	Kim, Ye Darm	1.9	Process revisions to PHI presentation to the DOJ.
7	7/21/2020	Kim, Ye Darm	1.3	Review business plan related documents on the dataroom for potential adjustments to distributable value presentation.
7	7/21/2020	Kim, Ye Darm	0.4	Source PEO information relied upon for the PHI presentation to the DOJ.
7	7/22/2020	Diaz, Matthew	1.2	Review the PHI diligence update presentation.
7	7/22/2020	Kim, Ye Darm	0.4	Process revisions to the PHI presentation to the DOJ.
7	7/27/2020	Bromberg, Brian	0.6	Prepare responses to questions re: public health initiatives updates.
7	7/27/2020	Kim, Ye Darm	0.7	Review YTD Nalmefene costs document from the Debtors.
7	7/27/2020	Kim, Ye Darm	1.4	Review new documents in dataroom to identify documents responsive to diligence requests.
7	7/29/2020	Bromberg, Brian	1.3	Review new product opportunity-related materials uploaded by the Debtors.
7	7/29/2020	Kim, Ye Darm	0.8	Review new product opportunity-related materials uploaded by the Debtors.
7	7/30/2020	Bromberg, Brian	0.4	Prepare for call with Debtors re: new product opportunity.
7	7/30/2020	Bromberg, Brian	0.4	Participate in call with Debtors re: new product opportunity.
7	7/30/2020	Bromberg, Brian	0.6	Coordinate with AHC advisors re: new product opportunity.
7	7/30/2020	Diaz, Matthew	0.7	Review the updated business plan sensitivity scenarios.
7	7/31/2020	Bromberg, Brian	0.5	Review the Debtors' public health initiative budget.
7	7/31/2020	Bromberg, Brian	3.1	Review new OxyContin projections from the Debtors.
7	8/3/2020	Diaz, Matthew	1.6	Review the Debtors' updated projections.
7	8/3/2020	Kim, Ye Darm	0.5	Review latest Adhansia/Foquest sales forecasts and compare to actual results.
7	8/3/2020	Kim, Ye Darm	1.1	Review Debtors' presentation to UCC re: YTD June results, CEO/CFO updates.
7	8/3/2020	Kim, Ye Darm	1.0	Review Debtors' dataroom updates for documents responsive to requests.
7	8/3/2020	Kurtz, Emma	0.3	Review updates to the distributable value report and June operating report.
7	8/3/2020	Bromberg, Brian	0.9	Review June YTD performance slides and provide revisions.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	8/3/2020	Bromberg, Brian	1.5	Prepare domestic business update summary for distribution to team.
7	8/3/2020	Bromberg, Brian	2.3	Create draft template for analysis on domestic business plan.
7	8/3/2020	Bromberg, Brian	1.6	Review the Debtors' new business update presentation.
7	8/3/2020	Bromberg, Brian	0.5	Discuss the draft business plan analysis with internal team.
7	8/4/2020	Kim, Ye Darm	1.6	Compile Adhansia/Foquest sales data and prepare comparative analysis.
7	8/4/2020	Bromberg, Brian	0.6	Provide revisions re: value scenario breakdown slides.
7	8/4/2020	Bromberg, Brian	1.1	Prepare draft outline re: value scenario breakdown slides.
7	8/4/2020	Bromberg, Brian	1.2	Prepare Purdue value scenario summary for presentation.
7	8/4/2020	Bromberg, Brian	0.9	Review June YTD performance slides and distribute overview to internal team.
7	8/4/2020	Bromberg, Brian	1.2	Review and provide revisions re: value scenario breakdown slides.
7	8/4/2020	Bromberg, Brian	0.7	Review ADHD product performance for the domestic company.
7	8/4/2020	Bromberg, Brian	0.9	Review comparison of ADHD products both internationally and domestically.
7	8/4/2020	Bromberg, Brian	2.8	Process revisions re: value scenario breakdown slides.
7	8/5/2020	Bromberg, Brian	0.5	Review business update presentation to screen for PEO information.
7	8/5/2020	Bromberg, Brian	0.7	Finalize value breakdown slides to send to team.
7	8/7/2020	Kim, Ye Darm	0.9	Review historical OxyContin sales forecasts to compare with new assumptions.
7	8/7/2020	Kim, Ye Darm	1.1	Review dataroom documents to identify potential sources of segment level historical performance.
7	8/7/2020	Bromberg, Brian	0.3	Finalize business update report to send to Houlihan Lokey for comments.
7	8/7/2020	Bromberg, Brian	0.9	Review Debtor-provided information on historical OxyContin figures.
7	8/7/2020	Bromberg, Brian	0.8	Review Debtors' updated OxyContin forecasts.
7	8/7/2020	Suric, Emil	1.1	Perform research to prepare internal OxyContin forecast analysis.
7	8/7/2020	Suric, Emil	1.9	Conduct preliminary OxyContin scenario based modeling.
7	8/7/2020	Suric, Emil	0.9	Review dataroom for documents re: OxyContin forecast modeling support.
7	8/9/2020	Diaz, Matthew	0.8	Review responses and related due diligence on the business plan update.
7	8/9/2020	Bromberg, Brian	0.7	Review historical financial information for Rhodes Pharma.
7	8/9/2020	Bromberg, Brian	0.5	Finalize PEO information list on business update presentation.
7	8/9/2020	Bromberg, Brian	1.8	Review newly uploaded dataroom documents re: product liability and bridges.
7	8/10/2020	Diaz, Matthew	0.5	Participate in call with Alix/PJT to discuss the liability reserves.
7	8/10/2020	Diaz, Matthew	0.8	Review the updated litigation costs estimates associated with the opioid business.
7	8/10/2020	Kim, Ye Darm	0.9	Process revisions to business update presentation re: royalty percentage updates.
7	8/10/2020	Kim, Ye Darm	1.2	Review historical financial files for product level actual results.
7	8/10/2020	Kim, Ye Darm	0.8	Prepare slide re: overview of expected go-forward liability assumptions.
7	8/10/2020	Kim, Ye Darm	1.1	Process revisions to domestic business update presentation per internal comments.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	8/10/2020	Kurtz, Emma	0.9	Discuss internally re: business plan update and additional information to share.
7	8/10/2020	Bromberg, Brian	1.2	Review comments and process revisions to slides re: domestic business updates.
7	8/10/2020	Bromberg, Brian	1.2	Continue review and processing revisions to business update slides.
7	8/10/2020	Bromberg, Brian	0.7	Participate in discussion with team re: new domestic data from the Debtors.
7	8/10/2020	Bromberg, Brian	0.5	Review dataroom for updated sales information from the Debtors.
7	8/10/2020	Bromberg, Brian	1.0	Discuss business update presentation with Houlihan.
7	8/10/2020	Bromberg, Brian	2.8	Review and distribute draft business update slides to Counsel.
7	8/10/2020	Bromberg, Brian	0.5	Participate in discussion re: future product liabilities with Debtor advisors.
7	8/10/2020	Bromberg, Brian	0.5	Screen additional information included in business update slides for PEO information.
7	8/10/2020	Suric, Emil	1.5	Review dataroom for data on OxyContin and related research on competing products.
7	8/11/2020	Nichols, David	0.9	Perform assessment of Purdue's insurance coverage re: go-forward product liabilities.
7	8/11/2020	Diaz, Matthew	0.9	Review Purdue's go forward product liability insurance needs.
7	8/11/2020	Kim, Ye Darm	1.3	Process updates to business update presentation per internal comments.
7	8/11/2020	Bromberg, Brian	0.4	Clarify PEO/protective order issues for Counsel.
7	8/11/2020	Bromberg, Brian	0.9	Finalize business update presentation and distribute to Counsel.
7	8/11/2020	Bromberg, Brian	0.7	Incorporate revisions to business plan presentation.
7	8/11/2020	Bromberg, Brian	0.7	Discuss go-forward product liability insurance needs for Purdue with team.
7	8/12/2020	Kim, Ye Darm	1.2	Prepare revisions to the business update presentation per internal comments.
7	8/12/2020	Bromberg, Brian	0.7	Revise presentation for the Ad Hoc Committee update.
7	8/12/2020	Bromberg, Brian	0.6	Review new product price data provided in dataroom.
7	8/12/2020	Bromberg, Brian	0.5	Participate in advisors call to coordinate presentation for AHC meeting.
7	8/13/2020	Bromberg, Brian	1.2	Review internal OxyContin forecast analysis and compare with Debtors' forecasts.
7	8/13/2020	Suric, Emil	2.2	Provide preliminary sensitivity forecasts of OxyContin to restructuring team and share follow up questions to Management on their assumptions in their base and upside case scenarios.
7	8/14/2020	Nichols, David	0.9	Participate in call re: analysis of Purdue's go-forward insurance options.
7	8/14/2020	Diaz, Matthew	0.5	Participate in a call with the Debtors to discuss their go forward insurance needs.
7	8/14/2020	Diaz, Matthew	0.9	Review the Company's historical insurance needs/assets in connection with reviewing go forward insurance practices.
7	8/14/2020	Bromberg, Brian	0.7	Participate in a call with the Debtors re: go forward insurance needs.
7	8/14/2020	Bromberg, Brian	1.2	Discuss and coordinate OxyContin forecast review with UCC Advisors.
7	8/14/2020	Bromberg, Brian	0.7	Discuss workplan for insurance diligence and transfers report.
7	8/14/2020	Suric, Emil	0.7	Review dataroom for information provided on Hysingla and Butrans for discussions with FTI team to share question list with management and to set up a call.
7	8/16/2020	Nichols, David	0.3	Participate in call with broker regarding product liability coverage.
7	8/17/2020	Bromberg, Brian	0.6	Finalize and send OxyContin forecast questions to Debtors.
7	8/18/2020	Kurtz, Emma	1.2	Prepare slides re: historical royalties payments between Purdue and the IACs and comparison to industry standards.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	8/19/2020	Nichols, David	0.5	Participate in call with broker re: product liability coverage.
7	8/19/2020	Suric, Emil	1.4	Participate in due diligence call with Debtors on OxyContin and update sensitivity scenarios.
7	8/21/2020	Kurtz, Emma	2.1	Review documents received from Counsel re: historical financial information regarding Purdue, IACs, and Sacklers to prepare summary for team.
7	8/21/2020	Bromberg, Brian	0.5	Continue review of internal OxyContin forecast analysis and compare with Debtors' forecasts.
7	8/21/2020	Bromberg, Brian	0.9	Review the Debtors' response to UCC letter.
7	8/21/2020	Suric, Emil	0.6	Include downside case in sensitivity analysis for OxyContin forecasts.
7	8/24/2020	Bromberg, Brian	0.5	Review updated OxyContin forecast presentation.
7	8/31/2020	Bromberg, Brian	0.6	Discuss workplan with team re: OxyContin forecast diligence and insurance diligence.
7	8/31/2020	Suric, Emil	2.8	Conduct statistical and regression analyses of Xtampza conversion rate and prepare summary of findings.
7	9/1/2020	Diaz, Matthew	1.3	Review open case items and prepare next steps on the business plan and the IAC workstreams.
7	9/1/2020	Bromberg, Brian	0.9	Follow up on outstanding business plan diligence items with Debtors.
7	9/1/2020	Bromberg, Brian	1.4	Discuss business plan diligence updates with team.
7	9/3/2020	Diaz, Matthew	0.5	Participate in a call with the Company to discuss the proposed Rhodes transaction.
7	9/3/2020	Diaz, Matthew	0.5	Review the updated analysis on the OxyContin forecast.
7	9/3/2020	Diaz, Matthew	0.7	Review the updated OxyContin forecast.
7	9/3/2020	Kim, Ye Darm	0.5	Participate in discussion re: FTI OxyContin forecast and differences from the Debtors forecast.
7	9/3/2020	Kim, Ye Darm	1.1	Review historical OxyContin forecast assumptions prior to call re: revised forecasts.
7	9/3/2020	Kurtz, Emma	0.5	Participate in discussion re: FTI OxyContin forecast and differences from the Debtors forecast.
7	9/3/2020	Bromberg, Brian	0.6	Participate in call with Debtors re: Rhodes Tech.
7	9/3/2020	Bromberg, Brian	0.6	Participate in discussion re: FTI OxyContin forecast and differences from the Debtors forecast.
7	9/3/2020	Suric, Emil	2.8	Prepare for and present on OxyContin due diligence and summary of findings.
7	9/10/2020	Bromberg, Brian	0.5	Review diligence documents re: proposed Rhodes transaction.
7	9/10/2020	Suric, Emil	0.5	Review IPD analytics report re: OxyContin forecasts.
7	9/11/2020	Diaz, Matthew	1.3	Review materials re: proposed Rhodes transaction.
7	9/12/2020	Diaz, Matthew	1.2	Review the proposed Rhodes transaction due diligence materials.
7	9/13/2020	Diaz, Matthew	0.6	Participate in a call with the Debtors and the UCC to discuss the Rhodes transaction.
7	9/18/2020	Bromberg, Brian	0.4	Prepare diligence requests for the updated Debtors' domestic business plan.
7	9/21/2020	Kim, Ye Darm	1.8	Review the Debtors' latest August business plan presentation.
7	9/21/2020	Bromberg, Brian	0.3	Follow up on outstanding business plan diligence items with Debtors.
7	9/21/2020	Bromberg, Brian	1.2	Review new domestic business plan files uploaded to dataroom.
7	9/21/2020	Suric, Emil	0.5	Review Management's responses to questions on OxyContin assumptions and summary to FTI team.
7	9/22/2020	Suric, Emil	0.5	Review IPD analytics report for OxyContin.
7	9/24/2020	Diaz, Matthew	1.3	Review the updated Purdue domestic business plan.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
7	9/25/2020	Bromberg, Brian	1.0	Participate in discussion re: OxyContin forecast with team.
7	9/25/2020	Bromberg, Brian	0.7	Follow up on outstanding business plan diligence items with Debtors and counsel.
7	9/25/2020	Suric, Emil	0.5	Review materials on OxyContin to prepare UCC presentation on sensitivities.
7	9/28/2020	Bromberg, Brian	0.5	Coordinate OxyContin forecast call with Debtors.
7	9/28/2020	Suric, Emil	2.9	Conduct OxyContin competitive landscape research.
7	9/28/2020	Suric, Emil	2.8	Prepare OyxContin sensitivity scenario summary and presentation.
7	9/28/2020	Suric, Emil	1.5	Process updates to OxyContin sensitivity Power Point presentation deliverable.
7	9/29/2020	Diaz, Matthew	1.3	Review the OxyContin sensitivity scenarios and related presentation materials.
7	9/29/2020	Kurtz, Emma	0.7	Participate in call re: OxyContin forecast and sensitivity analyses.
7	9/29/2020	Bromberg, Brian	0.7	Review source files for OxyContin forecast and sensitivity scenarios.
7	9/29/2020	Bromberg, Brian	0.5	Review OxyContin forecast slides.
7	9/29/2020	Bromberg, Brian	1.1	Review OxyContin forecast model.
7	9/29/2020	Bromberg, Brian	0.7	Participate in discussion re: OxyContin forecasts with team.
7	9/29/2020	Suric, Emil	2.2	Process additional updates to OxyContin deliverable based on internal discussion.
7	9/29/2020	Suric, Emil	0.8	Participate in internal discussion to prepare for presentation on OxyContin sensitivity analysis and deliverable review.
7	9/30/2020	Diaz, Matthew	0.6	Review the updated OxyContin forecast presentation to the Debtors.
7	9/30/2020	Bromberg, Brian	0.7	Finalize and transmit final OxyContin sensitivity presentation to Debtors.
7 Total			250.4	
8	6/18/2020	Diaz, Matthew	1.0	Review the Debtors' valuation analysis presentation.
8	6/22/2020	Diaz, Matthew	1.2	Participate in a call with the Committee and the Debtors' advisors to discuss PJT's valuation of the business.
8	6/22/2020	Diaz, Matthew	1.8	Review of the updated PJT valuation analysis.
8 Total			4.0	
9	9/4/2020	Diaz, Matthew	0.5	Participate in call with the Debtors re: the employee compensation plan.
9	9/4/2020	Diaz, Matthew	1.4	Review the proposed updates to the employee compensation plan.
9	9/4/2020	Kim, Ye Darm	0.6	Participate in call with the Debtors re: the employee compensation plan issues.
9	9/4/2020	Kim, Ye Darm	1.2	Review WTW presentation and prior diligence documents re: KEIP KERP and compensation plans.
9	9/4/2020	Kim, Ye Darm	0.5	Participate in internal discussion re: KEIP KERP diligence.
9	9/4/2020	Kim, Ye Darm	3.3	Prepare draft presentation re: KEIP KERP diligence overview.
9	9/4/2020	Kurtz, Emma	0.3	Participate in call re: Debtors' proposed 2020 KEIP and KERP plans.
9	9/4/2020	Bromberg, Brian	0.7	Participate in discussion re: KEIP and KERP with Debtors' counsel.
9	9/4/2020	Bromberg, Brian	1.0	Review KEIP and KERP diligence materials sent by Debtors.
9	9/4/2020	Bromberg, Brian	1.8	Continue review of KEIP and KERP information provided by Debtors.
9	9/4/2020	Bromberg, Brian	0.5	Participate in internal discussion re: KEIP and KERP with team.
9	9/4/2020	Bromberg, Brian	1.3	Continue review of KEIP and KERP diligence documents provided by Debtors.
9	9/5/2020	Bromberg, Brian	2.1	Review and process revisions to presentation on KEIP and KERP.
9	9/5/2020	Bromberg, Brian	3.7	Review supporting data provided for KEIP and KERP compensation figures.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
9	9/7/2020	Kim, Ye Darm	1.7	Process revisions to KEIP KERP diligence presentation.
9	9/7/2020	Kim, Ye Darm	2.3	Review Debtor provided KEIP KERP diligence materials.
9	9/7/2020	Bromberg, Brian	0.4	Review latest presentation on KERP KEIP diligence.
9	9/7/2020	Bromberg, Brian	0.5	Correspond with Debtors on KEIP KERP issues.
9	9/8/2020	Diaz, Matthew	1.4	Review the proposed employee compensation programs re: KEIP KERP.
9	9/8/2020	Diaz, Matthew	1.1	Review the latest presentation on the employee compensation plans diligence re: KEIP KERP.
9	9/8/2020	Kim, Ye Darm	1.8	Process updates to KEIP KERP diligence presentation.
9	9/8/2020	Kim, Ye Darm	1.6	Review historical compensation plans for comparable analyses.
9	9/8/2020	Kim, Ye Darm	0.6	Participate in internal meeting re: KEIP/KERP diligence presentation.
9	9/8/2020	Kim, Ye Darm	2.3	Prepare updated format for KEIP KERP diligence presentation.
9	9/8/2020	Kurtz, Emma	1.0	Participate in call with Debtors to discuss proposed KEIP/KERP plans for 2020.
9	9/8/2020	Bromberg, Brian	1.4	Prepare for call with Debtors on KEIP KERP support files.
9	9/8/2020	Bromberg, Brian	0.8	Participate in discussion re: KEIP KERP deck with team.
9	9/8/2020	Bromberg, Brian	1.8	Review latest presentation on KERP KEIP diligence.
9	9/8/2020	Bromberg, Brian	1.3	Compile question list for Debtors on KEIP KERP issues.
9	9/8/2020	Bromberg, Brian	0.7	Participate in call with Debtors on KERP KEIP plans.
9	9/8/2020	Bromberg, Brian	0.8	Review newly provided answers and support files on KEIP KERP plans.
9	9/9/2020	Diaz, Matthew	1.9	Review the updated employee compensation comparable analysis.
9	9/9/2020	Kim, Ye Darm	2.4	Prepare updates to the KEIP KERP diligence analysis and prepare responses to questions.
9	9/9/2020	Kim, Ye Darm	2.2	Process revisions to KEIP KERP diligence presentation per internal comments.
9	9/9/2020	Bromberg, Brian	1.7	Review updates and provide revisions to presentation on KEIP KERP diligence.
9	9/9/2020	Bromberg, Brian	2.1	Review KEIP and KERP presentation and supporting documents sent by Debtors.
9	9/10/2020	Diaz, Matthew	0.7	Review the UCC's presentation on the employee incentive plans.
9	9/10/2020	Diaz, Matthew	1.0	Participate in call with the UCC's professionals to discuss their opinion on the employee incentive plans.
9	9/10/2020	Diaz, Matthew	2.4	Review the employee compensation plan motion re: KEIP KERP.
9	9/10/2020	Kim, Ye Darm	0.5	Participate in internal discussion re: KEIP KERP diligence analysis.
9	9/10/2020	Kim, Ye Darm	1.5	Process revisions to KEIP KERP diligence presentation.
9	9/10/2020	Bromberg, Brian	0.7	Review UCC presentation on wages diligence re: KEIP KERP.
9	9/10/2020	Bromberg, Brian	0.6	Conduct analysis on wages files provided by Debtors re: KEIP KERP Diligence.
9	9/10/2020	Bromberg, Brian	1.1	Participate in call with UCC advisors on KEIP KERP motion.
9	9/10/2020	Bromberg, Brian	0.8	Review latest changes to presentation re: KEIP KERP diligence.
9	9/10/2020	Bromberg, Brian	0.6	Discuss KEIP KERP motion and related issues with Counsel.
9	9/10/2020	Bromberg, Brian	1.4	Review Debtor responses to KEIP KERP diligence question list.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
9	9/11/2020	Diaz, Matthew	2.1	Review of the updated employee comp analysis re: KEIP KERP diligence.
9	9/11/2020	Kim, Ye Darm	2.3	Review KEIP KERP motion and update latest diligence presentation.
9	9/11/2020	Kim, Ye Darm	1.2	Review the UCC's KEIP KERP diligence analysis.
9	9/11/2020	Kim, Ye Darm	0.5	Participate on internal call re: KEIP KERP diligence analysis.
9	9/11/2020	Kim, Ye Darm	0.6	Participate in call with UCC re: UCC analysis of KEIP KERP.
9	9/11/2020	Kim, Ye Darm	3.4	Prepare additional analysis and revisions to the KEIP KERP Diligence presentation.
9	9/11/2020	Bromberg, Brian	0.8	Review comparable KERP KEIP motions for comparison of terms.
9	9/11/2020	Bromberg, Brian	1.3	Participate on internal call re: KEIP KERP diligence analysis.
9	9/11/2020	Bromberg, Brian	2.4	Revise and process updates to KEIP KERP presentation based on commentary.
9	9/11/2020	Bromberg, Brian	2.3	Review KEIP KERP motion and prepare diligence questions for Debtors.
9	9/11/2020	Bromberg, Brian	0.5	Discuss KEIP KERP motion diligence with UCC advisors.
9	9/12/2020	Bromberg, Brian	1.7	Revise and process updates to KEIP KERP presentation based on internal comments.
9	9/13/2020	Diaz, Matthew	0.9	Participate in a call with the UCC and the Non Debtor states to discuss the proposed KEIP KERP plans.
9	9/13/2020	Diaz, Matthew	0.7	Review of the KERP recommendations and related analysis.
9	9/13/2020	Bromberg, Brian	0.6	Participate in call with UCC advisors and Debtors on KEIP KERP diligence.
9	9/13/2020	Bromberg, Brian	1.0	Review KEIP KERP analysis calculations and performance metrics.
9	9/14/2020	Diaz, Matthew	2.5	Review the updated KEIP KERP comp diligence presentation.
9	9/14/2020	Diaz, Matthew	1.2	Review Willis Towers Watson KEIP KERP benchmarking analysis.
9	9/14/2020	Kim, Ye Darm	1.8	Review UCC analysis of KEIP KERP awards and create analysis of comp calculations.
9	9/14/2020	Kim, Ye Darm	2.2	Process revisions to the KEIP KERP presentation per internal discussion.
9	9/14/2020	Kim, Ye Darm	0.9	Update KEIP KERP presentation to reflect counterproposals.
9	9/14/2020	Kim, Ye Darm	1.0	Participate in call re: revisions to the KEIP KERP diligence presentation.
9	9/14/2020	Kim, Ye Darm	1.9	Process revisions to KEIP KERP diligence presentation.
9	9/14/2020	Kim, Ye Darm	0.9	Process additional revisions to KEIP KERP diligence presentation.
9	9/14/2020	Kim, Ye Darm	1.2	Process additional revisions to KEIP KERP diligence presentation per latest comments.
9	9/14/2020	Bromberg, Brian	2.2	Review and process updates to KEIP KERP presentation based on discussion.
9	9/14/2020	Bromberg, Brian	1.3	Participate in discussion re: KEIP KERP diligence with internal team.
9	9/14/2020	Bromberg, Brian	1.2	Review KEIP KERP supporting diligence materials.
9	9/14/2020	Bromberg, Brian	0.9	Review updated KEIP KERP proposal presentation.
9	9/14/2020	Bromberg, Brian	2.5	Review and incorporate UCC KEIP KERP proposal into presentation.
9	9/14/2020	Bromberg, Brian	1.6	Process revisions to KEIP KERP diligence presentation.
9	9/15/2020	Diaz, Matthew	0.8	Participate in call with counsel to discuss the proposed employee compensation plans and related recommendations.
9	9/15/2020	Diaz, Matthew	1.6	Perform detailed review and provide revisions for the updated presentation on the KEIP and KERP plans.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
9	9/15/2020	Diaz, Matthew	1.9	Perform review of the updated KEIP and KERP plans.
9	9/15/2020	Kim, Ye Darm	2.3	Process updates to KEIP KERP diligence presentation per advisor call.
9	9/15/2020	Kim, Ye Darm	1.0	Participate in discussion with AHC advisors re: KEIP KERP diligence.
9	9/15/2020	Kim, Ye Darm	1.6	Process revisions to the KEIP KERP diligence presentation.
9	9/15/2020	Kim, Ye Darm	0.9	Continue processing revisions to the KEIP KERP diligence presentation.
9	9/15/2020	Kim, Ye Darm	1.1	Review prior year's wage settlement impact to compare with current proposal.
9	9/15/2020	Kim, Ye Darm	0.9	Participate in internal discussion re: KEIP KERP presentation updates per call with advisors.
9	9/15/2020	Kim, Ye Darm	0.3	Participate in internal discussion re: KEIP KERP diligence next steps.
9	9/15/2020	Bromberg, Brian	2.3	Review and provide revisions to KEIP KERP presentation based on latest discussions.
9	9/15/2020	Bromberg, Brian	0.6	Finalize draft KEIP KERP presentation to send to Counsel for discussion.
9	9/15/2020	Bromberg, Brian	0.8	Participate in discussion re: KEIP KERP proposal with Counsel.
9	9/15/2020	Bromberg, Brian	1.0	Discuss KEIP KERP proposal with internal team after discussion with Counsel.
9	9/15/2020	Bromberg, Brian	1.0	Prepare KEIP KERP diligence questions for Debtors.
9	9/16/2020	Diaz, Matthew	0.8	Participate in a call with the AHC professionals to discuss recommendations to the KEIP KERP compensation plans.
9	9/16/2020	Diaz, Matthew	0.6	Participate in a call with the UCC's financial advisors to discuss the proposed KEIP KERP compensation plans.
9	9/16/2020	Diaz, Matthew	1.5	Finalize written materials for the AHC on the proposed KEIP KERP compensation plans.
9	9/16/2020	Kim, Ye Darm	0.8	Process revisions to the KEIP KERP presentation.
9	9/16/2020	Kim, Ye Darm	0.6	Continue processing revisions to the KEIP KERP presentation.
9	9/16/2020	Kim, Ye Darm	0.5	Participate in internal call re: KEIP KERP diligence presentation.
9	9/16/2020	Kim, Ye Darm	2.1	Perform detailed QC of KEIP KERP diligence presentation.
9	9/16/2020	Kim, Ye Darm	0.7	Participate in discussion re: updates to KEIP KERP deck per UCC comments.
9	9/16/2020	Kim, Ye Darm	0.5	Participate in call with AHC advisors re: KEIP KERP presentation.
9	9/16/2020	Bromberg, Brian	2.0	Review newly provided files by Debtors on KEIP KERP diligence.
9	9/16/2020	Bromberg, Brian	2.1	Finalize presentation on KEIP KERP for Committee Call.
9	9/16/2020	Bromberg, Brian	0.7	Discuss KEIP KERP proposal with UCC advisors.
9	9/16/2020	Bromberg, Brian	1.8	Perform detailed QC of KEIP KERP diligence presentation.
9	9/16/2020	Bromberg, Brian	0.7	Discuss diligence questions with Debtors on KEIP and KERP.
9	9/17/2020	Diaz, Matthew	0.3	Draft recommendations to the proposed KEIP KERP compensation plans.
9	9/17/2020	Diaz, Matthew	0.3	Participate in a call with counsel to discuss the AHC recommendations to the proposed employee compensation plans.
9	9/17/2020	Kim, Ye Darm	0.3	Process minor revisions to KEIP KERP presentation before distribution to Counsel.
9	9/17/2020	Bromberg, Brian	0.5	Review latest version of presentation on KEIP KERP diligence.
9	9/18/2020	Diaz, Matthew	0.6	Coordinate and revise proposed joint creditor "ask" re changes to the Debtors' proposed employee compensation plans.
9	9/22/2020	Bromberg, Brian	0.4	Review the latest KERP proposal detail.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
9	9/24/2020	Diaz, Matthew	0.8	Participate in a call with key creditor professionals to discuss a coordinate response to the Debtors' propose KEIP/KERP motion.
9	9/24/2020	Diaz, Matthew	0.4	Review of the updated KEIP/KERP proposal.
9	9/24/2020	Diaz, Matthew	0.7	Review the UCC's draft KERP/KEIP objection.
9	9/24/2020	Kim, Ye Darm	0.7	Review UCC draft pleading re: KEIP KERP proposal.
9	9/25/2020	Diaz, Matthew	0.4	Review correspondence on revisions to the proposed KEIP KERP settlements.
9	9/28/2020	Kim, Ye Darm	0.9	Review Counsel's update re: KEIP KERP negotiations, mediation, and injunction extension.
9 Total			147.4	
10	6/4/2020	Joffe, Steven	0.5	Call with Brown Rudnick and Kramer regarding current tax matters.
10	6/4/2020	Joffe, Steven	0.5	Review prior rulings on qualified settlement funds.
10	6/4/2020	Bromberg, Brian	0.6	Participate in weekly tax call with Counsel.
10	6/11/2020	Joffe, Steven	0.4	Call with Brown Rudnick and Kramer regarding current tax matters.
10	6/11/2020	Bromberg, Brian	0.5	Participate in weekly tax call with Counsel.
10	6/12/2020	Joffe, Steven	0.6	Review KPMG presentation on tax considerations.
10	6/12/2020	Joffe, Steven	0.9	Participate on call with KPMG to review model.
10	6/12/2020	Bromberg, Brian	0.9	Participate in call with KPMG re: tax considerations.
10	6/13/2020	Diaz, Matthew	0.6	Review updated IAC tax analysis.
10	6/15/2020	Joffe, Steven	0.3	Review KPMG presentation on tax considerations.
10	6/17/2020	Joffe, Steven	1.2	Review proposed regulations regarding restitution.
10	6/18/2020	Joffe, Steven	0.6	Participate in call with Counsel re: tax considerations.
10	6/18/2020	Bromberg, Brian	0.5	Participate in weekly tax call with Counsel.
10	6/23/2020	Joffe, Steven	0.3	Review presentation to Creditors re: tax considerations.
10	6/24/2020	Joffe, Steven	0.3	Review recovery comparison presentation re: tax considerations.
10	6/29/2020	Joffe, Steven	0.7	Participate in call with Counsel re: tax considerations.
10	6/29/2020	Bromberg, Brian	0.5	Participate in weekly tax call with Counsel.
10	7/2/2020	Joffe, Steven	0.5	Review of PJT deck on go-forward scenarios for potential tax impacts.
10	7/9/2020	Joffe, Steven	0.6	Participate in call with DPW, KL, BR re: PBC structure.
10	7/10/2020	Joffe, Steven	0.3	Review of internal summary of DPW call re: potential tax issues.
10	7/15/2020	Bromberg, Brian	0.3	Review CARES act tax refund impact on Purdue.
10	7/15/2020	Diaz, Matthew	0.5	Review of the CARES legislation impact on tax refunds.
10	7/22/2020	Joffe, Steven	1.4	Participate on AHC call re: values of different go-forward scenarios.
10	8/6/2020	Joffe, Steven	0.5	Participate in discussion with internal team re: restitution.
10	8/6/2020	Joffe, Steven	1.5	Review NYSBA report on restitution for discussion purposes.
10	8/6/2020	Diaz, Matthew	0.5	Analyze tax consequences associated with the proposed settlement.
10	8/6/2020	Bromberg, Brian	0.7	Participate in discussion re: tax implications of IAC sale with internal team.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
10	8/13/2020	Joffe, Steven	0.7	Participate in call with Kramer and Brown Rudnick re: tax considerations.
10	8/13/2020	Joffe, Steven	0.7	Participate in call with Davis Polk re: tax considerations.
10	8/13/2020	Bromberg, Brian	0.5	Participate in call with Kramer and Brown Rudnick re: tax considerations.
10	8/27/2020	Joffe, Steven	1.0	Call with Brown Rudnick and Kramer regarding tax considerations.
10	9/3/2020	Bromberg, Brian	0.6	Participate in discussion with Counsel re: tax structure charts.
10	9/4/2020	Bromberg, Brian	0.5	Review tax structure charts sent by Counsel.
10	9/8/2020	Joffe, Steven	2.0	Perform review of latest tax issue documents from Counsel.
10	9/8/2020	Joffe, Steven	0.9	Participate in discussion with Counsel re: latest tax issue documents.
10	9/8/2020	Bromberg, Brian	0.4	Prepare summary of cash flow projections for tax group.
10	9/8/2020	Bromberg, Brian	0.5	Review tax structuring diagrams presentation.
10	9/8/2020	Bromberg, Brian	0.5	Participate in tax call on post emergence structure.
10	9/9/2020	Joffe, Steven	1.0	Review presentations on tax structuring diagrams and post-emergence structure.
10	9/9/2020	Bromberg, Brian	0.5	Discuss tax considerations on distributable value with team.
10	9/10/2020	Joffe, Steven	0.4	Participate in tax call on post emergence structure.
10	9/10/2020	Bromberg, Brian	0.4	Participate in tax call on post emergence structure.
10	9/17/2020	Joffe, Steven	0.8	Participate in weekly tax call with Counsel.
10	9/17/2020	Bromberg, Brian	0.6	Participate in weekly tax call with Counsel.
10	9/18/2020	Joffe, Steven	0.6	Participate in discussion with team regarding tax stakes in setting up trusts.
10	9/18/2020	Diaz, Matthew	0.5	Review go-forward tax structuring issues.
10	9/18/2020	Kim, Ye Darm	0.9	Update sale proceeds/operational cash flow tax impact analysis.
10	9/18/2020	Kim, Ye Darm	1.5	Prepare tax impact analysis of sale proceeds and operational cash flow.
10	9/18/2020	Kim, Ye Darm	0.8	Process updates to sale proceeds/operational cash flow tax impact analysis.
10	9/18/2020	Kim, Ye Darm	1.0	Update tax impact analysis for untaxed cash flow assumptions.
10	9/18/2020	Kim, Ye Darm	1.1	Process updates to the tax impact analysis for new assumptions.
10	9/18/2020	Bromberg, Brian	0.9	Revise tax impact analysis for new assumptions.
10	9/18/2020	Bromberg, Brian	1.4	Work on creating draft tax impact analysis slide.
10	9/18/2020	Bromberg, Brian	0.6	Discuss trust structure analysis slides with internal team.
10	9/18/2020	Bromberg, Brian	1.3	Review updates and changes to tax impact analysis.
10	9/19/2020	Bromberg, Brian	2.0	Continue reviewing updates and changes to tax impact analysis.
10	9/21/2020	Joffe, Steven	0.5	Participate in discusison with team regarding numerical example of tax breakage on distributions to QSF.
10	9/21/2020	Diaz, Matthew	1.1	Review the trust tax analysis and related presentation to the AHC counsel.
10	9/21/2020	Kim, Ye Darm	0.6	Participate in discussion re: tax impact analysis.
10	9/21/2020	Kim, Ye Darm	1.3	Process revisions to the tax impact analysis per internal discussion.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
10	9/21/2020	Bromberg, Brian	0.5	Process revisions and changes to tax impact analysis slide and send to Counsel.
10	9/21/2020	Bromberg, Brian	0.5	Review the trust tax analysis and related slide.
10	9/21/2020	Bromberg, Brian	1.0	Participate in discussion re: tax impact analysis.
10	9/22/2020	Joffe, Steven	0.6	Review of revised tax impact analysis slide and supporting analysis.
10	9/22/2020	Diaz, Matthew	0.5	Review the updated trust tax analysis and related presentation slide.
10	9/22/2020	Kim, Ye Darm	0.6	Participate in internal discussion re: tax impact analysis.
10	9/22/2020	Kim, Ye Darm	0.3	Process revisions to the tax impact analysis slide.
10	9/22/2020	Kim, Ye Darm	0.7	Continue processing revisions to the tax impact analysis slide.
10	9/22/2020	Bromberg, Brian	0.6	Participate in internal discussion re: tax impact analysis.
10	9/22/2020	Bromberg, Brian	1.2	Review updates and revisions to tax impact analysis slides.
10	9/23/2020	Joffe, Steven	0.6	Review presentation from Counsel re: tax issues.
10	9/23/2020	Joffe, Steven	0.8	Participate in weekly Committee call re: tax issues.
10	9/23/2020	Bromberg, Brian	1.1	Review distributable value analysis to process updates to tax impact analysis slide.
10	9/25/2020	Bromberg, Brian	0.3	Review tax commentary re: meeting with Davis Polk.
10	9/30/2020	Joffe, Steven	1.2	Participate in conference call with DPW re: tax impact issues.
10 Total			55.3	
11	6/23/2020	Kim, Ye Darm	1.6	Participate telephonically in the Omnibus hearing.
11	6/23/2020	Kim, Ye Darm	0.9	Draft summary of omnibus hearing for distribution to internal team.
11 Total			2.5	
13	6/24/2020	Kim, Ye Darm	0.6	Review Counsel's summary re: omnibus hearing and UCC discovery stipulation.
13 Total			0.6	
16	6/1/2020	Kim, Ye Darm	0.6	Participate in diligence meeting with Counsel and HL re: 1B Report.
16	6/8/2020	Kim, Ye Darm	0.6	Participate in internal meeting re: available distributable value.
16	6/8/2020	Bromberg, Brian	1.0	Discuss distributable value analysis with Houlihan.
16	6/8/2020	Bromberg, Brian	2.5	Prepare analysis re: distributable value over time.
16	6/8/2020	Bromberg, Brian	0.5	Discuss distributable value analysis with team.
16	6/8/2020	Bromberg, Brian	2.7	Edit distributable value analysis based based on internal discussions.
16	6/8/2020	Diaz, Matthew	1.0	Participate in a call with KL to discuss the recovery analysis.
16	6/8/2020	Diaz, Matthew	1.8	Develop and review draft distributable value analysis.
16	6/8/2020	Diaz, Matthew	0.8	Participate in a call with HL to discuss the distributable value analysis.
16	6/11/2020	Bromberg, Brian	0.8	Compile diligence questions on distributable value presentation.
16	6/11/2020	Diaz, Matthew	0.6	Review outline of Purdue waterfall analysis.
16	6/12/2020	Kim, Ye Darm	0.9	Review latest sale considerations presentation by PJT.
16	6/14/2020	Bromberg, Brian	1.0	Review questions on distributable value and send to Houlihan for discussion.
16	6/15/2020	Bromberg, Brian	0.9	Review latest distributable value analysis and prepare question list to Debtors' advisors.
16	6/15/2020	Diaz, Matthew	1.7	Review the updated PJT valuation presentation re: sale considerations.
16	6/15/2020	Diaz, Matthew	1.2	Review the updated waterfall analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	6/17/2020	Bromberg, Brian	1.2	Review latest draft of distributable value analysis.
16	6/17/2020	Diaz, Matthew	1.2	Review the waterfall analysis.
16	6/18/2020	Kim, Ye Darm	0.5	Participate in call re: illustrative distributable value.
16	6/18/2020	Bromberg, Brian	1.3	Edit distributable value presentation based on internal comments.
16	6/18/2020	Bromberg, Brian	0.8	Discuss distributable value presentation with counsel.
16	6/18/2020	Bromberg, Brian	1.5	Edit distributable value analysis based on conversations with team.
16	6/18/2020	Bromberg, Brian	2.2	Prepare additional slides re: distributable value presentation.
16	6/18/2020	Bromberg, Brian	0.3	Request Non-PEO version of information re: distributable value analysis.
16	6/18/2020	Bromberg, Brian	1.2	Process revisions to distributable value presentation.
16	6/18/2020	Bromberg, Brian	0.8	Edit distributable value presentation based on discussions with counsel.
16	6/18/2020	Diaz, Matthew	0.9	Review the presentation to the committee on the waterfall analysis.
16	6/18/2020	Diaz, Matthew	1.2	Review the updated waterfall analysis.
16	6/19/2020	Kim, Ye Darm	0.9	Review latest draft of illustrative distributable value analysis.
16	6/19/2020	Bromberg, Brian	1.5	Edit distributable value presentation based on internal comments.
16	6/19/2020	Bromberg, Brian	0.9	Continue to revise distributable value presentation based on internal comments.
16	6/19/2020	Diaz, Matthew	1.2	Review the updated waterfall analysis report to the AHC.
16	6/20/2020	Bromberg, Brian	0.5	Prepare responses to questions on distributable value analysis.
16	6/21/2020	Diaz, Matthew	1.5	Finalize the waterfall recovery analysis.
16	6/22/2020	Kim, Ye Darm	0.6	Process updates to comparison of nominal and sale value comparison analysis.
16	6/22/2020	Kim, Ye Darm	0.5	Participate in call re: illustrative distributable value.
16	6/22/2020	Kim, Ye Darm	1.8	Prepare comparison of nominal and sale values for distributable value analysis.
16	6/22/2020	Bromberg, Brian	0.5	Participate in discussion re: distributable value analysis with Houlihan.
16	6/22/2020	Bromberg, Brian	2.2	Process revisions to distributable value analysis presentation.
16	6/22/2020	Bromberg, Brian	0.8	Discuss tax considerations re: distributable value analysis.
16	6/22/2020	Bromberg, Brian	2.2	Revise distributable value analysis based on internal discussions.
16	6/22/2020	Bromberg, Brian	0.5	Participate in distributable value analysis with internal team.
16	6/22/2020	Bromberg, Brian	2.3	Continue to revise distributable value analysis.
16	6/22/2020	Bromberg, Brian	1.0	Participate in meeting with Debtors re: valuation considerations.
16	6/22/2020	Bromberg, Brian	2.5	Process revisions to distributable value analysis for updates from Debtors' presentation.
16	6/22/2020	Bromberg, Brian	2.5	Discount valuation cash flows per distributable value analysis.
16	6/22/2020	Diaz, Matthew	1.6	Review the updated recovery analysis presentation.
16	6/22/2020	Kim, Ye Darm	1.1	Participate in call re: distributable value PJT analysis.
16	6/23/2020	Kim, Ye Darm	0.4	Review discounted PBC scenario analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	6/23/2020	Bromberg, Brian	1.9	Prepare revisions to value waterfall model.
16	6/23/2020	Bromberg, Brian	1.8	Revise presentation on total value based on conversation with internal team.
16	6/23/2020	Bromberg, Brian	0.8	Continue to revise presentation on total value based on conversation with team.
16	6/23/2020	Bromberg, Brian	1.0	Discuss distributable value with internal team.
16	6/23/2020	Bromberg, Brian	0.6	Participate in discussion re: distributable value with Houlihan.
16	6/23/2020	Bromberg, Brian	2.5	Review and revise distributable value presentation based on counsel's comments.
16	6/23/2020	Diaz, Matthew	2.4	Review the Debtors' presentation re: valuation analysis.
16	6/23/2020	Diaz, Matthew	2.5	Review the updated recovery analysis.
16	6/24/2020	Kim, Ye Darm	0.6	Participate in call re: illustrative distributable value.
16	6/24/2020	Bromberg, Brian	0.7	Participate in discussion re: distributable value with counsel.
16	6/24/2020	Bromberg, Brian	1.2	Finalize distributable value presentation draft for meeting with Committee.
16	6/24/2020	Bromberg, Brian	1.5	Participate in AHC call re: distributable value.
16	6/24/2020	Diaz, Matthew	1.2	Finalize the Purdue waterfall analysis for the report to the Committee.
16	6/25/2020	Bromberg, Brian	0.4	Discuss distributable value analysis with Debtor advisors.
16	6/30/2020	Kim, Ye Darm	2.2	Prepare shorter presentation for distributable value.
16	6/30/2020	Bromberg, Brian	0.7	Review condensed distributable value presentation.
16	6/30/2020	Bromberg, Brian	0.3	Discuss updates on distributable value analysis with internal team.
16	6/30/2020	Diaz, Matthew	0.7	Review presentation re: domestic business diligence to the tribal group.
16	7/1/2020	Bromberg, Brian	0.6	Review distributable value presentation for call with tribes.
16	7/3/2020	Diaz, Matthew	1.8	Review the updated waterfall/distributable value analysis.
16	7/6/2020	Bromberg, Brian	3.7	Create new distributable value scenario from opioid only model.
16	7/6/2020	Bromberg, Brian	1.7	Participate in call with UCC and NCSG on distributable value.
16	7/6/2020	Bromberg, Brian	0.5	Review distributable value presentation for PEO issues.
16	7/6/2020	Bromberg, Brian	0.8	Update distributable value presentation based on comments.
16	7/6/2020	Bromberg, Brian	0.7	Discuss distributable value presentation with counsel.
16	7/6/2020	Bromberg, Brian	1.5	Participate in call with NCSG on distributable value.
16	7/6/2020	Diaz, Matthew	2.4	Review the recovery sensitivity scenarios re: waterfall/distributable value .
16	7/6/2020	Diaz, Matthew	2.1	Review of the updated distributable value/waterfall analysis.
16	7/6/2020	Kim, Ye Darm	1.9	Prepare analysis of potential fee expense to estate for professional fee burn analysis.
16	7/7/2020	Kim, Ye Darm	0.8	Process additional updates re: distributable value analysis.
16	7/7/2020	Kim, Ye Darm	1.6	Update presentation slides re: distributable value analysis.
16	7/7/2020	Kim, Ye Darm	1.1	Process revisions to distributable value presentation re: LOE 2027 scenario.
16	7/7/2020	Kim, Ye Darm	0.6	Participate in call re: distributable value analysis scenarios.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	7/7/2020	Kim, Ye Darm	1.8	Prepare model for distributable value analysis presentation.
16	7/7/2020	Kim, Ye Darm	0.9	Review financial information for updated distributable value analysis.
16	7/7/2020	Kim, Ye Darm	0.5	Participate in discussion re: distributable value analysis presentation.
16	7/7/2020	Bromberg, Brian	1.5	Discuss new distributable value presentation with team.
16	7/7/2020	Bromberg, Brian	1.7	Review revisions to opioid only scenario.
16	7/7/2020	Bromberg, Brian	2.8	Create slides for new scenario on distributable value.
16	7/7/2020	Bromberg, Brian	3.0	Finalize draft of revised distributable value presentation.
16	7/7/2020	Kim, Ye Darm	1.1	Update professional fee burn analysis per Counsel's revisions.
16	7/8/2020	Kim, Ye Darm	1.1	Update distributable value analysis presentation for OyxContin sales scenarios.
16	7/8/2020	Kim, Ye Darm	0.4	Process revisions to distributable value analysis presentation.
16	7/8/2020	Kim, Ye Darm	2.3	Update distributable value analysis re: OxyContin sale scenarios.
16	7/8/2020	Kim, Ye Darm	1.0	Participate in call with PJT re: delayed bankruptcy scenario.
16	7/8/2020	Kim, Ye Darm	0.9	Review OxyContin sale scenarios for distributable value analysis.
16	7/8/2020	Diaz, Matthew	0.8	Participate on a call with the UCC to discuss the waterfall/distributable value analysis.
16	7/8/2020	Diaz, Matthew	1.3	Review the updated waterfall/distributable value analysis.
16	7/8/2020	Kim, Ye Darm	0.5	Process revisions to professional fee burn rate analysis.
16	7/9/2020	Bromberg, Brian	1.4	Prepare summary of cash projection findings for distributable value.
16	7/9/2020	Bromberg, Brian	0.8	Prepare for call on Debtors' cash projections for distributable value.
16	7/9/2020	Bromberg, Brian	0.5	Discuss Debtors' cash projections for distributable value with internal team.
16	7/9/2020	Bromberg, Brian	0.5	Prepare for internal team discussion on cash projections for distributable value.
16	7/9/2020	Bromberg, Brian	0.9	Participate in discussion re: cash projections with Debtor advisors for distributable value.
16	7/9/2020	Kim, Ye Darm	0.6	Participate in discussion with Debtors re: PPLP forecast assumptions.
16	7/9/2020	Kim, Ye Darm	2.3	Update model for additional cash flow assumptions re: distributable value analysis.
16	7/9/2020	Kim, Ye Darm	0.9	Review call notes re: cash call with Alix/PJT for distributable value.
16	7/9/2020	Kim, Ye Darm	1.9	Update model for operating cash flows and PBC scenario re: distributable value analysis.
16	7/9/2020	Kim, Ye Darm	0.8	Process revisions to presentation to injury claimants re: distributable value.
16	7/9/2020	Kim, Ye Darm	0.5	Participate in cash forecasts re: distributable value analysis.
16	7/9/2020	Bromberg, Brian	0.5	Participate in call with personal injury claimants on distributable value.
16	7/9/2020	Bromberg, Brian	2.8	Work on additional scenarios for the distributable value analysis.
16	7/9/2020	Diaz, Matthew	1.5	Review the updated waterfall/distributable value and related sensitivities.
16	7/9/2020	Simms, Steven	0.3	Review latest draft of distributable value recovery presentation.
16	7/9/2020	Simms, Steven	0.9	Participate on call with claimants re: distributable value recovery analysis.
16	7/10/2020	Bromberg, Brian	0.4	Discuss Debtors' cash projection with internal team team re: distributable value.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	7/10/2020	Kim, Ye Darm	1.8	Process revisions to the presentation for new base case assumptions re: distributable value analysis.
16	7/10/2020	Kim, Ye Darm	2.6	Process revisions to distributable value analysis model for restricted cash.
16	7/10/2020	Kim, Ye Darm	1.3	Process updates to model for distributable value analysis for PBC case.
16	7/10/2020	Kim, Ye Darm	2.4	Process revisions to the presentation re: Distributable Value Analysis.
16	7/10/2020	Bromberg, Brian	3.2	Edit presentation and excel model on distributable value.
16	7/10/2020	Bromberg, Brian	1.2	Review and comment on distributable value presentation.
16	7/10/2020	Bromberg, Brian	1.7	Review latest distributable value presentation and comment on new scenarios.
16	7/10/2020	Diaz, Matthew	2.1	Review the updated waterfall/distributable value analysis.
16	7/12/2020	Kim, Ye Darm	1.0	Participate on call re: distributable value presentation updates.
16	7/12/2020	Kim, Ye Darm	2.3	Process revisions to the presentation re: distributable value analysis.
16	7/12/2020	Kim, Ye Darm	1.9	Process revisions to the presentation re: distributable value analysis.
16	7/12/2020	Bromberg, Brian	0.8	Discuss distributable value presentation with team.
16	7/12/2020	Bromberg, Brian	3.0	Review and comment on distributable value presentation.
16	7/12/2020	Diaz, Matthew	2.5	Review the updated waterfall/distributable value recovery analysis for the committee.
16	7/13/2020	Bromberg, Brian	1.7	Review Debtor-provided opioid only business model.
16	7/13/2020	Kim, Ye Darm	0.6	Participate in internal meeting re: revisions to distributable value presentation.
16	7/13/2020	Kim, Ye Darm	2.2	Process revisions to distributable value analysis presentation.
16	7/13/2020	Kim, Ye Darm	1.1	Participate in internal discussion re: revisions to distributable value presentation.
16	7/13/2020	Kim, Ye Darm	1.2	Update model for new assumptions re: distributable value analysis.
16	7/13/2020	Bromberg, Brian	1.6	Discuss latest distributable presentation with internal team.
16	7/13/2020	Bromberg, Brian	0.7	Discuss distributable presentation with internal team.
16	7/13/2020	Bromberg, Brian	1.2	Discuss distributable value scenarios with UCC after discussion with Debtors.
16	7/13/2020	Bromberg, Brian	1.1	Discuss distributable value scenarios with UCC.
16	7/13/2020	Bromberg, Brian	3.5	Revise and review distributable value scenarios.
16	7/13/2020	Bromberg, Brian	1.1	Discuss OxyContin only scenario with Debtors.
16	7/13/2020	Bromberg, Brian	2.3	Review latest distributable value presentation and comment on new scenarios.
16	7/13/2020	Diaz, Matthew	1.0	Participate in a call with Province and HL to discuss the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	0.9	Participate in a follow up call with HL and Province to discuss the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	2.6	Review the slides to the UCC and the Company on the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	1.0	Participate on a call with the Debtors to discuss the waterfall/distributable value analysis.
16	7/13/2020	Diaz, Matthew	3.5	Review the updated waterfall/distributable value analysis.
16	7/13/2020	Kim, Ye Darm	1.0	Participate in call with Debtors' advisors re: opioid only oxy-only scenario for distributable value analysis.
16	7/13/2020	Kim, Ye Darm	0.6	Participate in call with PJT re: joint presentation on distributable value.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	7/14/2020	Kim, Ye Darm	2.7	Review and process revisions from the UCC professionals re: distributable value presentation.
16	7/14/2020	Kim, Ye Darm	1.2	Process additional comments and revisions from the UCC professionals re: distributable value presentation.
16	7/14/2020	Bromberg, Brian	1.7	Review latest distributable value presentation and comment.
16	7/14/2020	Bromberg, Brian	1.8	Prepare comments for the updated distributable value deck.
16	7/14/2020	Diaz, Matthew	0.3	Participate in a call with the case financial advisors to discuss the waterfall/distributable value analysis.
16	7/14/2020	Diaz, Matthew	1.6	Review of the updated waterfall/distributable value presentation.
16	7/14/2020	Kim, Ye Darm	0.3	Participate in call with PJT re: joint presentation on distributable value.
16	7/15/2020	Bromberg, Brian	3.2	Review newly provided models for scenarios re: PBC case, opioid-only.
16	7/15/2020	Diaz, Matthew	1.2	Review the new opioid only business plan model from the Debtors.
16	7/15/2020	Kim, Ye Darm	0.8	Update figures in model for latest distributable value assumptions.
16	7/15/2020	Kim, Ye Darm	2.3	Process revisions to presentation on distributable value analysis for new model assumptions.
16	7/15/2020	Kim, Ye Darm	3.4	Process updates to distributable value model for new assumptions.
16	7/15/2020	Kim, Ye Darm	1.4	Process revisions to presentation on distributable value per internal comments.
16	7/15/2020	Kim, Ye Darm	1.3	Process updates to distributable value analysis model for new assumptions.
16	7/15/2020	Kim, Ye Darm	0.5	Participate in internal call re: updates to distributable value presentation.
16	7/15/2020	Kim, Ye Darm	1.6	Continue processing updates to distributable value analysis model for new assumptions.
16	7/15/2020	Kim, Ye Darm	1.5	Process revisions to presentation on distributable value for new model assumptions.
16	7/15/2020	Kim, Ye Darm	0.6	Prepare diligence questions re: distributable value assumptions.
16	7/15/2020	Kim, Ye Darm	0.6	Participate in internal call re: call with Debtors' on distributable value analysis.
16	7/15/2020	Kim, Ye Darm	0.5	Participate in internal call re: updates to distributable value presentation.
16	7/15/2020	Bromberg, Brian	2.5	Review and comment on new version of distributable value presentation.
16	7/15/2020	Bromberg, Brian	1.3	Discuss distributable value analysis with internal team.
16	7/15/2020	Bromberg, Brian	2.0	Review and comment on distributable value presentation.
16	7/15/2020	Bromberg, Brian	1.3	Participate in call with Debtors on new operating scenarios.
16	7/15/2020	Bromberg, Brian	1.3	Discuss changes to distributable value presentation after Debtor call with team.
16	7/15/2020	Bromberg, Brian	0.5	Review updated distributable value deck.
16	7/15/2020	Bromberg, Brian	0.6	Review Debtors' notes on latest operating scenarios.
16	7/15/2020	Bromberg, Brian	0.9	Review internal comments received on distributable value presentation.
16	7/15/2020	Diaz, Matthew	2.5	Review the updated waterfall/distributable value analysis scenarios from the Debtors.
16	7/15/2020	Diaz, Matthew	3.4	Review the updated waterfall/distributable value analysis materials and related changes.
16	7/15/2020	Diaz, Matthew	1.5	Participate in a call with the Debtors and other key stakeholder advisors to discuss various waterfall/distributable value recovery scenarios.
16	7/15/2020	Kim, Ye Darm	1.6	Participate in call with PJT and Debtors re: distributable value analysis assumptions.
16	7/16/2020	Bromberg, Brian	1.2	Create question and diligence list for Debtors re: new scenarios.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	7/16/2020	Kim, Ye Darm	0.7	Participate in internal discussion re: joint presentation on distributable value.
16	7/16/2020	Kim, Ye Darm	2.1	Process revisions to model and presentation re: distributable value analyses.
16	7/16/2020	Kim, Ye Darm	1.7	Process revisions to presentation on distributable value per comments from Debtors and UCC advisors.
16	7/16/2020	Kim, Ye Darm	2.3	Process updates to joint presentation on distributable value per comments from UCC advisors.
16	7/16/2020	Kim, Ye Darm	1.0	Participate in preparation meeting for call with Debtors re: joint presentation.
16	7/16/2020	Bromberg, Brian	0.8	Respond to UCC comments on distributable value presentation.
16	7/16/2020	Bromberg, Brian	1.0	Discuss additional diligence questions and distributable value presentation with team.
16	7/16/2020	Bromberg, Brian	2.1	Review and comment on updated distributable value presentation.
16	7/16/2020	Bromberg, Brian	1.0	Discuss latest distributable presentation with internal team.
16	7/16/2020	Bromberg, Brian	0.8	Review updated distributable value deck and prepare comments.
16	7/16/2020	Bromberg, Brian	1.0	Discuss distributable value scenario diligence questions with Debtor advisors.
16	7/16/2020	Bromberg, Brian	1.0	Catch up with team on latest diligence responses from Debtors re: operating scenarios.
16	7/16/2020	Diaz, Matthew	3.4	Perform detailed review of the updated presentation materials incorporating the new scenarios from the Debtors.
16	7/16/2020	Diaz, Matthew	0.5	Participate in a call with Province and Houlihan to discuss the updated scenarios.
16	7/16/2020	Diaz, Matthew	1.0	Call with the Debtors to discuss our questions on the waterfall/distributable value sensitivities.
16	7/16/2020	Diaz, Matthew	2.6	Review the new waterfall/distributable value scenarios and sensitivities from the Debtors.
16	7/16/2020	Kim, Ye Darm	1.0	Participate in call with Debtors and PJT re: distributable value analysis presentation.
16	7/17/2020	Kim, Ye Darm	0.6	Review comments and revisions from UCC advisors re: distributable value model.
16	7/17/2020	Kim, Ye Darm	2.9	Process revisions to distributable value analysis model and presentation for new assumptions.
16	7/17/2020	Kim, Ye Darm	2.3	Process updates to distributable value analysis model and presentation for new assumptions.
16	7/17/2020	Kim, Ye Darm	1.4	Process updates to distributable value presentation for internal comments and UCC advisor revisions.
16	7/17/2020	Bromberg, Brian	1.3	Review updated version of distributable value presentation and share with Debtors.
16	7/17/2020	Bromberg, Brian	0.5	Discuss UCC comments on distributable value presentation with team.
16	7/17/2020	Bromberg, Brian	1.3	Prepare comments on latest distributable value presentation.
16	7/17/2020	Diaz, Matthew	0.9	Review comments from the UCC on the waterfall/distributable value presentation.
16	7/17/2020	Diaz, Matthew	1.2	Review the updated waterfall/distributable value presentation to send to the Debtors.
16	7/18/2020	Kim, Ye Darm	2.1	Process revisions to the distributable value analysis and presentation per comments from the Debtors' advisors.
16	7/18/2020	Kim, Ye Darm	2.3	Process revisions to the distributable value presentation per comments from UCC advisors.
16	7/18/2020	Bromberg, Brian	3.1	Prepare comments on latest distributable value presentation based on Debtor and UCC comments.
16	7/18/2020	Diaz, Matthew	1.9	Review diligence questions and related due diligence on the waterfall/distributable value analysis.
16	7/19/2020	Kim, Ye Darm	2.7	Process updates to model re: distributable value analysis.
16	7/19/2020	Kim, Ye Darm	2.3	Process revisions to the distributable value analysis per the Debtors comments.
16	7/19/2020	Kim, Ye Darm	0.6	Prepare analysis in response to Debtors' questions about distributable value assumptions.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	7/19/2020	Bromberg, Brian	2.2	Review updated distributable value presentation and illustrative bridge per Debtor and UCC comments.
16	7/19/2020	Diaz, Matthew	2.4	Review the updated waterfall/distributable value analysis.
16	7/20/2020	Kim, Ye Darm	0.4	Prepare responses to PJT's questions re: distributable value assumptions.
16	7/20/2020	Kim, Ye Darm	2.1	Process revisions to distributable value presentation for new assumptions from the Debtors' advisors.
16	7/20/2020	Kim, Ye Darm	0.9	Process revisions to the distributable value model for new assumptions.
16	7/20/2020	Bromberg, Brian	0.9	Review edits to updated distributable value analysis.
16	7/20/2020	Bromberg, Brian	0.9	Review Debtors' comments re: distributable value analysis.
16	7/20/2020	Diaz, Matthew	1.7	Review the updated waterfall/distributable value analysis.
16	7/21/2020	Kim, Ye Darm	0.8	Process revisions to the distributable value joint presentation for internal comments.
16	7/21/2020	Kim, Ye Darm	1.8	Process revisions to distributable value analysis model for new assumptions.
16	7/21/2020	Kim, Ye Darm	0.8	Process revisions to joint presentation on distributable value for internal comments.
16	7/21/2020	Kim, Ye Darm	0.7	Process revisions to the distributable value presentation per internal comments.
16	7/21/2020	Kim, Ye Darm	0.5	Participate in call re: coordination on distributable value joint presentation.
16	7/21/2020	Kim, Ye Darm	0.5	Process revisions to distributable value presentation per Debtors' comments.
16	7/21/2020	Kim, Ye Darm	0.5	Participate in internal meeting re: distributable value presentation.
16	7/21/2020	Kim, Ye Darm	2.5	Process revisions to the distributable value analysis model for adjustment to assumptions from the Debtors.
16	7/21/2020	Kim, Ye Darm	1.1	Perform detailed QC of distributable value joint presentation.
16	7/21/2020	Kim, Ye Darm	1.2	Process additional updates to the distributable value model per assumptions from the Debtors.
16	7/21/2020	Bromberg, Brian	1.3	Finalize distributable value presentation and share with Counsel.
16	7/21/2020	Bromberg, Brian	1.3	Review additional changes based on UCC comments on to distributable value presentation.
16	7/21/2020	Bromberg, Brian	2.5	Process revisions to distributable value presentation.
16	7/21/2020	Bromberg, Brian	0.5	Review latest draft of distributable value analysis ahead of discussion with team.
16	7/21/2020	Bromberg, Brian	0.5	Discuss distributable value analysis with internal team.
16	7/21/2020	Bromberg, Brian	1.5	Review edits to updated distributable value presentation.
16	7/21/2020	Bromberg, Brian	1.0	Review new scenario changes to distributable value presentation.
16	7/21/2020	Bromberg, Brian	0.8	Discuss distributable value presentation with UCC.
16	7/21/2020	Diaz, Matthew	3.1	Perform detailed review of the updated waterfall/distributable value analysis.
16	7/21/2020	Diaz, Matthew	2.5	Review the updated changes to the waterfall/distributable value scenarios in the joint presentation.
16	7/21/2020	Diaz, Matthew	0.5	Participate in call with the Debtors to discuss the joint presentation meeting.
16	7/21/2020	Diaz, Matthew	0.6	Participate in a call with the case financial advisors to prepare for the joint presentation meeting.
16	7/21/2020	Diaz, Matthew	3.5	Perform detailed review of the slides for the joint waterfall/distributable value recovery presentation.
16	7/22/2020	Diaz, Matthew	0.9	Review the Debtors' updated opioid-only scenario assumptions and model.
16	7/22/2020	Bromberg, Brian	0.8	Revise distributable value presentation for upcoming meeting.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	7/22/2020	Diaz, Matthew	0.6	Review follow ups and additional workstreams coming out of the joint presentation call.
16	7/22/2020	Kim, Ye Darm	1.8	Participate in call re: joint financial presentation on distributable value.
16	7/29/2020	Diaz, Matthew	1.2	Review the updated distributable value/waterfall analysis.
16	7/31/2020	Bromberg, Brian	2.7	Review updates to distributable value analysis and value breakdown.
16	8/3/2020	Kim, Ye Darm	0.6	Review docket for claims filings re: Third Party Payors.
16	8/3/2020	Kim, Ye Darm	0.4	Participate in discussion re: updates to distributable value presentation.
16	8/4/2020	Kim, Ye Darm	1.2	Process revisions to distributable value update presentation per internal comments.
16	8/4/2020	Kim, Ye Darm	2.1	Prepare additional slides re: distributable value analysis update.
16	8/4/2020	Kim, Ye Darm	0.5	Participate in call re: distributable value update presentation.
16	8/4/2020	Kim, Ye Darm	2.3	Prepare draft distributable value update presentation.
16	8/4/2020	Diaz, Matthew	2.3	Review the updated waterfall recovery analysis and provide comments to internal team.
16	8/5/2020	Kim, Ye Darm	0.9	Prepare summary of PEO information relied upon in the distributable value update presentation.
16	8/5/2020	Kim, Ye Darm	0.4	Process revisions to the distributable value update presentation.
16	8/7/2020	Kim, Ye Darm	0.5	Update list of PEO files relied on for distributable value analysis update presentation.
16	8/10/2020	Kim, Ye Darm	0.9	Update distributable value deck for information on historical Rhodes losses.
16	8/10/2020	Kim, Ye Darm	1.3	Process revisions to distributable value presentation for updated executive summary.
16	8/10/2020	Kim, Ye Darm	0.6	Process updates to the distributable value presentation.
16	8/10/2020	Kim, Ye Darm	2.3	Review Debtors' updates to new distributable value scenario estimates.
16	8/17/2020	Diaz, Matthew	1.6	Review the updated waterfall recovery analysis and provide comments to internal team.
16	8/17/2020	Diaz, Matthew	0.6	Participate on a call with Province to discuss their updated recovery analysis.
16	8/19/2020	Bromberg, Brian	1.7	Prepare slides on UCC distributable value analysis.
16	8/19/2020	Bromberg, Brian	3.2	Prepare response to UCC distributable value analysis.
16	8/19/2020	Bromberg, Brian	1.2	Participate in call with the AHC re: distributable value.
16	8/19/2020	Diaz, Matthew	1.7	Review slides on the updated recovery analysis.
16	8/21/2020	Bromberg, Brian	1.1	Revise slides on distributable value based on internal discussions.
16	8/21/2020	Bromberg, Brian	0.7	Discuss distributable value slides with team and Houlihan.
16	8/21/2020	Bromberg, Brian	1.3	Process revisions to slides re: distributable value.
16	8/28/2020	Bromberg, Brian	0.4	Review the updated distributable value analysis.
16	9/1/2020	Kim, Ye Darm	1.2	Update distributable value spreadsheet model for additional toggles.
16	9/2/2020	Bromberg, Brian	1.3	Review updated distributable value scenario figures.
16	9/2/2020	Bromberg, Brian	3.7	Review spreadsheet with updated 2020 methodology for distributable value.
16	9/2/2020	Diaz, Matthew	1.9	Review the updated distributable value recovery analysis.
16	9/3/2020	Bromberg, Brian	0.6	Process updates to spreadsheet analysis on distributable value.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
16	9/3/2020	Diaz, Matthew	1.2	Review the updated distributable value recovery analysis.
16	9/4/2020	Diaz, Matthew	1.5	Review the updated distributable value recovery analysis.
16	9/4/2020	Diaz, Matthew	0.6	Participate in call with Counsel to discuss the updated distributable value recovery analysis.
16	9/4/2020	Diaz, Matthew	1.2	Review the source materials to the distributable value recovery analysis.
16	9/4/2020	Kim, Ye Darm	0.9	Continue updating distributable value spreadsheet model for revised term sheets.
16	9/4/2020	Kim, Ye Darm	0.4	Update distributable value spreadsheet model based on internal comments.
16	9/8/2020	Diaz, Matthew	0.6	Review the updated distributable value analysis.
16	9/30/2020	Diaz, Matthew	0.7	Develop outline on presentation re: strategic alternatives for distributable value.
16	9/30/2020	Diaz, Matthew	0.6	Participate in a call with Houlihan to discuss presentation to the AHC on strategic alternatives for distributable value.
16	9/30/2020	Diaz, Matthew	0.9	Participate in a call with Counsel to discuss strategic alternatives in connection with the Sackler mediation.
16	9/30/2020	Bromberg, Brian	1.8	Participate in discussion and outline mediation preparation materials.
16 Total			398.2	
18	6/1/2020	Kim, Ye Darm	0.6	Participate in internal pre-call meeting re: 1B report diligence meeting with KL and HL.
18	6/1/2020	Costaldo, Nicole	2.3	Conduct preliminary review of the inventory of documents provided to date re: non cash transfers of value report
18	6/1/2020	Kyviakidis, Peter	1.0	Participate on a call to discuss the detailed information requests and questions to be posed to AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/1/2020	Kyviakidis, Peter	0.5	Analyze the Intercompany and Non-Cash Transfer of Value Analysis.
18	6/1/2020	Kyviakidis, Peter	0.8	Read listing of information items provided by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/1/2020	Bromberg, Brian	1.8	Review Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/2/2020	Greenblatt, Matthew	0.8	Prepare and review detailed questions and document request list for AlixPartners based upon continued review of Cash Transfers Report
18	6/2/2020	Greenblatt, Matthew	1.2	Conduct initial review of the Non-Cash Transfers Report prepared by AlixPartners.
18	6/2/2020	Mazzari, Meredith	1.1	Participate in call re: document index for Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/2/2020	Mazzari, Meredith	0.4	Participate in call to debrief on AlixPartners inquiries re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/2/2020	Mazzari, Meredith	1.1	Document reconciliation procedures performed re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/2/2020	Kyviakidis, Peter	1.5	Analyze the Intercompany and Non-Cash Transfers of Value Analysis by AlixPartners.
18	6/3/2020	Costaldo, Nicole	2.4	Review the executive summary of the non-cash transfers report and prepare for internal call with team to continue to discuss the non-cash transfers report
18	6/3/2020	Mazzari, Meredith	0.7	Document completeness procedures performed by AlixPartners from Cash Transfers of Value Report
18	6/3/2020	Kyviakidis, Peter	2.9	Draft internal document on observations and questions for AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/3/2020	Kyviakidis, Peter	2.9	Analyze the Intercompany and Non-Cash transfers of value Analysis.
18	6/3/2020	Bromberg, Brian	1.7	Review 1B transfers report re: re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/3/2020	Bromberg, Brian	1.2	Participate in Ad Hoc Committee update call re: IACs and 1B report.
18	6/3/2020	Bromberg, Brian	1.2	Prepare presentation notes for ad hoc committee call on the 1B report.
18	6/4/2020	Costaldo, Nicole	0.9	Conference with team regarding additional diligence questions to review results of the non-cash transfers report.
18	6/4/2020	Diaz, Matthew	1.5	Review the Intercompany and Non-Cash Transfers Of Value Analysis report.
18	6/4/2020	Kim, Ye Darm	0.5	Participate in internal discussion re: 1B report.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	6/4/2020	Kyviakidis, Peter	3.3	Draft internal document on observations and questions for AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/4/2020	Kyviakidis, Peter	3.5	Continue analysis of the Intercompany and Non-cash transfers of Value Analysis.
18	6/4/2020	Bromberg, Brian	2.3	Review Intercompany and Non-Cash Transfers Of Value Analysis..
18	6/4/2020	Kurtz, Emma	0.3	Discuss internally re: non-cash transfers report and related presentation.
18	6/5/2020	Kim, Ye Darm	1.2	Process updates to 1B report summary presentation.
18	6/5/2020	Kim, Ye Darm	2.7	Prepare summary presentation of 1B report.
18	6/5/2020	Kyviakidis, Peter	2.8	Continue analysis of the Intercompany and Non-Cash Transfers of Value Analysis.
18	6/7/2020	Bromberg, Brian	1.2	Review summary presentation on 1B report.
18	6/8/2020	Costaldo, Nicole	0.3	Conduct final review of questions and information requests to AlixPartners re: Cash and Non-Cash Transfers of Value Report
18	6/8/2020	Greenblatt, Matthew	1.8	Conduct review of the Non-Cash Transfers report and drafted document request and list of inquiries for AlixPartners team.
18	6/8/2020	Kim, Ye Darm	1.9	Prepare additional overview slides for presentation summarizing 1B Report.
18	6/8/2020	Bromberg, Brian	0.5	Review initial inquiries list to AlixPartners related to transfer reports.
18	6/8/2020	Bromberg, Brian	1.6	Provide comments on 1B report presentation and discuss with internal team.
18	6/9/2020	Greenblatt, Matthew	1.4	Prepare further analysis of AlixPartners' Non-Cash Transfers report and continued summary of preliminary thoughts and observations.
18	6/9/2020	Mazzari, Meredith	1.6	Document assumptions made by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/9/2020	Mazzari, Meredith	1.7	Prepare review of completeness procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/9/2020	Kim, Ye Darm	1.7	Process revisions to summary presentation re: 1B report.
18	6/9/2020	Bromberg, Brian	0.6	Finalize 1B report presentation slides for internal review.
18	6/9/2020	Bromberg, Brian	0.8	Review latest version of 1B report presentation slide.
18	6/9/2020	Bromberg, Brian	0.8	Review public version of 1B report filed in the docket.
18	6/10/2020	Costaldo, Nicole	1.2	Prepare for and correspond with accounting team re: call with AlixPartners to discuss the Cash and Non-Cash Transfers.
18	6/10/2020	Diaz, Matthew	1.8	Perform detailed review re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/10/2020	Diaz, Matthew	1.4	Review the draft presentation to the AHC re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/10/2020	Kim, Ye Darm	2.3	Prepare schedules of categories of transfers re: 1B Report.
18	6/10/2020	Kim, Ye Darm	1.6	Process updates and revisions to 1B Report presentation for the diligence subcommittee.
18	6/10/2020	Kyviakidis, Peter	0.5	Prepare diligence questions to AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/10/2020	Bromberg, Brian	0.7	Discuss transfer reports and diligence questions with internal team.
18	6/10/2020	Bromberg, Brian	1.5	Provide revisions to the latest version of non cash transfer presentation slides.
18	6/10/2020	Bromberg, Brian	1.6	Review non cash transfer presentation slides.
18	6/10/2020	Kyviakidis, Peter	0.5	Review proposed initial work plan and questions on investigatory work re: the Cash Transfers of Value Analysis and the Intercompany and Non-Cash Transfers Of Value.
18	6/11/2020	Greenblatt, Matthew	0.8	Develop investigative procedures to identify additional potential insider payments to disclosed and undisclosed Sackler family members.
18	6/11/2020	Greenblatt, Matthew	0.4	Prepare summary of initial observations and inquiries for AlixPartners team for both the Cash Transfers and the Non-Cash Transfers reports.
18	6/11/2020	Mazzari, Meredith	0.8	Document assumptions made by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	6/11/2020	Kim, Ye Darm	1.1	Prepare schedule of variances by category re: 1B report.
18	6/11/2020	Kyviakidis, Peter	2.3	Review analyses re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/11/2020	Kyviakidis, Peter	2.3	Review internal analyses re: the Cash Transfers of Value report.
18	6/12/2020	Greenblatt, Matthew	0.8	Correspond AlixPartners and FTI teams regarding FTI's initial observations and inquiries for AlixPartners team for both the Cash Transfers and the Non-Cash Transfers reports.
18	6/12/2020	Kyviakidis, Peter	0.5	Participate on call to discuss certain observations re: internal analyses on the Cash Transfers of Value report.
18	6/15/2020	Greenblatt, Matthew	1.3	Continue review of AlixPartners' Non-Cash Transfers report and develop a detailed document request and question list for AlixPartners team.
18	6/15/2020	Mazzari, Meredith	1.1	Document reconciliation procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/15/2020	Kyviakidis, Peter	0.5	Participate on call to discuss the initial project work plan re: investigatory work on the Intercompany and Non-Cash Transfers of Value Analysis.
18	6/17/2020	Mazzari, Meredith	0.9	Document reconciliation procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/17/2020	Mazzari, Meredith	0.5	Document assumptions made by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/17/2020	Mazzari, Meredith	0.5	Document completeness procedures performed by AlixPartners re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/17/2020	Bromberg, Brian	0.5	Review questions on cash transfers report.
18	6/18/2020	Greenblatt, Matthew	1.2	Continue review of the Non-Cash Transfers report.
18	6/18/2020	Mazzari, Meredith	1.7	Document assumptions made by AlixPartners in Intercompany & Non-Cash Transfers Analysis
18	6/18/2020	Mazzari, Meredith	0.5	Document reconciliation procedures performed by AlixPartners from Intercompany & Non-Cash Transfers Analysis
18	6/19/2020	Kyviakidis, Peter	1.8	Review internal analyses re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/19/2020	Kyviakidis, Peter	1.8	Review internal analyses re: the Intercompany and Non-Cash Transfers of Value Analysis.
18	6/23/2020	Costaldo, Nicole	1.8	Prepare for call with AlixPartners re: scope and procedures performed for the Cash Transfers of Value report.
18	6/23/2020	Greenblatt, Matthew	1.5	Continue review of AlixPartners' Non-Cash Transfers report and develop a detailed document request and question list for AlixPartners team.
18	6/24/2020	Costaldo, Nicole	1.7	Attend call with AlixPartners and prepare summary of discussion re: the Cash Transfers of Value Report.
18	6/24/2020	Greenblatt, Matthew	0.3	Prepare summary of preliminary observations from discussion with AlixPartners team and coordinate next steps with FTI team.
18	6/24/2020	Greenblatt, Matthew	2.3	Review the Cash Transfers Report and update draft outline of questions for discussion with AlixPartners.
18	6/24/2020	Greenblatt, Matthew	1.2	Participate in conference call with Alix and FTI teams regarding the Cash Transfers report.
18	6/24/2020	Mazzari, Meredith	0.2	Participate in internal discussion on work plan re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/24/2020	Kyviakidis, Peter	1.3	Participate on call with AlixPartners to discuss the nature and scope of AlixPartners's project work procedures performed re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/24/2020	Bromberg, Brian	0.8	Participate in call with AlixPartners re: cash transfers report.
18	6/24/2020	Kyviakidis, Peter	1.3	Participate on call with AlixPartners re: nature and scope of AlixPartners's work procedures performed in connection with the information included in the Cash Transfers of Value
18	6/25/2020	Greenblatt, Matthew	1.0	Participate in conference call with Alix and FTI teams regarding the Non-Cash Transfers report.
18	6/25/2020	Greenblatt, Matthew	1.5	Continue review of the Non-Cash Transfers Report and update FTI's draft outline of questions for discussion with AlixPartners' team.
18	6/25/2020	Greenblatt, Matthew	0.2	Coordinate next steps with FTI team following discussion with AlixPartners team regarding the Non-Cash Transfers Report.
18	6/25/2020	Mazzari, Meredith	3.0	Review and analyze Appendix B & D from Cash Transfers of Value Analysis, Appendix 1 from Intercompany and Non-Cash Transfers of Value Analysis.
18	6/25/2020	Mazzari, Meredith	0.6	Participate in internal discussion on analyses re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/25/2020	Mazzari, Meredith	0.3	Continue to review and analyze Appendix B & D from Cash Transfers of Value Analysis, Appendix 1 from Intercompany and Non-Cash Transfers of Value Analysis.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	6/25/2020	Mazzari, Meredith	1.1	Participate in discussion with AlixPartners re: re: Intercompany and Non-Cash Transfers Of Value Analysis.
18	6/25/2020	Kyviakidis, Peter	1.0	Participate on call with AlixPartners in order to discuss the nature and scope of AlixPartners's project work procedures procedures re: Intercompany and Non-Cash Transfers
18	6/25/2020	Kyviakidis, Peter	1.0	Participate on call with AlixPartners re: nature and scope of AlixPartners's work procedures performed in connection with the information included in the Intercompany and Non-Cash
18	6/29/2020	Greenblatt, Matthew	1.3	Summarize observations from both Cash and Non-Cash Transfers of Value reports by Alix Partners.
18	6/29/2020	Costaldo, Nicole	3.0	Conference with team to discuss work plan and deck re: opinion on the coverage of Alix Partners analyses.
18	6/29/2020	Mazzari, Meredith	0.3	Quality check review of slide deck summarizing call with AlixPartners and proposed analyses.
18	6/29/2020	Mazzari, Meredith	2.2	Document and review files provided by AlixPartners in connection with Cash Transfers of Value Analysis.
18	6/29/2020	Mazzari, Meredith	1.3	Review and analyze Appendix B & D from Cash Transfers of Value Analysis, Appendix 1 from Intercompany and Non-Cash Transfers of Value Analysis/
18	6/29/2020	Kyviakidis, Peter	0.8	Participate on call to discuss information shared by AlixPartners re: Cash Transfers of Value Analysis and Intercompany and Non-Cash Transfers of Value Analysis.
18	6/29/2020	Kyviakidis, Peter	1.0	Discuss next steps per information shared by AlixPartners re: Cash Transfers of Value Analysis and Intercompany and Non-Cash Transfers of Value Analysis.
18	6/30/2020	Kyviakidis, Peter	1.3	Discuss workplan post-AlixPartners calls re: Cash Transfers of Value Analysis and Intercompany and Non-Cash Transfers of Value Analysis.
18	7/2/2020	Bromberg, Brian	0.8	Discuss historical cash transfer report with internal team.
18	7/2/2020	Costaldo, Nicole	1.2	Attend internal discussion with team to discuss Alix Partner's analyses re: 1B report.
18	7/2/2020	Diaz, Matthew	1.1	Perform review of AlixPartner's 1B report.
18	7/2/2020	Greenblatt, Matthew	1.2	Attend internal discussion with team to discuss Alix Partner's analyses re: 1B report.
18	7/2/2020	Mazzari, Meredith	0.3	Participate in post-call discussion re: Transfers of Value reports.
18	7/6/2020	Costaldo, Nicole	3.2	Review and analyze the AlixPartners Intercompany and Non-Cash Transfers report to identify transfers that require further testing re: Arms Length negotiations.
18	7/6/2020	Costaldo, Nicole	1.2	Continue analysis of the AlixPartners Intercompany and Non-Cash Transfers report to identify transfers that require further testing re: Arms Length negotiations.
18	7/6/2020	Costaldo, Nicole	2.7	Attend meeting and discuss with forensic accountants re: workplan for analysis of arms length negotiations of transfers.
18	7/6/2020	Kyviakidis, Peter	1.0	Prepare for call re: selection of transfers for potential further investigatory inquiry re: arms length negotiations.
18	7/6/2020	Kyviakidis, Peter	2.5	Analyze Intercompany and Non-Cash Transfers of Value Analysis re: identification of potential further investigatory inquiry.
18	7/6/2020	Kyviakidis, Peter	1.3	Participate in call re: selection of tranfers for potential further investigatory inquiry re: arms length negotiations.
18	7/6/2020	Mazzari, Meredith	1.2	Participate in call re: selection of tranfers for potential further investigatory inquiry re: arms length negotiations.
18	7/6/2020	Mazzari, Meredith	0.4	Continue to review audited financial statements for notes/references to non-cash transfers
18	7/6/2020	Mazzari, Meredith	1.0	Prepare for internal call re: 1B Report additional inquiries.
18	7/6/2020	Mazzari, Meredith	3.0	Review audited financial statements for notes/references to non-cash transfers.
18	7/7/2020	Costaldo, Nicole	3.1	Participate in meeting re: transfers requiring further testing and next steps to explain and identify 3rd party support or disclosures in the audited financial statements.
18	7/7/2020	Greenblatt, Matthew	0.8	Continue review of AlixPartners' Non-Cash Transfers report and discuss with team to develop investigative workplan.
18	7/7/2020	Kyviakidis, Peter	0.8	Participate on internal call re: selection of certain intercompany transactions and non-cash transfers of value between the Debtor Entities and related IACs for potential further
18	7/7/2020	Mazzari, Meredith	0.5	Quality check and review slide deck summarizing proposed selection of transfers for testing.
18	7/7/2020	Mazzari, Meredith	0.5	Participate on internal status update call re: transfers of value reports.
18	7/8/2020	Bromberg, Brian	0.4	Review discovery files produced by Milbank.
18	7/8/2020	Costaldo, Nicole	1.0	Participate in discussion re: updates to transfers requiring further testing.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	7/8/2020	Kyviakidis, Peter	1.0	Participate in discussion re: updates to transfers requiring further testing.
18	7/8/2020	Mazzari, Meredith	0.9	Participate in discussion re: updates to transfers requiring further testing.
18	7/8/2020	Mazzari, Meredith	2.5	Review selected transfers and determine whether they are disclosed in the audit financial statements.
18	7/8/2020	Mazzari, Meredith	0.5	Quality check and review latest slide deck summarizing proposed selection of transfers for testing.
18	7/9/2020	Costaldo, Nicole	1.3	Participate on call with team re: transfers that require further testing.
18	7/9/2020	Costaldo, Nicole	2.5	Revise presentation of selected transfers by type of transfer (e.g. from Purdue to IAC) and by additional recoupable value.
18	7/9/2020	Kyviakidis, Peter	1.3	Participate on call with team re: transfers that require further testing.
18	7/9/2020	Mazzari, Meredith	0.7	Review selected transfers and determine whether they are disclosed in the audit financial statements.
18	7/9/2020	Mazzari, Meredith	0.5	Prepare spreadsheet compiled of names comprised of bankruptcy estate to compare against those entities included within audited financial statements.
18	7/9/2020	Mazzari, Meredith	1.2	Participate on call with team re: transfers that require further testing.
18	7/10/2020	Costaldo, Nicole	2.5	Finalize draft presentation of select Intercompany and Non-Cash transfers identified that require further testing.
18	7/10/2020	Greenblatt, Matthew	1.2	Participate in discussions with team re: continued development of proposed workplan for testing of AlixPartners' Non-Cash Transfers report.
18	7/10/2020	Kyviakidis, Peter	0.5	Participate on a call to discuss workplan re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/10/2020	Kyviakidis, Peter	1.0	Participate on a call with larger internal team in order to discuss the selection of certain intercompany and non-cash transfers of value between the Debtor Entities and related IACs
18	7/10/2020	Mazzari, Meredith	1.1	Review selected transfers to determine whether non-debtor entities/counterparties are included in audited financial statements.
18	7/10/2020	Mazzari, Meredith	0.3	Review selected transfers and determine whether they are disclosed in the audit financial statements.
18	7/10/2020	Mazzari, Meredith	1.1	Participate on a call with larger internal team in order to discuss the selection of certain intercompany and non-cash transfers of value between the Debtor Entities and related IACs
18	7/10/2020	Mazzari, Meredith	0.4	Participate on a call to discuss workplan re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/10/2020	Mazzari, Meredith	0.1	Update spreadsheet compiled of names comprised of bankruptcy estate to compare against those entities included within audited financial statements.
18	7/13/2020	Greenblatt, Matthew	0.8	Continued reviewing the AlixPartners' Non-Cash Transfers report and initial testing procedures.
18	7/13/2020	Kyviakidis, Peter	0.5	Participate on a call to discuss the draft presentation re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/13/2020	Mazzari, Meredith	0.3	Participate on a call to discuss the draft presentation re: diligence of the selection of certain transfers of value between the Debtor Entities and related IACs.
18	7/13/2020	Mazzari, Meredith	0.3	Review selected transfers to determine whether non-debtor entities/counterparties are included in audited financial statements.
18	7/14/2020	Greenblatt, Matthew	1.2	Conduct detailed review of the AlixPartners' Non-Cash Transfers report and continue work to develop initial testing procedures.
18	7/16/2020	Bromberg, Brian	0.5	Participate in discussion with forensic team to discuss cash transfer report.
18	7/16/2020	Costaldo, Nicole	1.0	Attend greater team call to debrief with Forensic Accounting team re: select transfers of value and Arms Length analysis.
18	7/16/2020	Greenblatt, Matthew	0.7	Continue review of AlixPartners' Non-Cash Transfers report and discuss with team to develop investigative workplan.
18	7/16/2020	Kyviakidis, Peter	0.5	Participate in discussion with restructuring team to discuss cash transfer report.
18	7/17/2020	Greenblatt, Matthew	1.4	Continue review of specific transactions and supporting documentation provided by AlixPartners related to the Non-Cash Transfers report.
18	7/20/2020	Bromberg, Brian	0.4	Participate in discussion with UCC re: cash transfers analysis.
18	7/20/2020	Greenblatt, Matthew	1.0	Participate with AlixPartners and FTI team and coordination of discussions with Province and Bates White regarding both the Cash Transfers report and the Non-Cash Transfers
18	7/21/2020	Costaldo, Nicole	0.5	Research Intralinks data room for the support for select transfers of interest and any associated agreements.
18	7/22/2020	Costaldo, Nicole	0.7	Participate in discussion with team regarding the agreements preliminarily identified in the Intralinks data room and what to review/details to extract from these agreements to further

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	7/22/2020	Kyviakidis, Peter	0.8	Participate in discussion with team regarding the agreements preliminarily identified in the Intralinks data room and what to review/details to extract from these agreements to further
18	7/23/2020	Greenblatt, Matthew	0.8	Participate in discussion with with Counsel, AlixPartners and FTI team to coordinate discussions with Province and Bates White regarding both the Cash Transfers report and the
18	7/24/2020	Costaldo, Nicole	0.4	Prepare inventory of agreements associated with selected transfers of value to be further analyzed on behalf of the Ad-Hoc Committee.
18	7/25/2020	Costaldo, Nicole	0.8	Continue to prepare inventory of agreements associated with selected transfers of value to be further analyzed on behalf of the Ad-Hoc Committee.
18	7/29/2020	Greenblatt, Matthew	0.5	Participate in discussion with Counsel, FTI team and UCC professionals regarding review of AlixPartners' workproduct.
18	7/29/2020	Mazzari, Meredith	0.8	Perform review and documentation of legal agreements governing select non-cash transfers.
18	7/30/2020	Mazzari, Meredith	3.0	Continue performing review and documentation of legal agreements governing select non-cash transfers.
18	7/31/2020	Mazzari, Meredith	2.8	Continue performing review and documentation of legal agreements governing select non-cash transfers.
18	7/31/2020	Mazzari, Meredith	1.2	Continue performing review and documentation of legal agreements governing select non-cash transfers.
18	8/3/2020	Greenblatt, Matthew	1.0	Develop agenda and prepare for call with Province to discuss work performed to date and additional testing of AlixPartners' work product.
18	8/3/2020	Greenblatt, Matthew	0.6	Correspond with advisors and Province to coordinate workstreams and testing of AlixPartners' work product.
18	8/3/2020	Diaz, Matthew	0.9	Perform review of the cash transfers analysis.
18	8/3/2020	Bromberg, Brian	0.3	Confirm information sharing agreement with Counsel ahead of call with UCC.
18	8/4/2020	Mazzari, Meredith	1.0	Perform review and documentation of legal agreements governing select non-cash transfers.
18	8/5/2020	Greenblatt, Matthew	1.2	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Greenblatt, Matthew	0.9	Prepare agenda for call with UCC professionals from Province regarding work performed to date.
18	8/5/2020	Diaz, Matthew	1.0	Participate in a call with Province to discuss the cash transfer analysis.
18	8/5/2020	Costaldo, Nicole	2.6	Prepare for, attend and debrief with team regarding the call with Province to discuss their diligence of the AlixPartners 1A and 1B reports.
18	8/5/2020	Mazzari, Meredith	1.8	Review and document of legal agreements governing select non-cash transfers.
18	8/5/2020	Mazzari, Meredith	1.1	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Mazzari, Meredith	1.0	Debrief with team regarding the call with Province to discuss their diligence of the AlixPartners 1A and 1B reports.
18	8/5/2020	Kyviakidis, Peter	1.0	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Kyviakidis, Peter	1.3	Participate in conference call with FTI team and the UCC professionals from Province to understand the testing of AlixPartners work and coordination of the parties collective efforts.
18	8/5/2020	Bromberg, Brian	1.1	Participate in call re: transfers of value with UCC advisors.
18	8/5/2020	Bromberg, Brian	0.4	Participate on call re: agenda for call with UCC professionals from Province regarding work performed to date.
18	8/6/2020	Costaldo, Nicole	1.1	Build out information requests and inquiries to further understand select transfers of the AlixPartners 1A and 1B reports.
18	8/7/2020	Diaz, Matthew	1.2	Review the updated draft of the transfers investigations report.
18	8/7/2020	Diaz, Matthew	0.5	Participate in call with the KL litigation team to discuss the cash and non-cash transfers analyses.
18	8/7/2020	Diaz, Matthew	0.5	Participate in call with Province to discuss the status of the investigation report.
18	8/7/2020	Costaldo, Nicole	1.4	Review of agreement inventory and continue to review 1B report to add information into the draft request list to be built out by FTI and Province
18	8/7/2020	Bromberg, Brian	1.8	Prepare outline and slides for transfer reports updates.
18	8/7/2020	Bromberg, Brian	0.5	Participate in discussion with team re: transfer report updates.
18	8/7/2020	Bromberg, Brian	0.5	Participate in call with the KL litigation team to discuss the cash and non-cash transfers analyses.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	8/9/2020	Diaz, Matthew	0.9	Continue review of the updated draft of the transfers investigations report.
18	8/9/2020	Bromberg, Brian	1.0	Process revisions and finalize slides re: transfers of value updates.
18	8/10/2020	Costaldo, Nicole	1.6	Conference with team re: review of the audited financial statements to determine cash balance per financial statements for analysis of funds distributed and identified by
18	8/10/2020	Kyviakidis, Peter	0.8	Participate in internal discussion re: reconciliation of cash available to pay distributions to the owners of the Debtor Entities over the time period of 2008 through 2017.
18	8/11/2020	Costaldo, Nicole	3.1	Document key metrics and continue to review of the audited financial statements for Purdue and Rhodes.
18	8/12/2020	Greenblatt, Matthew	1.0	Continue reconciliation of the cash distributions to the Sacklers in the audited financials to the AlixPartners report.
18	8/12/2020	Costaldo, Nicole	2.1	Update analysis re: cash on hand for distributions and how that number compares to the amount of funds distributed and identified by AlixPartners in the 1A report.
18	8/12/2020	Kyviakidis, Peter	1.0	Provide revisions re: reconciliation of cash available to pay distributions to owners of the Debtor Entities over the time period of 2008 through 2017.
18	8/13/2020	Diaz, Matthew	1.5	Review of the Sackler cash and non cash transfer analysis provided by Milbank and Huron.
18	8/13/2020	Diaz, Matthew	0.8	Participate in a call with Milbank and Huron to discuss the cash and non cash transfer report.
18	8/13/2020	Bromberg, Brian	0.8	Participate in a call with Milbank and Huron to discuss the cash and non cash transfer report.
18	8/14/2020	Diaz, Matthew	0.9	Review the Sackler report on the cash and non cash transfers and related next steps.
18	8/14/2020	Kim, Ye Darm	2.2	Review Raymond-side non cash activity presentation and summary.
18	8/14/2020	Bromberg, Brian	2.5	Review Raymond-side non cash activity presentation and summary.
18	8/17/2020	Kurtz, Emma	1.8	Prepare revisions to analysis re: historical transfers between Sackler entities to prepare slides re: cash transfers and net investments by entity.
18	8/17/2020	Kurtz, Emma	1.7	Prepare Sackler entity organizational chart to track cash flows between them and outside the network.
18	8/17/2020	Bromberg, Brian	1.9	Prepare slides summarizing B side report.
18	8/17/2020	Bromberg, Brian	1.7	Review non-cash transfers presentation and prepare summary for internal distribution.
18	8/18/2020	Greenblatt, Matthew	1.2	Continue review of the AlixPartners Cash Transfers Report and further reconciliation between the Alix report and the audited financial statements.
18	8/19/2020	Greenblatt, Matthew	1.8	Participate in discussions with team and continue summary of observations and development of proposed next steps for review and testing of the AlixPartners Cash Transfers Reports.
18	8/19/2020	Costaldo, Nicole	1.4	Attend call with team to go over the results of the analysis to determine the cash available after distributions when compared to AlixPartners' Cash Transfers of Value report.
18	8/19/2020	Mazzari, Meredith	0.6	Participate in internal discussion re: reconciliation of cash available to distributions for the relevant period.
18	8/19/2020	Mazzari, Meredith	2.6	Prepare reconciliation of cash distributions by Purdue and Rhodes.
18	8/19/2020	Mazzari, Meredith	0.8	Participate in internal discussion re: reconciliation of cash available to distributions for the relevant period.
18	8/19/2020	Kyviakidis, Peter	1.8	Participate in discussion with team re: summary of observations and next steps re: testing of the AlixPartners Cash Transfers Reports.
18	8/19/2020	Kyviakidis, Peter	1.5	Attend call with team to go over the results of the analysis to determine the cash available after distributions when compared to AlixPartners' Cash Transfers of Value report.
18	8/19/2020	Bromberg, Brian	2.2	Review and prepare additional diligence items to supplement UCC questions on B side transfer report.
18	8/20/2020	Diaz, Matthew	1.1	Review the updated cash reconciliation analysis versus the dividends received by the Sacklers.
18	8/20/2020	Costaldo, Nicole	1.8	Continue conference with team regarding the reconciling items per FTI and AlixPartners' review of the partners cash distributions from Purdue and Rhodes.
18	8/20/2020	Mazzari, Meredith	2.2	Participate in internal meeting re: revisions to preliminary reconciliation of cash distributions.
18	8/20/2020	Mazzari, Meredith	0.4	Draft email on status of reconciliation of cash distributions.
18	8/20/2020	Mazzari, Meredith	0.4	Revise reconciliation of cash distributions.
18	8/20/2020	Mazzari, Meredith	0.6	Review updates to analysis of reconciliation of cash distributions.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	8/20/2020	Mazzari, Meredith	1.8	Continue conference with team regarding the reconciling items per FTI and AlixPartners' review of the partners cash distributions from Purdue and Rhodes.
18	8/20/2020	Kyviakidis, Peter	0.8	Prepare for call to discuss a preliminary reconciliation of cash available to pay distributions over the time period of 2008 through 2017.
18	8/20/2020	Kyviakidis, Peter	1.5	Review updated version of analysis re: reconciliation of cash available to pay distributions over the time period of 2008 through 2017.
18	8/20/2020	Kyviakidis, Peter	2.3	Participate in internal meeting re: revisions to preliminary reconciliation of cash distributions.
18	8/20/2020	Bromberg, Brian	1.2	Review the Sackler net asset reports.
18	8/20/2020	Bromberg, Brian	0.8	Prepare slides for business update re: update on transfers diligence.
18	8/20/2020	Bromberg, Brian	1.2	Prepare additional diligence questions to supplement UCC question list for shareholders on transfers.
18	8/24/2020	Greenblatt, Matthew	1.2	Review summary of open items and reconciling items between Alix Report and Audited Financial Statements.
18	8/24/2020	Costaldo, Nicole	0.4	Discuss the results of the analysis of the reconciling items per AlixPartners Cash Transfers of Value report.
18	8/24/2020	Mazzari, Meredith	0.4	Attend call with forensic accounting team to discuss the results of the analysis of the reconciling items per AlixPartners Cash Transfers of Value report.
18	8/24/2020	Mazzari, Meredith	0.8	Participate in internal call re: updates to reconciliation of cash distributions.
18	8/24/2020	Mazzari, Meredith	0.6	Participate in discussion re: reconciliation of cash distributions
18	8/24/2020	Mazzari, Meredith	0.9	Revise reconciliation of cash distributions.
18	8/24/2020	Kyviakidis, Peter	0.8	Participate in internal call re: updates to reconciliation of cash distributions.
18	8/24/2020	Kyviakidis, Peter	0.5	Participate in discussion re: reconciliation of cash distributions
18	8/24/2020	Kyviakidis, Peter	0.5	Attend call with forensic accounting team to discuss the results of the analysis of the reconciling items per AlixPartners Cash Transfers of Value report.
18	8/25/2020	Mazzari, Meredith	0.3	Participate in internal call re: reconciliation of cash distributions memo.
18	8/25/2020	Mazzari, Meredith	1.5	Participate in internal call re: updates to reconciliation of cash distributions memo.
18	8/25/2020	Mazzari, Meredith	0.7	Revise reconciliation of cash distributions.
18	8/25/2020	Mazzari, Meredith	0.4	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/25/2020	Mazzari, Meredith	0.6	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	2.5	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Mazzari, Meredith	0.3	Quality check review of reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	1.2	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	1.1	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.7	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.6	Process revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.4	Continue processing revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	0.9	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Mazzari, Meredith	2.5	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Kyviakidis, Peter	0.8	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Kyviakidis, Peter	2.5	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Kyviakidis, Peter	1.3	Participate in internal call re: revisions to reconciliation of cash distributions memo.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	8/26/2020	Kyviakidis, Peter	3.0	Participate on call to revise preliminary reconciliation of cash available for distributions.
18	8/26/2020	Kyviakidis, Peter	1.0	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Kyviakidis, Peter	0.3	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/26/2020	Kyviakidis, Peter	1.0	Participate in internal call re: revisions to reconciliation of cash distributions memo.
18	8/27/2020	Greenblatt, Matthew	1.7	Finalize review and circulate summary memorandum of open items for the comparison between the Alix Partners report and the audited financial statements.
18	8/27/2020	Bromberg, Brian	1.1	Participate in call with Huron re: Side B transfers.
18	8/27/2020	Bromberg, Brian	0.3	Prepare summarize of diligence call with Huron re: Side B transfers.
18	8/31/2020	Diaz, Matthew	0.4	Review the Sackler deposition summary.
18	8/31/2020	Bromberg, Brian	1.5	Participate call with Committee re: mediation issues and discovery review.
18	8/31/2020	Bromberg, Brian	0.8	Review the latest financial discovery documents.
18	9/1/2020	Kurtz, Emma	1.2	Prepare comparison analysis of distributions received from IACs by B Side entities and IAC distributions captured in the IAC cash flow statement.
18	9/1/2020	Bromberg, Brian	1.7	Continue review of Sackler net asset reports and transfers report.
18	9/1/2020	Bromberg, Brian	1.8	Review Sackler net asset reports and transfers report.
18	9/1/2020	Bromberg, Brian	1.4	Review IAC transfers comparison analysis to cash flow statements.
18	9/3/2020	Kurtz, Emma	1.3	Review files received from Counsel re: Sackler B-Side report diligence.
18	9/3/2020	Kurtz, Emma	0.7	Prepare revisions to cash distribution comparison between the IAC financial statements and the Sackler B-Side report.
18	9/3/2020	Bromberg, Brian	0.8	Review IAC historical distributions to Sacklers.
18	9/3/2020	Bromberg, Brian	0.4	Discuss transfers and net assets discovery review with Counsel.
18	9/3/2020	Bromberg, Brian	1.7	Review discovery files produced by Milbank.
18	9/3/2020	Bromberg, Brian	1.4	Compare IAC distributions to IAC cash flow statements.
18	9/9/2020	Kurtz, Emma	0.7	Participate in call with Huron and other advisors to review Sackler B side cash transfers report.
18	9/9/2020	Diaz, Matthew	2.1	Review the Side B model on the historical transfers.
18	9/9/2020	Diaz, Matthew	0.8	Participate in call with Huron to discuss their report on the historical transfers.
18	9/9/2020	Kim, Ye Darm	1.0	Participate in call re: Sackler side B questions.
18	9/9/2020	Bromberg, Brian	1.9	Continue to review supporting model on Side B transfers.
18	9/9/2020	Bromberg, Brian	1.5	Review newly provided model for Side B transfers.
18	9/9/2020	Bromberg, Brian	0.9	Participate in call with Huron re: Side B transfers.
18	9/17/2020	Diaz, Matthew	1.3	Review the historical IAC cash transfers.
18	9/21/2020	Diaz, Matthew	0.9	Review the Side B transfers analysis supporting model.
18	9/21/2020	Bromberg, Brian	1.3	Continue review of the Side B transfers analysis support.
18	9/22/2020	Greenblatt, Matthew	0.5	Prepare summary of observations from review of Alix Partners Transfers Reports.
18	9/22/2020	Diaz, Matthew	1.5	Review the historical cash tracing analysis.
18	9/22/2020	Kim, Ye Darm	1.8	Review analyses of Sackler transfers and assets summaries.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	9/22/2020	Kim, Ye Darm	1.9	Prepare skeleton presentation re: Sackler asset reports and transfer analyses.
18	9/22/2020	Bromberg, Brian	3.2	Review Sackler net asset reports for Side A and Side B.
18	9/22/2020	Bromberg, Brian	2.8	Prepare outline of Side B Assets and Transfers deck.
18	9/23/2020	Kim, Ye Darm	0.5	Participate in call re: Sackler Assets and Transfers deck workplan.
18	9/23/2020	Kurtz, Emma	1.2	Analyze Raymond side net asset value for initial covered Sackler persons and trusts to tie out the total net asset value.
18	9/23/2020	Kurtz, Emma	1.3	Review net asset reports prepared for the Mortimer and Raymond Sackler sides to evaluate net asset value.
18	9/23/2020	Kurtz, Emma	1.7	Prepare slides re: Sackler net asset reports to include in Sackler assets and transfers update presentation to Committee.
18	9/23/2020	Bromberg, Brian	3.0	Review and process revisions to outline the net asset report and create diligence request list.
18	9/24/2020	Kim, Ye Darm	1.6	Review latest draft of the Sackler assets and transfer presentation.
18	9/24/2020	Kim, Ye Darm	1.8	Review FTI forensic team's workproduct re: reconciliation of cash transfers and excel support.
18	9/24/2020	Kim, Ye Darm	0.9	Update draft Sackler asset and transfers presentation for FTI forensic team workproduct.
18	9/24/2020	Kim, Ye Darm	0.9	Process revisions to the Sackler assets and transfers presentation.
18	9/24/2020	Kurtz, Emma	0.9	Prepare revisions to slides re: Sackler net asset reports.
18	9/24/2020	Bromberg, Brian	0.3	Prepare summary of transfer report analysis call for team.
18	9/24/2020	Bromberg, Brian	1.4	Review draft version of transfers presentation and process revisions.
18	9/24/2020	Bromberg, Brian	2.3	Review Huron reports and backup Excel on historical transfers.
18	9/24/2020	Bromberg, Brian	2.8	Review FTI forensic team workproduct on historical distributions.
18	9/24/2020	Bromberg, Brian	0.6	Participate in call with Huron re: Side B transfers.
18	9/25/2020	Diaz, Matthew	0.6	Review the deposition notes of Theresa Sackler re: historical transfers.
18	9/25/2020	Kim, Ye Darm	1.9	Review Huron's side B reconciliation analysis.
18	9/25/2020	Kim, Ye Darm	1.3	Review historical licensing agreements with Napp Pharmaceutical Holding Ltd.
18	9/25/2020	Kim, Ye Darm	1.3	Continue review of Huron's side-B reconciliation analysis.
18	9/25/2020	Kurtz, Emma	0.7	Analyze historical licensing agreements to evaluate reasonability of IAC royalty rates.
18	9/25/2020	Bromberg, Brian	1.3	Review and process revisions to Sackler net asset report presentation.
18	9/25/2020	Bromberg, Brian	0.8	Discuss workplan with team re: transfers and net asset diligence.
18	9/25/2020	Bromberg, Brian	3.3	Continue review and processing revisions to Sackler net asset report presentation.
18	9/28/2020	Kim, Ye Darm	1.1	Process revisions to Sackler assets and transfers update presentation.
18	9/28/2020	Kim, Ye Darm	1.9	Process revisions to Sackler asset and transfer presentation.
18	9/28/2020	Bromberg, Brian	1.6	Review latest version of Sackler asset report presentation.
18	9/28/2020	Bromberg, Brian	1.5	Continue review of the latest Sackler asset transfer report presentation.
18	9/29/2020	Greenblatt, Matthew	1.6	Participate in discussions with team re: summary of observations of Alix Partners Cash Report.
18	9/29/2020	Diaz, Matthew	0.9	Review the cash reconciliation analysis re: historical transfers.
18	9/29/2020	Diaz, Matthew	0.4	Review the reconciliation between the Alix report and the Side B report.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
18	9/29/2020	Costaldo, Nicole	1.0	Participate in conference with team re: cash distribution reconciliation analysis.
18	9/29/2020	Mazzari, Meredith	0.5	Participate in conference with team re: cash distribution reconciliation analysis.
18	9/29/2020	Mazzari, Meredith	0.4	Participate in call to prepare for meeting re: Reconciliation of AlixPartners Cash Transfers Report
18	9/29/2020	Kyviakidis, Peter	0.5	Participate in conference with team re: cash distribution reconciliation analysis.
18	9/29/2020	Kyviakidis, Peter	0.5	Participate in call to prepare for meeting re: Reconciliation of AlixPartners Cash Transfers Report
18	9/29/2020	Bromberg, Brian	3.7	Process revisions to the historical transfers and net assets presentation.
18	9/29/2020	Bromberg, Brian	0.6	Participate in discussion re: historical cash transfers with internal team.
18	9/30/2020	Bromberg, Brian	2.3	Process revisions to the net asset and historical transfers presentation.
18	9/30/2020	Bromberg, Brian	0.5	Participate in discussion re: historical cash transfers with internal team.
18	9/30/2020	Bromberg, Brian	1.8	Continue review and revisions to the net asset and historical transfers presentation.
18 Total			406.6	
19	6/1/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/3/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/9/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/12/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/15/2020	Kurtz, Emma	0.6	Update dataroom index to incorporate recently uploaded documents to share with team.
19	6/16/2020	Kim, Ye Darm	1.2	Prepare historical AHC professional fee tracker to forecast run rate for committee.
19	6/16/2020	Bromberg, Brian	0.8	Review historical AHC professional fee tracker to forecast run rate for committee.
19	6/16/2020	Bromberg, Brian	0.8	Process revisions to historical AHC professional fee tracker to forecast run rate for committee.
19	6/17/2020	Kim, Ye Darm	0.6	Update the historical AHC professional fee tracker per Counsel's comments to forecast run rate for committee.
19	6/17/2020	Bromberg, Brian	0.9	Coordinate with Counsel on assumptions re: historical AHC professional fee tracker to forecast run rate for committee.
19	6/18/2020	Kim, Ye Darm	0.4	Review historical allocation related time re: historical AHC professional fee tracker to forecast run rate for committee.
19	6/18/2020	Kim, Ye Darm	0.6	Update the historical AHC professional fee tracker per Counsel's comments to forecast run rate for committee.
19	6/26/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	6/29/2020	Kurtz, Emma	0.6	Update the dataroom index to include recently uploaded documents to share with team.
19	6/30/2020	Simms, Steven	0.4	Participate in internal correspondence on outstanding workstreams.
19	7/1/2020	Simms, Steven	0.4	Review current engagement workstreams and coordindate with team on workplan.
19	7/6/2020	Kurtz, Emma	0.4	Update dataroom indexes to incorporate recently uploaded documents to share with team.
19	7/6/2020	Simms, Steven	0.4	Review current engagement workstreams and updates on diligence progress.
19	7/9/2020	Simms, Steven	0.3	Participate on update call on case status and process.
19	7/13/2020	Kurtz, Emma	0.6	Prepare updates to the dataroom index to include recently uploaded files to share with team.
19	7/13/2020	Simms, Steven	0.4	Review current engagement workstreams and updates on diligence progress.
19	7/16/2020	Kurtz, Emma	0.7	Review recently shared documents to the dataroom to update dataroom index.
19	7/17/2020	Simms, Steven	0.4	Review current engagement workstreams and coordindate with team on workplan.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
19	7/21/2020	Simms, Steven	0.4	Participate on update call on case status and process.
19	7/27/2020	Kurtz, Emma	0.9	Review recently uploaded documents to the dataroom to update dataroom index and share with team.
19	7/28/2020	Simms, Steven	0.4	Review current engagement workstreams and updates on diligence progress.
19	8/3/2020	Simms, Steven	0.4	Participate in correspondence on open case items and ongoing workstreams.
19	8/3/2020	Kurtz, Emma	0.8	Prepare updates to the dataroom index to include recently uploaded documents to share with team.
19	8/10/2020	Kurtz, Emma	0.7	Prepare update to dataroom index to include recently shared documents to update team.
19	8/14/2020	Diaz, Matthew	0.6	Review of open and outstanding case issues and related next steps for diligence.
19	8/18/2020	Kurtz, Emma	0.4	Prepare updates to dataroom index to incorporate recently uploaded documents to share with team.
19	8/20/2020	Kurtz, Emma	0.4	Update dataroom index to include recently uploaded documents to share with team.
19	8/25/2020	Simms, Steven	0.4	Participate in discussion re: updates on case status.
19	8/25/2020	Simms, Steven	0.3	Participate in correspondence on case items related to UCC issues.
19	8/27/2020	Kurtz, Emma	1.1	Prepare updates to dataroom index to incorporate recently uploaded documents to share with team.
19	8/31/2020	Kim, Ye Darm	0.5	Discuss ongoing case work streams and upcoming deliverables to the Committee with internal team.
19	8/31/2020	Kurtz, Emma	1.2	Update dataroom index to include recently uploaded documents to share with team.
19	8/31/2020	Kurtz, Emma	0.6	Discuss ongoing case work streams and upcoming deliverables to the Committee with internal team.
19	9/1/2020	Simms, Steven	0.4	Participate in correspondence on case items re: outstanding workstreams.
19	9/1/2020	Kurtz, Emma	1.0	Participate in internal discussion re: outstanding case items and next steps.
19	9/9/2020	Simms, Steven	0.6	Participate in discussion re: next steps for mediation.
19	9/15/2020	Kurtz, Emma	0.6	Update dataroom index to incorporate recently uploaded documents to share with team.
19	9/18/2020	Bromberg, Brian	1.1	Participate in discussion with team re: outstanding workstreams.
19	9/18/2020	Simms, Steven	0.4	Participate in meeting re: ongoing Purdue workstreams.
19	9/18/2020	Kim, Ye Darm	0.8	Participate in meeting re: ongoing Purdue workstreams.
19	9/18/2020	Kurtz, Emma	1.0	Participate in meeting re: ongoing Purdue workstreams.
19	9/22/2020	Simms, Steven	0.4	Review updates on case issues of current workstreams.
19	9/25/2020	Diaz, Matthew	1.0	Participate in internal call re: IAC business plan update presentation, Sackler assets and transfers update, and additional upcoming deliverables.
19	9/25/2020	Kim, Ye Darm	1.0	Participate in internal call re: IAC business plan update presentation, Sackler assets and transfers update, and additional upcoming deliverables.
19	9/25/2020	Kurtz, Emma	0.7	Participate in internal call re: IAC business plan update presentation, Sackler assets and transfers update, and additional upcoming deliverables.
19	9/28/2020	Kurtz, Emma	1.1	Review recently received dataroom documents to update dataroom index to share with team.
19	9/30/2020	Simms, Steven	0.4	Participate in discussion re: next steps for mediation.
19 Total			32.1	
21	6/1/2020	Diaz, Matthew	0.5	Participate in a call with Kramer to discuss open due diligence items.
21	6/3/2020	Diaz, Matthew	1.2	Participate in the hearing with the AHC to discuss the non cash report and other topics.
21	6/11/2020	Diaz, Matthew	1.1	Participate in a call with the diligence subcommittee to discuss IAC, Purdue USA and non cash transfer due diligence.
21	6/11/2020	Diaz, Matthew	0.5	Participate in call with counsel and Houlihan to prepare for the due diligence sub committee meeting.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
21	6/11/2020	Kim, Ye Darm	1.0	Participate in call with diligence subcommittee re: IAC, domestic business plan, 1B report updates.
21	6/11/2020	Kim, Ye Darm	0.6	Participate in internal prep call before diligence subcommittee call.
21	6/11/2020	Kim, Ye Darm	0.5	Participate in pre-call with KL and HL for diligence subcommittee call.
21	6/17/2020	Diaz, Matthew	1.0	Participate in a meeting with the AHC to discuss business due diligence, the bar date and other topics.
21	6/17/2020	Diaz, Matthew	0.7	Review materials to prepare for the call with the Committee.
21	6/17/2020	Kim, Ye Darm	1.1	Participate in meeting with AHC re: diligence updates.
21	6/22/2020	Kim, Ye Darm	0.5	Participate in follow up call re: diligence subcommittee call.
21	6/24/2020	Joffe, Steven	1.2	Participate in weekly AHC committee call re: tax considerations.
21	6/24/2020	Diaz, Matthew	1.5	Participate on a call with the AHC to discuss the waterfall analysis.
21	6/24/2020	Diaz, Matthew	0.7	Review materials to prepare for the call with the Committee.
21	6/24/2020	Kim, Ye Darm	1.1	Participate in weekly AHC meeting re: illustrative cash value.
21	6/30/2020	Joffe, Steven	1.8	Participate in weekly AHC committee call re: tax considerations.
21	6/30/2020	Kim, Ye Darm	1.9	Participate in call with AHC re: bankruptcy strategies.
21	7/8/2020	Kim, Ye Darm	1.5	Participate in call with committee re: distributable value discussions.
21	7/14/2020	Diaz, Matthew	0.2	Draft correspondence to the committee's professional re: updates on the distributable value/waterfall analysis.
21	7/15/2020	Kim, Ye Darm	1.5	Participate in weekly call with AHC re: diligence updates.
21	7/29/2020	Bromberg, Brian	1.4	Participate in weekly Committee call re: distributable value and public health initiatives.
21	7/29/2020	Diaz, Matthew	0.9	Prepare for the call with the AHC on recovery analysis and hearing updates.
21	7/29/2020	Diaz, Matthew	1.5	Participate in a call with the AHC to discuss the recovery analysis and the hearing update.
21	7/29/2020	Kim, Ye Darm	1.0	Participate in weekly call with AHC re: diligence updates.
21	8/12/2020	Diaz, Matthew	0.7	Prepare for the weekly call with the AHC.
21	8/12/2020	Diaz, Matthew	1.8	Perform detailed review of the updated presentation to the AHC on business update, recovery analysis and transfers analysis for the weekly meeting.
21	8/12/2020	Kim, Ye Darm	0.5	Participate in pre-call for the weekly committee call re: business update presentation.
21	8/19/2020	Joffe, Steven	1.0	Participate in call with AHC re: tax considerations.
21	8/31/2020	Diaz, Matthew	1.3	Participate in the call with the AHC re: case updates and issues.
21	9/3/2020	Bromberg, Brian	1.4	Participate in weekly Committee call re: case updates.
21	9/3/2020	Kim, Ye Darm	1.1	Participate in weekly Committee call re: case updates.
21	9/9/2020	Bromberg, Brian	1.1	Participate in weekly Committee call re: compensation matters.
21	9/9/2020	Diaz, Matthew	1.3	Participate in weekly Committee call re: compensation matters.
21	9/9/2020	Kim, Ye Darm	1.0	Participate in weekly Committee call re: compensation matters.
21	9/16/2020	Bromberg, Brian	1.3	Participate in weekly Committee call re: KEIP KERP issues.
21	9/16/2020	Diaz, Matthew	1.1	Participate in weekly Committee call re: KEIP KERP issues.
21	9/16/2020	Kim, Ye Darm	1.1	Participate in weekly Committee call re: KEIP KERP issues.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
21	9/23/2020	Diaz, Matthew	1.2	Participate in weekly Committee call re: go forward mediation with the Sacklers, the employee compensation plans and the IAC current results.
21	9/23/2020	Kim, Ye Darm	1.0	Participate in weekly Committee call re: diligence updates.
21	9/23/2020	Bromberg, Brian	1.2	Participate in weekly Committee call re: IAC performance.
21 Total			43.0	
22	6/12/2020	Diaz, Matthew	1.4	Participate in a call with the NCSG re: the non cash transfers report, the IAC business plan and the domestic business plan.
22	6/12/2020	Diaz, Matthew	0.6	Review materials to prepare for the call with the NCSG.
22	6/12/2020	Kim, Ye Darm	1.4	Participate in meeting with NCSG re: IAC, US business plan, 1B report updates.
22	6/30/2020	Bromberg, Brian	1.5	Participate in call re: bankruptcy strategy with public side entities.
22	7/1/2020	Diaz, Matthew	0.6	Review the financial update presentation for the tribal group.
22	7/1/2020	Diaz, Matthew	1.0	Participate on a call with the tribal group re: diligence updates.
22	7/1/2020	Diaz, Matthew	0.3	Participate in a call with Counsel to prepare for the call with the tribal group.
22	7/1/2020	Diaz, Matthew	0.5	Participate in a call with Houlihan to prepare for a call with the tribes.
22	7/1/2020	Kim, Ye Darm	1.0	Participate in meeting re: Tribal group diligence updates.
22	7/3/2020	Diaz, Matthew	0.7	Participate in calls with counsel to discuss the non consenting states presentation.
22	7/6/2020	Diaz, Matthew	1.2	Participate in a call with the non consenting states to discuss expected case proceeds.
22	7/6/2020	Diaz, Matthew	1.1	Prepare for the update call with the mediators.
22	7/6/2020	Diaz, Matthew	0.9	Participate in a call with Counsel to prepare for the calls with the NCSG and the mediators.
22	7/6/2020	Diaz, Matthew	1.8	Participate in a call with the mediators to discuss expected waterfall proceeds.
22	7/6/2020	Kim, Ye Darm	1.9	Participate in call re: financial update presentation to the mediators.
22	7/9/2020	Kim, Ye Darm	1.5	Participate in mediation financial presentation with claimant group.
22	7/9/2020	Diaz, Matthew	1.0	Participate in a call with the personal injury ad hoc group.
22	7/9/2020	Diaz, Matthew	0.5	Prepare for the call with the personal injury ad hoc group.
22	7/13/2020	Kim, Ye Darm	1.0	Participate in discussion with UCC advisors re: distributable value assumptions.
22	7/16/2020	Kim, Ye Darm	0.5	Participate in call with UCC advisors re: joint presentation on distributable value.
22	7/22/2020	Diaz, Matthew	2.0	Participate on call with the creditor body, mediators and the Debtors to discuss the presentation on estimated distributable value.
22	7/22/2020	Diaz, Matthew	1.5	Preparation for the call with the creditors and the mediators to discuss the joint creditor presentation on distributable value.
22	7/22/2020	Diaz, Matthew	1.7	Participate in meeting with the DOJ to discuss the PHI presentation.
22	7/22/2020	Kim, Ye Darm	1.2	Participate in call re: PHI initiatives with DOJ.
22 Total			26.8	
24	6/9/2020	Tirabassi, Kathryn	0.2	Prepare updated billing summary.
24	6/10/2020	Tirabassi, Kathryn	0.4	Finalize April 2020 Fee Statement.
24	6/11/2020	Hellmund-Mora, Marili	0.5	Finalize the April fee application.
24	6/16/2020	Kim, Ye Darm	2.7	Prepare May Fee application.
24	6/16/2020	Kim, Ye Darm	1.1	Continue preparation of May fee application.
24	6/16/2020	Kim, Ye Darm	2.6	Continue preparation of May fee application.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
24	6/17/2020	Diaz, Matthew	0.6	Review the May fee statement.
24	6/18/2020	Kim, Ye Darm	1.8	Process revisions to May fee application.
24	6/26/2020	Kim, Ye Darm	0.9	Review and finalize May fee app for distribution to Counsel.
24	7/6/2020	Kim, Ye Darm	0.6	Process revisions to the May fee application.
24	7/8/2020	Kim, Ye Darm	3.6	Prepare draft of second interim fee application.
24	7/11/2020	Kim, Ye Darm	2.4	Process revisions to draft second interim fee application.
24	7/13/2020	Kim, Ye Darm	3.1	Process revisions to the second interim fee application.
24	7/13/2020	Kim, Ye Darm	1.2	Process revisions to the May fee application.
24	7/17/2020	Kim, Ye Darm	0.7	Prepare excel support for May fee application.
24	7/21/2020	Kim, Ye Darm	0.4	Prepare backup data for May fee application.
24	7/31/2020	Kim, Ye Darm	1.9	Review the June fee application.
24	7/31/2020	Kim, Ye Darm	2.6	Review the June fee application.
24	7/31/2020	Kim, Ye Darm	1.8	Prepare draft of June fee application.
24	7/31/2020	Kim, Ye Darm	2.8	Review the June fee application.
24	8/3/2020	Kim, Ye Darm	2.6	Process revisions to draft June Fee application.
24	8/6/2020	Kim, Ye Darm	0.8	Process revisions to June fee application draft.
24	8/7/2020	Diaz, Matthew	0.8	Review the June bill.
24	8/7/2020	Kim, Ye Darm	0.6	Prepare update tracker of historical billing and receipts.
24	8/12/2020	Diaz, Matthew	0.5	Review of the June fee statement.
24	8/12/2020	Kim, Ye Darm	1.6	Prepare final version of the June Fee application.
24	8/25/2020	Bromberg, Brian	0.3	Review latest June FTI fee application.
24	9/1/2020	Kim, Ye Darm	3.1	Prepare the July Fee Application.
24	9/1/2020	Kim, Ye Darm	2.2	Review the July Fee Application.
24	9/1/2020	Kim, Ye Darm	2.9	Continue review of the July Fee Application.
24	9/2/2020	Diaz, Matthew	1.4	Review the July bill.
24	9/2/2020	Kim, Ye Darm	1.3	Finalize draft of the July Fee Application.
24	9/2/2020	Kim, Ye Darm	0.8	Process revisions to the draft of the July Fee Application.
24	9/23/2020	Kim, Ye Darm	1.8	Prepare draft of the August fee app.
24	9/23/2020	Kim, Ye Darm	2.0	Prepare exhibits for the August fee app.
24	9/23/2020	Kim, Ye Darm	2.8	Review the August fee app.
24	9/23/2020	Kim, Ye Darm	2.6	Review the August fee app.
24	9/25/2020	Diaz, Matthew	0.7	Review the August bill.
24	9/25/2020	Hellmund-Mora, Marili	0.5	Finalize the July fee application.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
24	9/25/2020	Kim, Ye Darm	0.5	Correspond with Counsel re: fee application updates.
24	9/28/2020	Kim, Ye Darm	0.6	Prepare draft August fee application.
24	9/28/2020	Kim, Ye Darm	2.3	Process revisions to August fee app.
24 Total			64.6	
28	6/1/2020	Diaz, Matthew	0.5	Review outstanding diligence items re: IACs.
28	6/1/2020	Kurtz, Emma	0.5	Participate in internal discussion re: IAC diligence progress and cash transfer report.
28	6/1/2020	Bromberg, Brian	1.1	Review and process revisions to IAC diligence report for the AHC.
28	6/1/2020	Bromberg, Brian	1.0	Review IAC diligence report to prepare notes for presentation.
28	6/2/2020	Diaz, Matthew	0.5	Review the discovery disputes letter between the UCC and the IACs.
28	6/2/2020	Bromberg, Brian	0.7	Review updated IAC diligence questions list.
28	6/2/2020	Bromberg, Brian	0.8	Review UCC letter re: IACs and diligence issues.
28	6/2/2020	Bromberg, Brian	1.0	Review newly provided dataroom documents re: IAC diligence.
28	6/3/2020	Diaz, Matthew	1.7	Review the updated IAC due diligence responses and outstanding questions.
28	6/3/2020	Kurtz, Emma	1.2	Prepare draft question list for call with IACs CFO.
28	6/3/2020	Bromberg, Brian	1.2	Review IAC diligence report for presentation notes.
28	6/4/2020	Diaz, Matthew	1.1	Continue review of the IAC diligence responses and outstanding questions list.
28	6/4/2020	Kurtz, Emma	0.5	Prepare revisions to proposed question list for call with IAC CFO.
28	6/4/2020	Bromberg, Brian	0.5	Review product liability claims for IAC partner.
28	6/4/2020	Bromberg, Brian	2.5	Prepare topics list for call with IAC CFO.
28	6/4/2020	Bromberg, Brian	1.3	Finalize agenda for diligence discussion and questions list re: IAC CFO call.
28	6/5/2020	Diaz, Matthew	0.9	Perform detailed review of the question list for the call with IAC CFO.
28	6/5/2020	Diaz, Matthew	0.6	Participate in call to discuss IAC due diligence status.
28	6/5/2020	Kurtz, Emma	0.3	Discuss internally re: next steps in IAC diligence process.
28	6/5/2020	Kurtz, Emma	2.6	Prepare detailed variance analysis of November plan to Revised plan by individual entity to evaluate changes to both historical results and projections.
28	6/5/2020	Kurtz, Emma	0.3	Prepare updated diligence request list to incorporate additional clarifying questions re: IACs financial performance.
28	6/5/2020	Bromberg, Brian	0.9	Finalize diligence question list to send to IACs re: IAC CFO call.
28	6/5/2020	Bromberg, Brian	2.8	Review IAC projection variance files.
28	6/5/2020	Bromberg, Brian	0.8	Discuss IAC diligence status with Debtor and UCC advisors.
28	6/5/2020	Bromberg, Brian	2.4	Review latest IAC financial information provided.
28	6/5/2020	Bromberg, Brian	0.5	Discuss changes to make to analysis re: IAC diligence.
28	6/5/2020	Bromberg, Brian	1.2	Finalize agenda and questions list after discussion with team re: IAC CFO call.
28	6/7/2020	Diaz, Matthew	0.5	Review the UCC letter and due diligence request list being sent to IAC CFO.
28	6/8/2020	Suric, Emil	0.5	Prepare follow up diligence information request re: product forecasts.
28	6/8/2020	Kurtz, Emma	1.3	Prepare analysis of net marketing support payments adjustment to the revised budget.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/8/2020	Bromberg, Brian	0.9	Finalize CFO question list to send to IACs.
28	6/8/2020	Bromberg, Brian	1.0	Review updated analysis on P&L variance and marketing support payments re: IAC diligence.
28	6/9/2020	Suric, Emil	0.5	Participate in Purdue diligence call re: product forecasts.
28	6/9/2020	Kurtz, Emma	0.4	Discuss internally re: analysis of revised business plan and preparation of revised presentation.
28	6/9/2020	Kurtz, Emma	1.3	Prepare revised business plan analysis presentation to incorporate the revised business plan.
28	6/9/2020	Kurtz, Emma	2.8	Prepare analysis of updated price/volume information to evaluate sales by product for the revised business plan.
28	6/9/2020	Bromberg, Brian	1.5	Review updated IAC P&L files.
28	6/9/2020	Bromberg, Brian	0.5	Provide list of IAC documents relied upon re: IAC diligence presentation.
28	6/9/2020	Bromberg, Brian	0.4	Discuss IAC business plan diligence with internal team.
28	6/9/2020	Bromberg, Brian	0.5	Discuss IAC diligence work plan with internal team.
28	6/9/2020	Bromberg, Brian	1.3	Review prior version of IAC presentation for additional updates.
28	6/10/2020	Diaz, Matthew	1.1	Review the updated IAC diligence report.
28	6/10/2020	Kim, Ye Darm	0.5	Participate in discussion re: revisions to IAC presentation.
28	6/10/2020	Kurtz, Emma	2.2	Prepare updated analysis of sales by product by country and region to evaluate revised business plan projections.
28	6/10/2020	Kurtz, Emma	2.6	Prepare revised business plan overview slides re: IAC revised business plan presentation.
28	6/10/2020	Kurtz, Emma	0.3	Discuss internally re: work plan to prepare revised IAC business plan analysis presentation.
28	6/10/2020	Bromberg, Brian	0.3	Review response from IAC management re: diligence question list.
28	6/10/2020	Bromberg, Brian	0.8	Review IAC diligence report for presentation notes.
28	6/11/2020	Diaz, Matthew	1.6	Perform final review of the IAC reports for the due diligence subcommittee.
28	6/11/2020	Diaz, Matthew	0.6	Review the updated IAC diligence request list.
28	6/11/2020	Kim, Ye Darm	0.4	Review central cost updates for IAC business plan diligence presentation.
28	6/11/2020	Kim, Ye Darm	2.1	Update country-level sales charts re: IAC business plan diligence presentation.
28	6/11/2020	Kurtz, Emma	2.7	Prepare slides for revised IAC business plan presentation re: consolidated and regional sales by product category to evaluate business plan projections.
28	6/11/2020	Kurtz, Emma	1.2	Analyze revised business plan projections by entity to prepare bridge analysis from 2019 to 2024.
28	6/11/2020	Bromberg, Brian	0.5	Present to diligence committee on IAC diligence report.
28	6/11/2020	Bromberg, Brian	0.7	Review proposed UCC letter to IAC management and provide comments.
28	6/11/2020	Bromberg, Brian	1.4	Review updated IAC P&L variance analysis.
28	6/12/2020	Kim, Ye Darm	0.8	Review direct / central cost figures in updated plan numbers.
28	6/12/2020	Kurtz, Emma	2.4	Prepare slides re: analysis of central costs in revised IAC business plan.
28	6/12/2020	Kurtz, Emma	1.3	Prepare analysis of central costs within the revised IAC business plan.
28	6/12/2020	Bromberg, Brian	0.3	Provide comments on UCC letter to IAC management.
28	6/12/2020	Bromberg, Brian	0.5	Participate in call with NCSG re: IACs.
28	6/13/2020	Bromberg, Brian	0.7	Send IAC diligence questions to Huron.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/13/2020	Bromberg, Brian	2.5	Review newly provided IAC diligence provided and prepare summary for team.
28	6/14/2020	Kurtz, Emma	2.2	Prepare analysis of Southeast Asia sales by product, as a region and by individual country, in preparation for call with head of Southeast Asia.
28	6/14/2020	Bromberg, Brian	0.5	Review diligence questions for southeast Asia IAC manager.
28	6/15/2020	Kim, Ye Darm	1.8	Review product P&L model provided by Huron for sales trends by country/entity.
28	6/15/2020	Kim, Ye Darm	1.4	Review latest IAC P&L model provided by Huron.
28	6/15/2020	Kurtz, Emma	1.3	Prepare analysis of Latin America sales by product to prepare for diligence call with regional manager.
28	6/15/2020	Kurtz, Emma	2.2	Prepare analysis of product-level P&L received from the Company to evaluate sales and costs by product by entity.
28	6/15/2020	Kurtz, Emma	0.5	Review revised budget received from the Company incorporating product-level information.
28	6/15/2020	Bromberg, Brian	3.2	Review product level backup files for IACs.
28	6/15/2020	Bromberg, Brian	2.8	Review newly provided P&L for IACs.
28	6/16/2020	Kurtz, Emma	1.4	Update sales by product analysis by country for Southeast Asia to reflect revised P&L in preparation for call with country manager.
28	6/16/2020	Kurtz, Emma	0.6	Prepare diligence questions in preparation for call with Southeast Asia country manager.
28	6/16/2020	Kurtz, Emma	0.9	Prepare revisions to analysis of revised product-level P&L to incorporate internal comments.
28	6/16/2020	Kurtz, Emma	1.1	Prepare revisions to Southeast Asia slides to include revised sales by product information and country-level P&Ls.
28	6/16/2020	Kurtz, Emma	1.8	Prepare analysis of product sales and costs build-up by entity to evaluate revised budget information.
28	6/16/2020	Bromberg, Brian	0.8	Review Southeast Asia IAC financials ahead of call with country manager.
28	6/16/2020	Bromberg, Brian	0.8	Continue to review analysis on newly provided product level backup.
28	6/16/2020	Bromberg, Brian	2.3	Review analysis on newly provided product level backup.
28	6/17/2020	Diaz, Matthew	1.3	Review the updated IAC business plan diligence materials.
28	6/17/2020	Kim, Ye Darm	2.8	Continue updating IAC diligence deck for qualitative sales trends information.
28	6/17/2020	Kim, Ye Darm	2.6	Continue updating IAC diligence deck for qualitative information on sales trends.
28	6/17/2020	Kim, Ye Darm	1.3	Update IAC diligence deck for qualitative sales trend information.
28	6/17/2020	Kurtz, Emma	0.8	Prepare additional questions for the Southeast Asia region manager to account for commentary previously received in response to diligence questions.
28	6/17/2020	Kurtz, Emma	0.4	Prepare revisions to analysis of revised product-level P&L to incorporate internal comments.
28	6/17/2020	Bromberg, Brian	0.8	Review diligenc questions for southeast Asia IAC manager.
28	6/17/2020	Bromberg, Brian	1.2	Review Southeast Asia IAC diligence responses ahead of call with country manager.
28	6/17/2020	Bromberg, Brian	1.6	Review IAC product analysis model and provide revisions.
28	6/18/2020	Kurtz, Emma	1.8	Update IAC April business plan review presentation to reflect revised product-level P&L received from the Company.
28	6/19/2020	Diaz, Matthew	1.7	Review responses to the IAC diligence questions and materials provided.
28	6/19/2020	Kim, Ye Darm	1.2	Review responses to China IAC diligence questions from Huron.
28	6/19/2020	Kurtz, Emma	1.8	Prepare revisions to Latin America slides to reflect latest analysis re: product-level P&L in preparation for call with regional manager.
28	6/19/2020	Bromberg, Brian	0.8	Review E&Y vendor due diligence report to compare with diligence responses.
28	6/19/2020	Bromberg, Brian	0.7	Review responses on diligence questions for China IAC.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/21/2020	Bromberg, Brian	0.5	Review E&Y consumer health vendor due diligence report to compare with diligence responses.
28	6/22/2020	Diaz, Matthew	0.6	Review diligence questions for E&Y re: vendor due diligence.
28	6/22/2020	Kim, Ye Darm	0.4	Review diligence topics for call with EY.
28	6/23/2020	Kim, Ye Darm	1.2	Prepare summary of EY call for distribution to internal team.
28	6/23/2020	Kim, Ye Darm	1.1	Participate in diligence call with EY re: IAC VDD report.
28	6/23/2020	Kurtz, Emma	0.6	Participate in call with E&Y to discuss progress on VDD report.
28	6/23/2020	Bromberg, Brian	0.3	Prepare summary of diligence call with E&Y re: IAC vendor due diligence status.
28	6/23/2020	Bromberg, Brian	0.5	Participate in call with E&Y re: IAC vendor due diligence status.
28	6/24/2020	Diaz, Matthew	1.8	Participate in a call with IAC CFO to review the IAC performance and diligence.
28	6/24/2020	Kim, Ye Darm	0.5	Review question list for LatAm regional manager in preparation of call the following day.
28	6/24/2020	Kim, Ye Darm	2.0	Participate in call with IAC global CFO re: business plan diligence.
28	6/24/2020	Kim, Ye Darm	1.2	Review LatAm product slides in preparation for call the following day.
28	6/24/2020	Kim, Ye Darm	1.1	Review materials shared for the CFO diligence call.
28	6/24/2020	Kim, Ye Darm	0.8	Review question list and diligence items to prepare for CFO call.
28	6/24/2020	Kurtz, Emma	1.7	Participate in call with Arnaud Breabout re: IAC 2020 business plan and YTD 2020 performance.
28	6/24/2020	Kurtz, Emma	0.9	Prepare diligence questions for call with Latin America regional manager.
28	6/24/2020	Bromberg, Brian	0.8	Review CFO provided diligence responses and materials.
28	6/24/2020	Bromberg, Brian	2.0	Participate in call with global CFO re: IAC diligence.
28	6/24/2020	Bromberg, Brian	0.7	Review LatAm diligence questions to prepare for diligence call.
28	6/24/2020	Bromberg, Brian	1.2	Review financial information to prepare for call with LatAm IAC.
28	6/24/2020	Bromberg, Brian	1.2	Review product P&L backup to prepare for LatAM IAC diligence call.
28	6/25/2020	Diaz, Matthew	1.4	Review the updated LATAM diligence requests and responses.
28	6/25/2020	Kim, Ye Darm	0.9	Prepare summary of LatAm diligence call for distribution to internal team.
28	6/25/2020	Kim, Ye Darm	1.1	Participate in meeting with LatAm regional manager re: business plan diligence.
28	6/25/2020	Kurtz, Emma	1.1	Participate in diligence call with Latin America regional manager re: revised business plan.
28	6/25/2020	Bromberg, Brian	1.0	Participate in call with LatAm IAC subregional manager.
28	6/25/2020	Bromberg, Brian	1.1	Review provided P&L information for Southeast Asia IAC.
28	6/25/2020	Bromberg, Brian	1.2	Review Project Malta model analysis and provide revisions.
28	6/25/2020	Bromberg, Brian	0.5	Review diligence questions for southeast Asia IAC manager.
28	6/25/2020	Bromberg, Brian	1.0	Prepare summary of IAC CFO call for internal distribution.
28	6/26/2020	Diaz, Matthew	1.1	Perform detailed review of the updated IAC due diligence requests and responses.
28	6/26/2020	Kim, Ye Darm	1.3	Review presentations from Huron re: SEA and LatAm regions.
28	6/26/2020	Kim, Ye Darm	1.1	Participate in diligence call with SEA regional manager re: business plan diligence.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	6/26/2020	Kim, Ye Darm	0.8	Review draft questions for meetings with Europe, LAM, and TechOps.
28	6/26/2020	Kim, Ye Darm	0.9	Prepare summary of call with SEA manager for internal distribution.
28	6/26/2020	Kurtz, Emma	0.8	Prepare diligence questions in preparation for call with Alberto Martinez.
28	6/26/2020	Kurtz, Emma	1.0	Participate in diligence call with Southeast Asia regional manager to discuss the revised business plan.
28	6/26/2020	Kurtz, Emma	0.6	Prepare questions for the call with Birgit Kudlek re: TechOps revised business plan and YTD performance.
28	6/26/2020	Kurtz, Emma	0.9	Prepare diligence questions for discussion with Raman Singh.
28	6/26/2020	Bromberg, Brian	1.0	Participate in diligence call with Southeast Asia IAC country manager.
28	6/26/2020	Bromberg, Brian	1.0	Review diligence materials to prepare for Southeast Asia IAC country manager call.
28	6/26/2020	Bromberg, Brian	1.4	Review provided materials to build question list for future management calls.
28	6/27/2020	Bromberg, Brian	2.1	Create topic list for call with Europe IAC CEO.
28	6/29/2020	Suric, Emil	1.5	Review of due diligence documents pertaining to new BD opportunity and call with Purdue Management to discuss opportunity.
28	6/29/2020	Diaz, Matthew	1.1	Review diligence question lists for calls on LATAM IACs and IAC head of tech ops.
28	6/29/2020	Kim, Ye Darm	0.6	Review updated question list re: LAM and TechOps.
28	6/29/2020	Bromberg, Brian	1.8	Review IAC financial information provided in dataroom to prepare for future management diligence calls.
28	6/29/2020	Bromberg, Brian	1.3	Create diligence question list for LatAm CEO.
28	6/29/2020	Bromberg, Brian	0.4	Review diligence question list for LatAm CEO.
28	6/29/2020	Bromberg, Brian	0.8	Review diligence question list for IAC head of technical operations.
28	6/29/2020	Bromberg, Brian	1.2	Create question list for IAC head of technical operations.
28	6/29/2020	Bromberg, Brian	0.3	Revise question lists for calls with IAC management.
28	6/30/2020	Diaz, Matthew	0.8	Review the updated IAC due diligence request list.
28	6/30/2020	Diaz, Matthew	0.7	Review the IAC due diligence update presentation for the committee.
28	6/30/2020	Kim, Ye Darm	1.0	Participate in call with EUR manager re: IAC diligence.
28	6/30/2020	Kim, Ye Darm	2.1	Prepare summary outline of IAC diligence updates for Committee re: EY VDD, IAC YTD financials, IAC budget to actual variances.
28	6/30/2020	Kurtz, Emma	0.4	Prepare revisions to Steve Jamieson question list to incorporate internal comments.
28	6/30/2020	Kurtz, Emma	1.1	Participate in diligence call with Alberto Martinez, the Europe regional manager, to discuss the revised business plan.
28	6/30/2020	Kurtz, Emma	1.2	Review outstanding questions for Steve Jamieson to prepare revised diligence question list.
28	6/30/2020	Bromberg, Brian	1.5	Review IAC product analysis model and provide revisions.
28	6/30/2020	Bromberg, Brian	1.3	Prepare update on ongoing IAC diligence for Committee.
28	6/30/2020	Bromberg, Brian	0.5	Prepare summary and review outstanding diligence items re: IAC CEO diligence Call.
28	6/30/2020	Bromberg, Brian	1.0	Participate in call with IAC Europe CEO.
28	6/30/2020	Bromberg, Brian	0.5	Review diligence materials and question lists to prepare for call with Europe CEO.
28	6/30/2020	Bromberg, Brian	1.7	Review updated diligence question list for IAC accountant.
28	7/1/2020	Bromberg, Brian	2.4	Revise and prioritize inquiries for IAC accountants.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	7/1/2020	Bromberg, Brian	0.4	Participate in call with counsel and Houlihan re: IAC reporting.
28	7/1/2020	Bromberg, Brian	0.2	Review proposed IAC diligence update summary.
28	7/1/2020	Bromberg, Brian	2.9	Review and edit updated question list for IAC accountant.
28	7/1/2020	Bromberg, Brian	0.6	Participate in call with Houlihan on IAC diligence.
28	7/1/2020	Bromberg, Brian	0.4	Review old list of diligence topics for call with Deutsche Bank.
28	7/1/2020	Bromberg, Brian	0.6	Discuss IAC sale process with Debtors' advisors.
28	7/1/2020	Diaz, Matthew	0.6	Draft email to the committee on the IAC due diligence.
28	7/1/2020	Diaz, Matthew	0.5	Participate in a call with KL and Houlihan to discuss IAC due diligence and next steps.
28	7/1/2020	Diaz, Matthew	1.1	Detail review of agenda and due diligence list for call with IAC accountant.
28	7/1/2020	Kim, Ye Darm	0.8	Review draft of diligence questions re: IAC accountant.
28	7/1/2020	Kim, Ye Darm	0.7	Participate in internal discussion re: IAC diligence meeting preparation.
28	7/2/2020	Bromberg, Brian	0.4	Summarize call notes from IAC Technical Operations diligence call.
28	7/2/2020	Bromberg, Brian	1.0	Participate in call with IAC Technical Operations head.
28	7/2/2020	Bromberg, Brian	0.7	Prepare for call with head of IAC Technical Operations.
28	7/2/2020	Bromberg, Brian	0.7	Revise and update Deutsche Bank diligence discussion topic list.
28	7/2/2020	Diaz, Matthew	0.5	Participate on a call with counsel and Houlihan to discuss the IAC due diligence.
28	7/2/2020	Diaz, Matthew	1.5	Review status of IAC due diligence and ongoing diligence calls.
28	7/2/2020	Kim, Ye Darm	0.7	Prepare updates for the IAC diligence summary update presentation.
28	7/2/2020	Kim, Ye Darm	1.0	Participate in diligence meeting re: IAC TechOps.
28	7/2/2020	Kim, Ye Darm	0.6	Review TechOps diligence question in preparation of meeting with Birgit Kudlek.
28	7/2/2020	Kim, Ye Darm	0.3	Process additional updates to IAC diligence update presentation.
28	7/3/2020	Bromberg, Brian	0.8	Revise new slides in IAC diligence update presentation.
28	7/3/2020	Bromberg, Brian	0.6	Participate in call on IAC diligence update presentations.
28	7/3/2020	Bromberg, Brian	2.2	Review IAC diligence update presentation and provide revisions.
28	7/3/2020	Kim, Ye Darm	0.6	Review revised questions list for IAC accountant re: IAC diligence.
28	7/3/2020	Kim, Ye Darm	1.2	Process revisions to IAC diligence update presentation.
28	7/3/2020	Kim, Ye Darm	0.9	Process updates to IAC diligence update presentation.
28	7/6/2020	Bromberg, Brian	0.5	Discuss IAC diligence updates with diligence subcommittee.
28	7/6/2020	Bromberg, Brian	1.1	Participate in diligence call with IAC LAM region head.
28	7/6/2020	Bromberg, Brian	0.6	Prepare for call with IAC LAM region head.
28	7/6/2020	Bromberg, Brian	0.4	Summarize notes from IAC LAM region head.
28	7/6/2020	Kim, Ye Darm	1.0	Participate in diligence meeting re: LAM diligence updates with region head.
28	7/6/2020	Kim, Ye Darm	1.0	Participate in meeting re: financial presentation on the IACs.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	7/6/2020	Kurtz, Emma	0.9	Prepare updated outstanding diligence request lists to include follow up questions from recent diligence calls.
28	7/6/2020	Kurtz, Emma	1.0	Participate in diligence call with LAM region head to discuss LAM performance YTD and 2020 business plan.
28	7/7/2020	Bromberg, Brian	0.8	Compile diligence questions for discussion with IAC chief compliance officer.
28	7/7/2020	Kim, Ye Darm	1.0	Participate in diligence meeting re: IAC accountant diligence questions.
28	7/8/2020	Diaz, Matthew	0.4	Review of the due diligence list for the chief compliance officer diligence call.
28	7/8/2020	Kurtz, Emma	0.6	Prepare revisions to outstanding diligence request list re: completed requests and additional questions post call with Raman.
28	7/9/2020	Bromberg, Brian	0.8	Summarize call with IAC Chief Compliance Officer to discuss with team.
28	7/9/2020	Bromberg, Brian	0.5	Participate in call with Chief Compliance Officer of Mundipharma.
28	7/9/2020	Kim, Ye Darm	0.6	Review call notes re: compliance diligence call.
28	7/9/2020	Kim, Ye Darm	1.1	Review Celltrion Agreement Amendments from IACs.
28	7/9/2020	Kim, Ye Darm	0.6	Participate in meeting re: IAC compliance overview.
28	7/9/2020	Kurtz, Emma	0.4	Participate in call with head of compliance, Lori Reber, to compliance function.
28	7/10/2020	Kurtz, Emma	0.4	Prepare revisions to outstanding diligence request list to include additional questions and responses.
28	7/13/2020	Kim, Ye Darm	0.7	Review IAC business diligence materials for call.
28	7/14/2020	Bromberg, Brian	0.3	Prepare comment and revisions to business development call summary.
28	7/14/2020	Bromberg, Brian	0.4	Prepare for call with Deutsche Bank re: IAC sale process.
28	7/14/2020	Bromberg, Brian	1.0	Participate in call with Deutsche Bank re: IAC sale process.
28	7/14/2020	Bromberg, Brian	1.1	Participate in diligence call with IAC business development head.
28	7/14/2020	Bromberg, Brian	0.8	Review notes to prepare for call with IAC head of business development.
28	7/14/2020	Diaz, Matthew	1.2	Participate in a call with Deutsche Bank to discuss the IAC sale process.
28	7/14/2020	Kim, Ye Darm	1.2	Participate in call with Deutsche Bank re: IAC sale considerations.
28	7/14/2020	Kim, Ye Darm	0.6	Prepare and review materials for IAC business development diligence call.
28	7/14/2020	Kim, Ye Darm	0.9	Prepare summary of diligence call re: IAC business development.
28	7/14/2020	Kim, Ye Darm	0.8	Review information from Huron re: IAC R&D diligence responses.
28	7/14/2020	Kim, Ye Darm	0.8	Summarize call with Deutsche Bank re: IAC sale considerations.
28	7/14/2020	Kim, Ye Darm	1.0	Participate in call re: IAC business development diligence.
28	7/14/2020	Kurtz, Emma	1.2	Participate in call with Deutsche Bank to discuss IAC sale process.
28	7/14/2020	Kurtz, Emma	1.0	Participate in diligence call with Marco Cerato, head of business development, to discuss business plan overlay.
28	7/15/2020	Bromberg, Brian	1.0	Review updates to IAC cash flow information provided by Huron.
28	7/15/2020	Kurtz, Emma	1.4	Prepare analysis of Research and Development breakdown provided by Company to compare to the original business plan and the revised business plan.
28	7/17/2020	Bromberg, Brian	2.6	Review IAC diligence responses provided by Huron.
28	7/17/2020	Bromberg, Brian	1.4	Review R&D and capex breakdowns compared to original business plan.
28	7/17/2020	Kurtz, Emma	0.4	Review breakdown of Capital Expenditures provided by the Company and compare to the Cash Flow statement.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	7/17/2020	Kurtz, Emma	1.1	Develop draft agenda and diligence questions in preparation for call with the Global Treasurer.
28	7/20/2020	Bromberg, Brian	2.6	Create consolidated diligence response for IACs.
28	7/20/2020	Bromberg, Brian	0.6	Prepare agenda for call with global treasurer.
28	7/20/2020	Bromberg, Brian	2.6	Prepare global follow up to provided IAC diligence responses.
28	7/20/2020	Bromberg, Brian	1.8	Review and answer Debtor questions on diligence update presentation.
28	7/20/2020	Kim, Ye Darm	0.9	Review summary of diligence responses from Huron re: IACs.
28	7/20/2020	Kurtz, Emma	0.8	Draft diligence responses to Huron re: recently received information and follow-up requests.
28	7/20/2020	Kurtz, Emma	1.7	Prepare comparison between diligence responses received from Huron and the previously received financial statements to evaluate responsiveness.
28	7/20/2020	Kurtz, Emma	0.4	Review responses to Steve Jamieson diligence requests to develop follow up questions.
28	7/20/2020	Kurtz, Emma	0.2	Prepare revisions to diligence response to Huron per internal comments.
28	7/21/2020	Bromberg, Brian	1.0	Finalize and send consolidated diligence response to IACs.
28	7/21/2020	Bromberg, Brian	0.7	Comment on non reliance letter re: IAC diligence.
28	7/22/2020	Kim, Ye Darm	0.7	Review Huron's running list of diligence questions re: IAC accountant.
28	7/22/2020	Kurtz, Emma	0.7	Prepare updates to outstanding diligence request list to incorporate responses from the Company and additional requests.
28	7/23/2020	Kim, Ye Darm	1.3	Review Huron diligence responses re: IAC accountant and prepare follow ups.
28	7/23/2020	Kurtz, Emma	1.2	Review additional responses received from the Company re: Steve Jamieson diligence questions.
28	7/24/2020	Bromberg, Brian	1.0	Participate in call with CEO of Mundipharma.
28	7/24/2020	Diaz, Matthew	1.0	Participate in a call with the CEO of Mundipharma to discuss his vision for the business.
28	7/24/2020	Diaz, Matthew	0.6	Prepare for the call with the CEO.
28	7/24/2020	Diaz, Matthew	1.5	Review the updated IAC diligence question list.
28	7/24/2020	Kim, Ye Darm	1.0	Participate in diligence call with IAC CEO.
28	7/24/2020	Kurtz, Emma	0.8	Participate in diligence call with Marc Princen, the global CEO of Mundipharma.
28	7/27/2020	Bromberg, Brian	0.7	Review topics for call with global treasurer.
28	7/27/2020	Bromberg, Brian	0.5	Coordinate outstanding IAC diligence requests with other case professionals.
28	7/27/2020	Bromberg, Brian	3.1	Review updated accountant files and question tracker for upcoming meeting.
28	7/27/2020	Bromberg, Brian	1.8	Review updated diligence questions list for IAC meeting with IAC treasurer.
28	7/27/2020	Kurtz, Emma	0.7	Analyze responses from company re: interest rate expense to evaluate variance from cash flow statement.
28	7/28/2020	Bromberg, Brian	0.6	Review call summary of diligence meeting with global treasurer.
28	7/28/2020	Bromberg, Brian	1.0	Participate in call with IAC global treasurer.
28	7/28/2020	Bromberg, Brian	0.5	Prepare for diligence call with IAC global treasurer.
28	7/28/2020	Kim, Ye Darm	1.0	Participate in diligence meeting with IAC treasurer.
28	7/28/2020	Kim, Ye Darm	0.9	Prepare summary of diligence call with IAC treasurer for internal distribution.
28	7/28/2020	Kurtz, Emma	1.0	Participate in diligence call with Daniel Jefferies, the newly hired global treasurer of Mundipharma.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	7/29/2020	Diaz, Matthew	0.4	Review notes and related next steps from the call with the IAC treasurer.
28	7/30/2020	Bromberg, Brian	0.6	Participate in call with Debtor and UCC advisors on status of IAC diligence.
28	7/30/2020	Bromberg, Brian	1.8	Review provided financial diligence support documents from IACs.
28	7/30/2020	Bromberg, Brian	0.8	Prepare follow up diligence list and summary of items received.
28	7/30/2020	Bromberg, Brian	1.8	Participate in call with IAC accountant.
28	7/30/2020	Bromberg, Brian	0.5	Prepare for call with IAC accountant.
28	7/30/2020	Bromberg, Brian	0.6	Review and prepare revisions on call notes from IAC accountant meeting.
28	7/30/2020	Diaz, Matthew	0.5	Review call notes and related implications coming out of the call with IAC accountant.
28	7/30/2020	Kim, Ye Darm	0.7	Participate in discussion with UCC and Debtors' advisors re: IAC diligence workplan.
28	7/30/2020	Kim, Ye Darm	1.7	Participate in diligence call with Steve Jamieson re: IAC financials.
28	7/30/2020	Kurtz, Emma	0.8	Prepare detailed summary to share with team re: Steve Jamieson diligence call.
28	7/30/2020	Kurtz, Emma	1.7	Participate in diligence call with Steve Jamieson to discuss outstanding questions re: IAC financial statements.
28	8/3/2020	Diaz, Matthew	1.8	Review the updated responses to questions on the IAC analysis and related diligence.
28	8/3/2020	Bromberg, Brian	1.2	Review dataroom for ADHD product information.
28	8/3/2020	Bromberg, Brian	0.9	Review ADHD product performance for IACs.
28	8/6/2020	Bromberg, Brian	1.8	Review diligence responses provided on Canadian financials in dataroom.
28	8/6/2020	Bromberg, Brian	0.5	Coordinate with Counsel re: non-reliance letter comments.
28	8/10/2020	Bromberg, Brian	1.3	Review IAC royalty agreements re: licensing agreement diligence.
28	8/10/2020	Bromberg, Brian	0.5	Discuss IAC diligence letter with Debtor and UCC advisors.
28	8/11/2020	Kurtz, Emma	3.2	Review historical IAC licensing agreements to prepare analysis of terms, including royalty rates.
28	8/11/2020	Bromberg, Brian	0.5	Review letter to IACs for discussion with Debtors and UCC advisors.
28	8/11/2020	Bromberg, Brian	0.6	Review IAC licensing agreements diligence status with team.
28	8/11/2020	Bromberg, Brian	1.3	Review IAC licensing agreements re: market royalty rates.
28	8/11/2020	Shah, Jayshree	3.1	Conduct research to understand the relationship between Purdue and Mundi IACs from a licensing perspective to benchmark against market.
28	8/12/2020	Shah, Jayshree	1.9	Continue research to understand the relationship between Purdue and Mundi IACs from a licensing perspective to benchmark against market.
28	8/12/2020	Shah, Jayshree	3.0	Continue research to understand the relationship between Purdue and Mundi IACs from a licensing perspective to benchmark against market.
28	8/13/2020	Bromberg, Brian	1.6	Review updated draft of IAC licensing agreement summary analysis.
28	8/13/2020	Shah, Jayshree	2.2	Review primary and secondary research conducted re: IAC licensing agreements.
28	8/13/2020	Shah, Jayshree	3.8	Conduct primary and secondary research re: IAC licensing agreement royalty rates.
28	8/14/2020	Diaz, Matthew	1.2	Review the transfer pricing policies between the IACs and Purdue.
28	8/14/2020	Diaz, Matthew	0.3	Review the letter to the IAC management re: open due diligence.
28	8/14/2020	Kim, Ye Darm	0.6	Review licensing agreements summary analysis to prepare for call.
28	8/14/2020	Kim, Ye Darm	0.6	Participate on call re: OxyContin licensing with Mundipharma.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	8/14/2020	Kim, Ye Darm	0.9	Review questions list re: market/product prepared by UCC advisors.
28	8/14/2020	Kim, Ye Darm	1.0	Review royalty percentages analysis prepared by UK team.
28	8/14/2020	Kurtz, Emma	0.5	Review comparable companies royalty rates to evaluate IAC licensing agreements.
28	8/14/2020	Kurtz, Emma	0.4	Update outstanding IAC business plan diligence request list to incorporate additional questions sent to Company.
28	8/14/2020	Bromberg, Brian	0.5	Participate in discussion re: licensing agreements diligence with internal team.
28	8/14/2020	Shah, Jayshree	2.0	Prepare and participate in meeting with US FTI team to discuss perspective on royalty fees.
28	8/17/2020	Shah, Jayshree	3.2	Review license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/17/2020	Shah, Jayshree	2.8	Continue review of license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/18/2020	Kurtz, Emma	0.4	Review diligence responses received from the Company re: central functions to evaluate responsiveness to outstanding questions.
28	8/18/2020	Bromberg, Brian	0.7	Review IAC diligence re: central functions responsiveness.
28	8/18/2020	Shah, Jayshree	3.0	Continue review of license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/19/2020	Kurtz, Emma	0.9	Review recent diligence responses from Company and additional questions submitted to update outstanding diligence request list.
28	8/19/2020	Shah, Jayshree	2.0	Continue review of license agreements for Oxycontin and Oxycontin tamper proof to understand royalty rate comps.
28	8/20/2020	Bromberg, Brian	0.8	Prepare slides for business update re: licensing agreement diligence.
28	8/24/2020	Bromberg, Brian	0.5	Review and discuss non reliance letter with Huron.
28	8/26/2020	Kurtz, Emma	0.9	Review Steve Jamieson diligence responses to evaluate responsiveness to outstanding questions.
28	8/26/2020	Kurtz, Emma	0.3	Update outstanding diligence request list to reflect latest responses from the Company.
28	8/28/2020	Diaz, Matthew	1.4	Review the updated IAC due diligence on licensing agreements.
28	8/28/2020	Kurtz, Emma	0.4	Review diligence responses from the Company re: central functions.
28	8/31/2020	Diaz, Matthew	1.4	Review responses from IAC re: outstanding diligence questions.
28	8/31/2020	Bromberg, Brian	1.2	Review information provided by IACs re: outstanding diligence requests.
28	9/1/2020	Kurtz, Emma	0.8	Review recently received diligence responses from the Company to evaluate responsiveness to outstanding questions.
28	9/1/2020	Kurtz, Emma	0.4	Update outstanding diligence request list to incorporate responses received from the Company and follow up queries.
28	9/2/2020	Diaz, Matthew	1.3	Review updated IAC due diligence summaries.
28	9/8/2020	Kurtz, Emma	1.1	Prepare updates to dataroom index to incorporate documents recently uploaded to share with team.
28	9/11/2020	Kurtz, Emma	0.7	Review LEK summary report re: assessment of IAC business plan projections.
28	9/11/2020	Bromberg, Brian	1.5	Review newly provided financial model for IACs.
28	9/11/2020	Bromberg, Brian	1.5	Review LEK summary report on the IAC business plan.
28	9/12/2020	Diaz, Matthew	1.6	Review of the updated IAC model received from Mundipharma.
28	9/14/2020	Kurtz, Emma	0.8	Build out summary analysis of product level P&L line items in revised business plan to evaluate impact of top products.
28	9/14/2020	Kurtz, Emma	1.3	Prepare analysis of revised business plan cash flow line items by legal entity.
28	9/14/2020	Kurtz, Emma	1.1	Prepare analysis of revised business plan balance sheet line items by legal entity.
28	9/14/2020	Kurtz, Emma	1.4	Review revised IAC business plan to evaluate changes from June business plan.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	9/14/2020	Bromberg, Brian	2.6	Review newly provided financial model for IACs.
28	9/15/2020	Kurtz, Emma	1.3	Prepare summary analysis of detailed P&L line items by entity to evaluate information not included in the main P&L tabs.
28	9/15/2020	Kurtz, Emma	1.8	Prepare analysis re: tie out of net income to EBITDA by entity.
28	9/15/2020	Bromberg, Brian	1.4	Continue review of the newly provided financial model for IACs.
28	9/15/2020	Bromberg, Brian	1.2	Review FTI summary analysis of the latest IAC financials.
28	9/16/2020	Diaz, Matthew	1.0	Participate in a call with the CFO of Mundipharma and the other case financial advisors to discuss 6 months 2020 financial performance.
28	9/16/2020	Diaz, Matthew	0.7	Review the presentation materials re: current IAC performance.
28	9/16/2020	Kim, Ye Darm	0.8	Participate in call with IAC CFO re: 2Q20 performance.
28	9/16/2020	Kurtz, Emma	1.9	Prepare analysis re: revised cash flow line items to Steve Jamieson support schedules re: other investing activities, other financing activities, and capital contributions to evaluate
28	9/16/2020	Kurtz, Emma	1.0	Participate in call with Arnaud Breabout, Mundipharma CFO, to discuss 1H 2020 results and risks for 2H 2020.
28	9/16/2020	Kurtz, Emma	1.4	Prepare analysis re: tie out of revised balance sheet line items to Steve Jamieson support schedules re: loans receivable and loans payable.
28	9/16/2020	Kurtz, Emma	1.1	Prepare comparison analysis of revised P&L to Steve Jamieson support schedules re: net interest expense to evaluate differences.
28	9/16/2020	Bromberg, Brian	1.0	Participate in call with Arnaud Breabout, Mundipharma CFO, to discuss 1H 2020 results.
28	9/17/2020	Kim, Ye Darm	0.6	Participate in call re: updated IAC model.
28	9/17/2020	Kurtz, Emma	1.6	Prepare presentation re: IAC 1H 2020 results and risks for 2H 2020 for Committee.
28	9/17/2020	Kurtz, Emma	0.2	Discuss internally re: revised IAC budget, IAC 1H 2020 results, and potential reporting to the Committee.
28	9/17/2020	Kurtz, Emma	1.4	Prepare analysis re: IAC 1H 2020 results to evaluate budget to actual variance.
28	9/17/2020	Bromberg, Brian	3.3	Create initial diligence questions list on new IAC model.
28	9/17/2020	Bromberg, Brian	0.5	Discuss updated IAC model summary slides with team.
28	9/17/2020	Bromberg, Brian	2.5	Review the FTI summary analysis of the latest IAC model.
28	9/17/2020	Bromberg, Brian	1.3	Review prior IAC diligence responses to prepare new request list.
28	9/18/2020	Diaz, Matthew	1.1	Review of updated IAC financials summary analysis and discuss related next steps.
28	9/18/2020	Kim, Ye Darm	0.9	Process revisions to the IAC 1H20 performance summary slides.
28	9/18/2020	Kim, Ye Darm	1.6	Process revisions to the IAC 1H20 performance summary slides.
28	9/18/2020	Kim, Ye Darm	1.0	Review IAC 1H20 performance summary slides.
28	9/18/2020	Kurtz, Emma	0.4	Prepare updates to the IAC diligence request list to incorporate questions surrounding the revised IAC business plan.
28	9/18/2020	Kurtz, Emma	0.4	Prepare revisions to analysis re: revised IAC budget to incorporate internal comments.
28	9/18/2020	Bromberg, Brian	2.4	Review and process revisions to the IAC diligence update slides.
28	9/21/2020	Diaz, Matthew	1.2	Review the updated IAC diligence analysis.
28	9/21/2020	Diaz, Matthew	0.9	Review the presentation to the AHC on the IAC year to date performance.
28	9/21/2020	Kim, Ye Darm	0.9	Review diligence responses for product data provided by IACs.
28	9/21/2020	Kim, Ye Darm	1.2	Process updates to IAC 1H20 performance summary slides per internal comments.
28	9/21/2020	Bromberg, Brian	1.8	Review IAC diligence materials provided in dataroom.

EXHIBIT C
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
DETAIL OF TIME ENTRIES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Task Category	Date	Professional	Hours	Activity
28	9/21/2020	Bromberg, Brian	1.5	Finalize draft of IAC update to send to Houlihan Lokey.
28	9/22/2020	Diaz, Matthew	1.1	Review the LEK report on the IAC business plan.
28	9/22/2020	Diaz, Matthew	0.9	Participate in a call with Houlihan to discuss the IAC presentation to the AHC.
28	9/22/2020	Kim, Ye Darm	0.6	Participate in call re: IAC financial update presentation.
28	9/22/2020	Kurtz, Emma	0.8	Participate in call with Houlihan to discuss IAC update presentation to Committee.
28	9/22/2020	Bromberg, Brian	0.5	Participate in disucssion re: IAC updates with Houlihan Lokey.
28	9/22/2020	Bromberg, Brian	1.2	Finalize the IAC update deck to send to Counsel.
28	9/23/2020	Bromberg, Brian	2.2	Review IAC provided materials on new product forecasts.
28	9/23/2020	Bromberg, Brian	0.5	Work on clearance for IAC update deck to the Committee.
28	9/24/2020	Bromberg, Brian	0.8	Review the IAC financial support materials provided in the dataroom.
28	9/25/2020	Diaz, Matthew	0.6	Review the agenda for the DB call re: IAC sale process.
28	9/25/2020	Kurtz, Emma	0.4	Prepare updates to outstanding diligence request list to reflect recent responses and additional requests re: revised business plan.
28	9/25/2020	Bromberg, Brian	0.9	Create diligence question list for call with Deutsche Bank re: IAC sale process.
28	9/28/2020	Kim, Ye Darm	0.5	Review topic list for call with Deustche Bank re: IAC sale process.
28	9/28/2020	Kim, Ye Darm	1.9	Review latest IAC financial model provided by Huron.
28	9/28/2020	Kurtz, Emma	1.4	Review revised business plan model to evaluate follow up questions for Steve Jamieson.
28	9/28/2020	Bromberg, Brian	1.9	Create outline of IAC presentation based on new diligence information.
28	9/29/2020	Diaz, Matthew	0.9	Review the updated IAC due diligence materials.
28	9/29/2020	Kurtz, Emma	2.2	Prepare analysis of revised budget product P&L to evaluate changes to financial projections.
28	9/29/2020	Bromberg, Brian	1.6	Review newly provided product-level files from IACs.
28	9/30/2020	Bromberg, Brian	0.5	Prepare revised question list for Deutsche Bank re: IAC sale process.
28	9/30/2020	Bromberg, Brian	2.2	Review of the worldwide product P&L files re: IAC forecasts.
28 Total			428.3	
Grand Total			1,905.1	

EXHIBIT D
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
SUMMARY OF EXPENSES
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Expense Type	Amount
Working Meals ¹	\$ 80.00
Other	125.15
Grand Total²	\$ 205.15

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.

2. Expenses incurred internationally have been translated to USD using the relevant spot rate.

EXHIBIT E
PURDUE PHARMA L.P., et al. - CASE NO. 19-23649
EXPENSE DETAIL
FOR THE PERIOD JUNE 1, 2020 TO SEPTEMBER 30, 2020

Date	Professional	Expense Type	Expense Detail	Amount
2/24/2020	Kim, Ye Darm	Working Meals	Working meal while working late in the office.	\$ 20.00
2/24/2020	Bromberg, Brian	Working Meals	Working meal while working late in the office.	20.00
2/25/2020	Bromberg, Brian	Working Meals	Working meal while working late in the office.	20.00
2/26/2020	Bromberg, Brian	Working Meals	Working meal while working late in the office.	20.00
Working Meals Total				\$ 80.00
6/1/2020	Harsha, Adam	Other	Access to Pennsylvania corporate records of Debtor-affiliated entities for the HRT 1	\$ 6.00
6/30/2020	Butterfield, Linda	Other	Access to Lexis Nexis for research regarding the HRT motion.	10.90
8/18/2020	Bromberg, Brian	Other	Court Call Charges - participated in telephonic court hearing	38.25
8/26/2020	Diaz, Matthew	Other	Court Call Charges - participated in telephonic court hearing	70.00
Other Total				\$ 125.15
Grand Total				\$ 205.15

1. Working Meals have been voluntarily reduced to the lesser of \$20 per person or the actual amount charged.
2. Expenses incurred internationally have been translated to USD using the relevant spot rate.